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Abstract
Heparin is a polydispersed sulfated molecule that is part of the family called
glycosaminoglycans found in the extracellular matrix and cell surfaces. This molecule is
extremely important for the activation of proteins and protein-receptor interactions that are
responsible for downstream cell signaling pathways. Heparin has been isolated from porcine
intestine and used as an anticoagulant for the prevention of embolisms, heart thrombosis, and
clotting during heart surgeries. This so-called miracle drug was in use until 2008, when isolated
batches were found to be contaminated with other glycosaminoglycans similar to heparin. From
2008, there has been a dire need for a more cost-effective purification of heparin in good yield,
to remove the contaminants.
Heparin has also been used for affinity chromatography to purify heparin-binding
proteins. Recombinant protein purification is an important aspect of biotechnology, with a heavy
emphasis on developing easy purification systems for large quantities of homogeneously pure
therapeutic proteins at low costs. Several affinity tags have been employed to aid in the
expression and purification of various proteins. There are, however, various disadvantages, such
as interference with the target protein structure, unsuitable elution conditions, multiple-step
purification procedures, and many others.
In this context, a novel heparin-binding peptide (HB-peptide) was designed based on the
heparin-binding region of acidic fibroblast growth factor (FGF-1). The HB-peptide has been
shown to bind to heparin with better affinity than other glycosaminoglycans. A one-step
Heparin-Sepharose-based purification procedure was developed for various recombinant proteins
using mild elution conditions. Using proteolytic cleavage, the affinity tag was removed to obtain
a folded protein. Polyclonal antibodies were also grown against the specific sequence of the HB-

peptide, which then were used to successfully and specifically bind fusion proteins that only
contained the HB-peptide even at the nanogram level.
HB-peptide was then coupled onto a solid matrix to be used as an affinity column, in a
similar fashion as heparin-Sepharose with HBPs. Glycosaminoglycans that were in a mixture
were separated from each other for the most part. In this context, our HB-peptide can be used as
a means to separate glycosaminoglycans, yielding pure heparin for future medical use.
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Chapter 1
Introduction
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1.1. Extracellular Matrix
The cell is a complex system of various organelles working together to achieve
homeostasis for the body. Part of this process involves cells communicating with one another to
start various downstream processes in order for cells to survive. Cell signaling allows cells to
influence each other’s fate and behavior1. Extracellular and intracellular signals orchestrate the
molecular mechanisms involved in signaling. Various signals include proteins, hormones, and
neurotransmitters that bind to specific cell-surface receptors for their activity2. The receptors can
be other proteins or sugar molecules that proteins in the surrounding environment bind to for
activity. Every cell type comes in contact with a dynamic molecular scaffold, known as the
extracellular matrix (ECM), in order to perform the process of cell signaling and downstream
processes3.
The ECM initiates crucial biochemical cues necessary for cell signaling and regulates
almost all cellular behavior and developmental processes4, 5. For endothelial cell proliferation,
cytokine function, and angiogenesis, adhesion of these cells to the ECM is critical6. Cell
adhesion to ECM triggers intracellular signaling pathways that regulate various cell processes,
such as progression, migration, and differentiation. The biochemical properties of the ECM are
highly variable from one tissue to another, within a specific tissue, and even from one
physiological state to another4. Frequent remodeling processes occur in the ECM, where
components are degraded, modified, or synthesized, enabling cellular functions to be regulated
tightly7. The ECM is a critical source for the growth, survival, and angiogenic factors that also
affect tumor progression8. Various proteins are present in this matrix that are important for cell
adhesion and regulation of growth factor bioavailability of which include (1) fibrous proteins
(collagen, elastin, fibronectin, and laminin), (2) proteoglycans (chondroitin sulfate proteoglycans
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(CSPG) and heparan sulfate proteoglycans (HSPG)), and (3) other proteins important for
development and disease (non-fibrous glycoproteins, hemostatic system proteins, neuronal
guidance molecules, and growth factor associated proteins)9,10. The various fibrous proteins are
present for tensile strength and stabilization, with collagens being the most abundant proteins
present in mammals (25% of total protein mass in mammalian animals)11,12. The polysaccharide
component in PGs form the hydrated gel composition of the ECM, with the fibrous proteins
embedded in it13. The ECM contains three families of PGs: (1) large aggregating CSPGs (also
known as lecticans), (2) small leucine-rich CSPGs, and (3) HSPGs14. Examples of the so-called
“other” proteins unlike proteoglycans or fibrous proteins include thrombospondins, von
Willebrand factor, neutrins, and insulin-like growth factor binding proteins10. Through posttranslational modifications by enzymatic and non-enzymatic pathways, remodeling of the ECM
occurs to release bioactive factors that enable downstream processes such as growth and
morphogenesis15.

1.2. Proteoglycans
As stated previously, one of the major classes of compounds found in the ECM are PGs,
which are ubiquitous macromolecules that play important structural and regulatory roles in the
ECM16,17. PGs are composed of a protein core that is attached to the cell surface and a
glycosaminoglycan (GAG) tails, by GPI-linked or membrane proteins18 (Table 1.1). HS and
CS/DS GAGs are attached to their respective core proteins by the same GAG-protein linkage
region, which consists of GlcA(β1-3)Gal(β1-3)Gal(β1-4)Xylβ1-O-Ser19.

3

Proteoglycan class

Proteoglycan

Glycosaminoglycan
Core protein size
chain
(kDa)
HSPG
Glypican 1-6
1-3 HS
57-69
Perlecan
1-4 HS
400
Agrin
2-3 HS
212
HS/CSPG
Syndecans 1-4
1-3 CS, 1-2 HS
31-45
β-Glycan
1-2 HS/CS
110
Serglycin
10-15 heparin/CS
10-19
CSPG
Bikunin
1 CS
18
Decorin
1 DS/CS
36
Thrombomodulin
1 CS
58
KSPG
Lumican
KS I
37
Fibromodulin
KS I
59
Aggrecan
KS II
200
Table 1.1 – Properties of well-known PGs present in the body, modified from Li et al17.
In the ECM, PGs interact with other components of the ECM, such as collagens, adhesion
molecules, and growth factors20. The main functions of PGs are cell adhesion and migration and
a structural role for the ECM21. The families of PGs in the ECM include the two CSPGs: (1)
large aggregating CSPGs known as lecticans (eg. Aggrecan, neurocan, brevican, versican), (2)
small leucine-rich CSPGs (eg. Decorin, biglycan, lumican) and HSPGs (eg. Perlecan, collagen
type XVIII, agrins)14,22,23,24. Other HSPGs include membrane-spanning syndecans, membrane
glycosylphosphatidylinositol-linked glypicans, and serglycin, present in secretory
vesicles25,26,27,28. PGs are also located on the surface of all animal cells, intracellular granules of
certain cell types, and in the basement membrane of various tissues17. These molecules are
thought to be the key players in disease control and progression by modulating growth factor
functions29. PGs interact with various proteins and growth factors to regulate signaling pathways
that are important for stem cell fate, such as Wnt and BMP30. PGs are extremely vital for cellcell interactions, but are also implicated in numerous diseases, such as arthritis and cancer31.
4

They also function as joint lubricants and structural components in connective tissue32. Small
PGs, such as decorin and biglycan, help form and modify collagen fibers in connective tissue for
example33. Also, in the central nervous system, PGs are extremely important for neurite
outgrowth in the regeneration of an injured spinal cord34. CSPGs are known to be present in the
CNS and are responsible for neuronal plasticity, neuroprotection against cell death inducing
processes, and homeostasis around neurons35,36. The location of HSPGs depends on the core
protein present. They can either be free in the ECM or at the cell-ECM interface37. The GAG
chain is the major constituent responsible for the biological functions of the PGs38. This GAG
portion can have a molecular weight of 5 to 50 kDa39.

1.3. Glycosaminoglycans
These GAGs are polysaccharides with complex structures, and are vital for growth and
signaling processes, including differentiation, proliferation, morphogenesis, and bacterial/viral
infections40,41. GAGs have been shown to be essential for multicellular life and crucial for
development from genetic knockout studies in various organisms42. Also known as
mucopolysaccharides, GAGs have very viscous and lubricating properties43. GAGs are present
on all surfaces of animal cells in the ECM43. There are four major classes that the GAGs fall
into: heparin/heparan sulfate (HS), keratan sulfate (KS), chondroitin sulfate (CS)/dermatan
sulfate (DS), and hyaluronic acid (HA)/hyaluronan44. The overall structure consists of a
repeating disaccharide that contains a hexosamine (N-acetyl-D-glucosamine, GlcNAc, or Nacetyl-D-galactosamine, GalNAc) and either uronic acid (glucuronic acid, GlcA, or iduronic
acid, IdoA) or galactose45 (Figure 1.1).
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Figure 1.1 – Structures of the repeating disaccharide units in naturally occurring GAGs present
in the body.
Modification by means of sulfation and epimerization occurs in the Golgi, leading to the
polydispersity in structure and function of GAGs42,46. With the exception of HA, hydroxyl
groups on the 2, 4, and 6 positions of the sugar can be sulfated by sulfotransferase enzymes45. At
least one of the sugars in the repeating unit has a negatively charged carboxylate or sulfate
group32. The biosynthesis of complex GAGs is highly regulated, and the sulfation patterns are
formed in an organ- and tissue-specific manner during development41. The sulfate GAGs are
ubiquitous to the animal kingdom, whereas in bacteria, these same GAGs are found in the nonsulfated form. For example, in pathogenic bacteria, heparanosan and chondrosan, the nonsulfated version of heparin and chondroitin sulfate, are present to protect the microbe and aid in
infection47. Sulfated GAGs are also absent in the fungi, plantae, and protista kingdoms. With
the exception of hyaluronic acid, GAGs are often covalently attached to a protein core that is
found inside cells, on the cell surface, or in the extracellular matrices48.
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Chondroitin Sulfate and Dermatan Sulfate
CS and DS are frequently found as hybrid chains in mammalian tissues, which leads to
their grouping together in description49. When getting into further detail about the individual
chains’ structures, separation of the two GAG types is called for. Structural stabilization was
thought to be their only role until recently. New roles have arisen such as modulation of the
CNS environment, cell division and morphogenesis, wound repair, infection, and many
others50,51,52,53,54. Chondroitin sulfate (CS) chains consist of repeating disaccharides of Dglucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc), with anywhere from 40 to 100
disaccharide units55. CS chains are classified as motifs according to their sulfation patterns (O
(non-sulfated), A (at GalNAc oxygen-4), C (at GalNAc oxygen-6), D (at GlcA oxygen-2 and
GalNAc oxygen-6), E (at GalNAc oxygen-4 and 6))56,55. CS-B is not listed because its formal
name is actually the DS GAG chain. The enzymes responsible for the sulfation patterns in CS
are: 4-O-sulfotransferases 1-3, 6-O-sulfotransferases 1 and 2, and 4-sulfate 6-O-sulfotransferase,
which work on the hexosamine moiety. Galactosaminyl uronyl 2-O-sulfotransferase works on
the uronic acid moiety57. Structures containing C-, D-, and E-units have roles in bone
development. CS or HS proteoglycans (CSPGs or HSPGs, respectively) are major components
of the ECM in the central nervous system (CNS)58. DS chains are extremely similar to CS
chains, with iduronic acid (IdoA) instead of glucoronic acid (GlcA). DS can be generated during
the CS assembly by epimerization of the GlcA into IdoA by two DS epimerases, DS-epi1 and
DS-epi259. Dermatan 4-O-sulfotransferase-1 adds sulfate groups on the IdoA moiety57. The
presence of IdoA actually likens DS to HS/heparin. DS chains are commonly sulfated at the
GalNAc oxygen-4 and 6 (like CS-A and C) and at IdoA oxygen-2 (like HS/heparin)53. CS/DS
are found bound to at least 32 core proteins to form their subsequence PG60. CS/DS, along with
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the respective proteoglycan, binds to a wide variety of molecules such as coagulation factors
(heparin cofactor II, which then inhibits thrombin), matrix molecules (Type II collagen, involved
in primary osteoarthritis), growth factors (fibroblast growth factors (FGF)-2 and 7, mainly DS
binds these), chemokines (stromal cell derived factor-1β, SDF-1β), and pathogen virulence
factors (glycoprotein C, responsible for the herpes simplex virus infection)61,62,49,44. The major
GAG synthesized in rat fetal liver is CS, representing over 50% of the sulfated GAGs, but in
adult liver, the dominant GAG present becomes HS, comprising over 80% of total GAG63. This
high level of CS GAG decreases after birth between the 10th and 15th day of life. The production
of CS is cell type dependent as seen by the decrease in levels in differentiated hepatocytes
compared to the undifferentiated hepatocytes present in fetuses63.

Keratan Sulfate
Keratan sulfate (KS) is a sulfated GAG that is composed of galactose (Gal) and
GlcNAc64. KS is distinct from the other GAGs because it can be synthesized on N-linked
oligosaccharides and on serine/threonine O-linked oligosaccharides65. KS is present in various
cartilages, the cornea, neural tissue (as seen by its expression at the site of neural injury), and
reproductive tissue66,67,68,16. KS plays an important role in maintaining transparency in the
cornea by providing proper hydration for the ECM in the stroma69. Other functions include
modulating axonal growth during development and endothelial cell migration70,71. KS modulates
fibromodulin and osteoadherin in cartilage72,73. Inflammation or chronic conditions of the
corneal stroma lead to marked decrease or loss of keratan sulfate74.
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Hyaluronic Acid
Hyaluronic acid (HA) is another GAG that is important for various biochemical processes
in the body. HA accounts for roughly 60% of the ECM75. HA is a relatively simple GAG that is
unsulfated and unbranched, and not attached to protein core76. It is synthesized at the inner face
of the plasma membrane as a linear chain by integral plasma membrane proteins called
hyaluronan synthases (HS1-3), in contrast to the other GAGs that are synthesized in the Golgi
and attached to protein cores77,78. HA chains consist of alternating (1 → 4)-β linked GlcA and (1
→ 3)-β linked GlcNAc residues79. This GAG is an extremely large molecule, with a typical
molecule ranging from 200-100,000 kDa in size80.
Even though HA is not attached to a core protein, it does interact in a noncovalent
fashion through its unique hyaluronan-binding motifs12,47. CD44 is a major cell-surface receptor
that interacts with HA, which is involved in cell proliferation and angiogenesis81. This
interaction stimulates migration and invasiveness in human melanoma cell lines82. HA is
ubiquitous and is present in almost all tissues but is most abundant in soft connective tissue83.
Long thought to be just a lubricating molecule in joints, HA has been shown to have various
signaling properties, such as tumor cell migration, wound healing, and apoptosis, depending on
its chain length84,85,86. HA is found to accumulate in the aortic smooth muscle cells during
mitotic stages since it facilitates nuclei separation and cell division87. In healthy tissues, HA is
high-molecular weight, but smaller fragments are obtained by enzyme-mediated degradation or
oxidative stress, and these small fragments have roles unlike the native HA in the body79. It has
been shown that the low-molecular-weight HA fragments (70-120 kDa) can be used for the
delivery of peptides and proteins, useful in chronic wound healing88. Native HA is also used in
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cosmetics and pharmaceuticals89. The specific details of the activity of this GAG are still being
studied today.

Heparin and Heparan Sulfate
Heparin, a GAG present in the ECM was discovered in 1916 and has been in the public
eye ever since for many amazing roles exogenously and endogenously90. It has been found that
the highest concentrations of heparin are in lung, liver, and muscle91. HSGAGs interact with
other ECM components to influence major processes such as normal development, wound
healing, and most notably tumor growth37. HS is the GAG that is found on all cell surfaces,
which is what proteins that interact with GAGs actually interact with instead of heparin.
Normally, HSGAG is ushered into the cell in a controlled manner, which is seen by its famous
interaction with FGF-2 and FGF receptor (FGFR1). When it binds to these components, this
ternary complex is localized to the nucleus to impact cell function37. The major repeating
disaccharide of heparin and HS consists of IdoA or GlcA attached to GlcNAc. The structures of
HS and heparin are very similar, but HS has fewer sulfo groups and is rich in GlcA and
GlcNAc92. HS is found on all cells, whereas heparin is only found on mast cells near the walls
of blood vessels and on the surfaces of endothelial cells32. HS is ubiquitously expressed as a
proteoglycan on most animal cells and as a component of extracellular matrices and basement
membranes93. HSGAG is also found in the cell nucleus with possible roles in cell differentiation
and proliferation94. Heparin, in the dense granules of the mast cells, is released into the
extracellular space when the cell is triggered to secrete32. Specifically, heparin is produced in the
lung, liver, and skin by mast cells95. Different numbers of polysaccharide chains can be attached
to various serine residues in heparin’s core to form the respective proteoglycan27. HSPGs are
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associated with the surface of epithelial cells at densities of 105-106 molecules/cell96. HS has
much diversity in its structure based on its tissue location, which in turn affects its activity97,98.
In this context, in order to adequately study the binding affinities of various proteins that interact
with the cell surface, heparin, the highly sulfated analog of HS, is used as an HS model since the
sulfate groups on HS are what the proteins interact with99.
Heparin/HS is unique in the fact that it is the only GAG that is biosynthesized in the
absence of a template100. The biosynthesis of heparin begins with the synthesis of a core protein
(serglycin) in ER with a tetrasaccharide linker attached to its serine residues in regions rich in
Ser-Gly repeats101. As it travels through the Golgi, a repeating 1→4-glycosidically-linked
copolymer of GlcA and GlcNAc is extended from this linked region through the addition of
uridine diphosphate-activated sugars catalyzed by the EXT enzyme102. The peptidoglycan
heparin is released from serglycin as a small peptide, to which a single polysaccharide chain (100
kDa) is added. This peptidoglycan is short-lived as it is immediately processed by βendoglucurodinase to a number of smaller polysaccharide chains called GAGs103. During its
formation, the copolymer is modified by N-deacetylase/N-sulfotransferase (NDST), C5
epimerase, and 2-, 6-, and 3-O-sulfotransferases104. Complete modification results in a GAG
rich in N- and O-sulfo-L-iduronic acid, “heparin”. Incomplete or partial modification results in a
GAG rich in O-sulfo-N-acetyl-D-glucosamine and GlcA, “heparan sulfate” 104. The biosynthetic
modification of HS is incomplete, resulting in sequence homogeneity important in the regulation
of HS interaction specificity with various cellular proteins105. HS is biosynthesized, as a
proteoglycan, through the same pathway as heparin, but, unlike heparin, its chain remains
attached to its core protein27. Although structurally similar, heparin and HS can be distinguished
through their different sensitivity towards a family of GAG-degrading microbial enzymes,
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heparin lyases27. Similar to other natural polysaccharides, heparin is a polydispersed mixture
containing chains varying in molecular weights and sulfation patterns106. In solution, heparin
exists as an extended helical structure with conserved glycosidic bond angles, yet it has a high
degree of conformational flexibility107. The chair and skew boat conformations of IdoA residues
abundant in heparin and S-domains of HS contribute to this flexibility108,109. This allows for
diverse spatial displays of negative charge thought to aid specific interactions with proteins
through induced fit binding mechanisms107. Pharmaceutical grade heparin consists of chains
ranging in size of 5 to 40 kDa110. GAG heparin has the same size range, but an average
molecular weight of 15 kDa and an average negative charge of -7527. The major component of
heparin (75-95%) is the trisulfated disaccharide form by replacing R1, R2, and R3 with sulfate
groups. HS is known for its ability to modulate the actions of morphogens in the ECM during
embryonic development111. Heparin interacts with specific proteins that have unique binding
sites that recognize heparin among the other GAGs. These proteins are known as heparinbinding proteins (HBPs). The most well-known and first studied in depth role of heparin studied
in the science world is its anticoagulation capabilities. In this process, exogenous heparin
interacts with antithrombin (ATIII) (a key player in the coagulation pathway) and upon binding,
there is an increase in its activity to inhibit thrombin and thus inhibiting blood clot formation103.
The interaction of ATIII and a pentasaccharide in heparin has marked one of the very few
“specific” binding models of heparin with proteins, in which exists a conformational change in
the protein and a subsequent increase in activity103. This very specific pentasaccharide (DEFGH)
makes up one-third of the heparin chains in nature, which is composed of GlcNAc6S→GlcA→
GlcNS3S6S→IdoA2S→GlcNS6S112. Besides the important biological functions of heparin, it
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has also been exploited for better purification techniques for proteins that are known to bind to it,
where it is immobilized as a resin (heparin-Sepharose) to be used in affinity chromatography.

Heparanase
The GAG chain of the PG can be degraded and removed from the cell surface for further
activity in their free form. Heparanase, an endoglucuronidase, is the only known mammalian
endoglycosidase to cleave HS, specifically between the uronic acid and glucosamine113,114. It is
highly expressed in cancer cells and its activity is associated with high metastasis of cancer.
This is thought to be because the disattachment of HS from the ECM surface and basement
membrane leads to cell invasion115. This degradation of HS leads to disassembly of the EMC,
resulting in cancer angiogenesis and metastasis116. Once heparanase has degraded the ECM
during tumor growth, the liberated HS has molecules still bound to it that are associated with
inflammation, metastasis, and angiogenesis. For example, HS-bearing syndecan-1 that is freed
from the cell surface binds to and upregulates activity of tumor-derived growth factors, leading
to further metastasis117. This essential enzyme has positive and negative effects on GAG
structure and in turn on the body.

1.4. Significance of Glycosaminoglycans
The most famous use of GAGs, in particular heparin, is for anticoagulation. Most cardiac
surgical operations are performed using cardiopulmonary bypass that maintains the systemic
blood circulation during cardioplegia118. Heparin is used to inhibit coagulation and prevent
thrombus formation on the surface of the bypass circuitry and oxygenator 118. This unique GAG
is one of the oldest drugs currently still in widespread use, one of the first biopolymeric drugs,
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and one of the few carbohydrate drugs119. During anticoagulation, heparin interacts with a
protein known as ATIII, which then leads to a multitude of reactions ultimately inhibiting clot
formation. ATIII is a member of the serine protease inhibitor superfamily involved in the blood
clotting cascade (coagulation), in which it rapidly inhibits proteases, thrombin, factor Xa, and
factor IXa120. In wound healing, blood clot formation is a major and necessary event for the
body. In this process, a key protein known as thrombin directly converts fibrinogen into fibrin,
the main component of a blood clot121. In order to stop the formation of fibrin, the inhibition of
thrombin is needed. ATIII exists in its repressed state able to slowly inhibit the proteins in the
cascade, but its interaction with heparin is crucial for anticoagulation to occur during wound
healing. Heparin, along with low-molecular-weight heparin (LMWH), binds to and activates
ATIII (coagulation protease inhibitor), ultimately inhibiting blood coagulation92. The activation
process of ATIII by means of heparin is actually very complex and occurs in various stages: (1)
ATIII binds a specific pentasaccharide present in heparin, which in turn causes (2)
conformational change in the inhibitory loop of ATIII (allosteric activation), (3) increasing the
inhibitor activity122,123. Binding of ATIII to the pentasaccharide in heparin is enough to inhibit
Factor Xa but not for thrombin. In most heparin molecules, the pentasaccharide is flanked on
both sides by repeating →4)-(2-O -sulfonato-a-L-idopyrano- syluronate)-(1→4)-(N-sulfonato-6O-sulfonato-a-D-glucosaminyl)-(1→disaccharidic sequences124. In the case of thrombin, once
ATIII is bound to heparin to the pentasaccharide site, thrombin then binds to heparin at a near yet
different site. This domino effect thus requires a longer chain of heparin, preferably 18
saccharides in length, instead of just the pentasaccharide for inhibition of Factor Xa125. This
ternary complex of ATIII-heparin-thrombin is then enough for the inhibition of thrombin126
(Figure 1.2).
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Figure 1.2 – Blood clotting cascade and the action of heparin as an anticoagulant, modified from
Zurawska et al127.
In the body, once heparin binds ATIII, the rate of formation of inhibitor-protein complex is
increased by at least three orders of magnitude32,128. Only a third of the chains found in
commercially prepared heparin/HS contain an ATIII binding site. There is a second serpin
called heparin cofactor II that selectively inhibits thrombin. This protein is activated by both
heparin and DS129.
Another role of medicinal importance is the involvement of heparin in cancer.
Components of the ECM change drastically during the progression of cancer. For example,
HSPGs known as the syndecan family are known to be involved in tumorigenesis of breast
15

cancer. In breast cancer cells, SD1 has been shown to promote their proliferation130. Of the
glypican family, GPC3 is a negative modulator of breast cancer, as seen by its ability to guide
breast cancer cells to apoptosis131. In breast cancer, this gene is silenced. Exogenous GAGs
have regulatory roles on the growth of cultured normal and cancerous cells20. For example, in
melanoma cells, exogenous CS, DS, and heparin/HS have been shown to inhibit cancer cell
growth132.
Angiogenesis is the growth of new blood vessels from pre-existing ones. Abnormal
angiogenesis leads to the onset of debilitating diseases, such as allergic dermatitis and warts,
obesity, cancer, pulmonary hypertension, endometriosis, inflammatory bowel disease, and most
famously arthritis133. Inflammation is the biological response to injury or harmful stimuli, such
as pathogens or damaged cells, in an attempt to heal or repair the organism134. In inflammation
and arthritis, patients suffer from debilitating pain in joints, especially in the knee. In the
incapacitating disease of osteoarthritis, blood vessel invasion allows for the infiltration of
osteoblasts in the cartilage, which then ultimately leads to the mineralization of the cartilage135.
This neurovascular invasion is also implicated in the onset of the pain and cartilage degradation
experienced in other debilitating diseases such as rheumatoid arthritis136. In short, blood vessel
growth leads to nerve growth into the tissue, which then leads to increased sensitivity and pain in
joints. Osteoarthritic cartilage has decreased levels of GAGs as compared to normal, healthy
cartilage, which allows for more neurovascularization and onset of the disease.
In the case of rheumatoid arthritis, angiogenesis promotes the destruction of cartilage and
bone. Heparin-binding growth factors are known to regulate angiogenesis. The systemic
administration of heparin, particularly LMWH, reduces the angiogenic activity of these growth
factors, which can aid in the inhibition of arthritis and related debilitating diseases. Specifically,
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orally administered, partially desulfated heparin pentasaccharide responsible for activating ATIII
inhibited articular angiogenesis and bone lesions commonly found in arthritis progression. The
pentasaccharide was desulfated and conjugated to deoxycholic acid in order to decrease the
concentration of heparin needed for anti-angiogenesis, which is associated with hemorrhage
risk137.
Aggrecan is a PG composed of CS or KS GAG side chains, which, due to its negative
charge, enables water retention and withstands compression in cartilage138. Aggrecanase is
primarily responsible for the destruction and loss of aggrecan in the early stages of arthritic joint
diseases139. The addition of exogenous KS was shown to decrease the release of aggrecan after
its cleavage in arthritis, showing that KS can be used to ameliorate inflammation in arthritic
patients138.

1.5. Use of Heparin in Disease
HS has been studied as a receptor for various pathogens such as Dengue virus, Herpes
simplex virus, Adeno-associated virus, Respiratory syncytial virus, Human immunodeficiency
virus, and many others140,141,142,143,144. Initial binding of a virus to its target cell marks the
beginning of pathogenesis145. This binding may result from a receptor-like interaction between
the viral coat protein molecule and the GAG chain of a proteoglycan expressed on cells27. Since
HS is found on nearly every mammalian cell, it is no surprise that viral proteins would exploit
this surface molecule for invasion into its target cell146,147. It has been reported though that the
addition of soluble GAGs such as heparin and the enzymatic removal of cell-surface GAGs
inhibits infection by various viruses such as respiratory syncytial virus and
metapneumovirus148,149. Recently, Hendricks et al have successfully placed heparin and HS-
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polysaccharides of varying sizes in liposomes that act as decoy receptors for various viruses150.
These decoys bind to viruses like their normal receptors, which gathers them away from their
actual cell-surface receptors, not allowing viral penetration into cells, inhibiting the infection in
the body. The liposome shell allowed the octasaccharide to be successfully delivered to its target
better than if there was the octasaccharide alone. Human immunodeficiency virus type-1 (HIV1) is a virus of increased interest all over the world that has shown to interact with heparin. This
virus targets cells that express a cellular receptor molecule CD4. HIV-1 binds to a loop of 20
amino acids in the first domain of CD4 by interacting with the viral surface glycoprotein
gp120151. The interaction of gp120 causes a conformational change responsible for the fusion of
virus and cell membranes. Heparin exerts anti-HIV activity by binding to the V3 loop, a major
epitope (part of antigen recognized by immune system) of gp120152,153,154. The V3 loop has an
essential role in the membrane fusion by the virus. Chemical studies have shown that Osulfation is also essential for membrane fusion. Cells lacking the CD4 receptor are still infected
by HIV-1 by its interaction with gp120 and cell surface HS155. This finding indicates that CD4
dependence by HIV-1 is cell line specific and in some cases, HS can act as another cell surface
receptor for HIV-1 to invade cells27. Heparin and HS can play another role in HIV-1 invasion.
The Tat protein is a protein that binds to cell-surface HS, which is released from cells, has
autocrine or paracrine activity, and is essential for HIV-1 replication156,157,158. This protein
primes the cells for invasion by HIV-1. This shows that heparin is a multi-protein compound
capable of affecting different aspects of the HIV-1 infection pathway. Rusnati et al has shown
exogenous heparin chains of varying sizes as an antagonistic activity toward Tat protein,
meaning heparin is capable of interfering with this deadly protein’s interaction with its cell
surface receptors as well as its biological activity159,160.
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The deadliest form of malaria is caused by Plasmodium falciparum, a protozoan parasite
that is released when female Anopheles mosquitoes bite human flesh. The sporozoites that are
released into the host travel through the cytosol of various cells before invading a hepatocyte,
liver cell. The invasion of liver cell has been attributed to the interaction of circumsporozoite
(CS) protein, 40 kDa antigen that covers the plasma membrane of invading sporozoites, with
GAG side chains of proteoglycans on the surface of the hepatocytes161. Highly sulfated HS on
the surface of liver cells is the GAG of choice and the natural receptor for binding and invasion
of CS protein. Heparin, at low concentrations, also enhanced CS binding, suggesting it acts as a
cross-linking agent capable of stabilizing multimeric CS complexes. The heparin decasaccharide
is the minimum sequence size for CS-protein-binding domain27. High concentrations of heparin
can also displace CS from the cell surface, inhibiting its invasion into hepatocytes162. Heparin
can regulate CS binding to HepG2 cells in a dose-dependent manner161. Plasmodium-infected
red blood cells (pRBCs) are the main target for antimalarial medications. One of the main
molecules that the pRBCs bind to is cell-surface GAGs, which have become major targets for
therapy. Soluble GAGs, especially heparin/HS have shown inhibitory effects against the pRBCs
and sporozoites163. The high concentrations of heparin that is needed for antimalarial activity
posed a significant problem due to the excessive intracranial bleeding164. In order to combat
these anticoagulation side effects, when heparin is covalently immobilized, by its carboxyl
groups, on substrates such as nanoparticles, its binding affinity for ATIII is greatly diminished,
leading to lower anticoagulation activity165. This immobilized heparin still showed inhibitory
effect for pRBC invasion, which could prove heparin to be a promising antimalarial medication
as well as an avenue to deliver antimalarial drugs to infected cells, without the undesirable
anticoagulant side effects166.
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1.6. Heparin Contamination
Pharmaceutical grade heparin is isolated from pig intestine, sheep intestine, and beef
lung, but the existence of mad cow disease and scrapies, has led heparin to be generally isolated
only from pig intestine today112,167. Warda et al has shown to isolate pharmaceutical grade
heparin from camel intestine that has moderately lower anti-factor Xa activity than the
commercially available heparin isolated from porcine intestine168. This animal source yielded
double the heparin per kg of tissue that commercial sources yield. The decrease in activity could
be due to the presence of small amounts of HS, so if these contaminating molecules could be
removed, greater activity could be achieved. In 2006, this same group isolated HS from camel
liver and lung, where they found that the HS from the lung had 50% the anti-factor Xa activity as
commercial heparin, which is still much higher than HS from other animal sources169. This
process is an extremely complicated one, which involves numerous enzymes and harsh
chemicals. Commercial heparin is isolated from porcine tissue in tons quantities. There are
three types of heparins that are accepted by the FDA: unfractionated heparin (UFH, MWavg
16,000 Da), low-molecular-weight heparin (LMWH, MWavg 3500-6000 Da), and fondaparinux
(MWavg 1700 Da)170. LMWH has also been introduced by controlled depolymerization and
fractionation of heparin for the use as an anticoagulant/antithrombotic agent for over 25 years.
These agents have more predictable pharmacological properties, sustained activity, and improved
bioavailability, thus replacing heparins as the anticoagulant of choice at the turn of the
millennium171,172,90. UFH and LMWH give rise to side effects of heparin-induced
thromboembolism when given in a prolonged state. Fondaparinux combats that side effect but
there is currently no antidote to counter the anticoagulant activity if hemorrhage occurs173,174.
The raw UF heparin that is isolated is ultimately purified using methods guarded by the Drug
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Master file submitted to the FDA. Heparin had been the most widely used clinical intravenous
anticoagulation agent for many years until 2008. This year brought with it adverse effects from
the use of isolated batches of unintentionally contaminated heparin, which include rash, fainting,
racing heart, and above all, hundreds of deaths worldwide175,176. During one or more of the
concealed processes of isolating heparin, other impurities were recently found in the final
product, such as DS and oversulfated chondroitin sulfate (OSCS)177. Recent files have shown
that several batches of LMWH from the same company are also contaminated with OSCS and
DS. DS is not found to contain biological activity that negatively affects the anticoagulation
activity of heparin178. Before 2008, manufacturers relied on coagulation assays for
characterization of heparin and the assessment of its purity179. The lack of effective quality tests
led to overlooking of the contaminants in the so-called pure heparin samples. OSCS, both the
isolated contaminant and synthetic molecule, activated the kinin-kallikrein pathway in human
plasma leading to the formation of bradykinin180,181. OSCS has also been shown to induce
complement protein C3a and C5a generation in the complement cascade182. The activation of
these pathways is linked to the activation of FXII183. This produces the vasoactive mediator
bradykinin and its corresponding anaphylatoxins184. The activation of all these pathways gave a
reasonable theory for why anaphylactic shock and death was seen in patients given contaminated
heparin. OSCS also binds to ATIII, but it does not, unlike heparin, induce the conformational
change of ATIII, leading to the inactivation of thrombin and FXa. FXIIa can tightly bind OSCS,
further boosting bradykinin production104 (Figure 1.3).
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Figure 1.3 – Pathways that are turned on by the presence of OSCS in contaminated heparin,
modified from Liu et al104.
Currently, synthetic and other natural methods of purifying heparin are underway, but no
effective method has been found and employed worldwide.

1.7. Heparin-Binding Proteins
More than 400 proteins interact with heparin/HS at the cell surface and in the ECM185,186. These
proteins are known as HBPs103. These proteins are involved in many biological processes,
including cell growth and development, tumor metastasis and angiogenesis, inflammation, viral
infection, and fertilization in human seminal fluid93,187,188,189. HBPs can also interact with other
GAGs, but due to heparin having the most sulfated groups and therefore highest negative charge,
the HBPs usually exhibit the highest affinity for this GAG190. Many proteins, when they bind to
heparin, undergo a conformational change, which is usually necessary for the full expression of
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biological properties of the specific protein38. HBPs mostly bind to HS instead of heparin in
most physiological events, since heparin is released from mast cells at certain inflammatory
events190. These HBPs include fibronectin, chemokines and cytokines, hepatic and lipoprotein
lipases, superoxide dismutase, antithrombin III, various growth factors, and many other less
well-known proteins191,192,193,194,195,196,197 (Table 1.2).
Heparin-Binding Protein

Physiological Role

Antithrombin III
Secretory leukocyte protease
inhibitor
C1 esterase inhibitor
Vaccinia complement protein

Coagulation cascade serpin
Inhibits elastase and cathpsin G

Binding Affinity (Kd)
range
nM
nM

Inhibits C1 esterase
nM
Protects host cell from
nM
complement
Fibroblast growth factors 1 and 2 Proliferation, differentiation,
nM
angiogenesis
Platelet factor-4
Inflammation and wound healing nM
Interleukin-8
Pro-inflammatory cytokine
µM
Stromal cell-derived factor-1α
Pro-inflammatory mediator
nM
Annexin II
Receptor for TPA and
nM
plasminogen, CMV, and
tenascin C
Apolipoprotein E
Lipid transport
nM
HIV-1 glycoprotein 120
Viral entry
nM
HIV-1 Tat protein
Transactivating factor
nM
Malaria circumsporozoite protein Sporozoite attachment to
nM
hepatocytes
Selectins
Adhesion, inflammation,
µM
metastasis
Vitronectin
Cell adhesion and migration
nM
Fibronectin
Adhesion and traction
µM
Amyloid P component
In amyloid plaque
µM
Table 1.2 – Heparin-binding proteins, their role, and binding affinity for heparin, modified from
Capila et al27. Binding study conditions are not kept constant between the proteins, so binding
affinity values are given in ranges not exact values.
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Fibroblast Growth Factors
The activity of various growth factors is regulated by their interactions with cell surface
HSPGs198,199. A specific and very well-known subgroup of HBPs is the family of FGFs. FGFs
are known for their roles in tissue repair, organogenesis, embryogenesis, cell proliferation and
differentiation, angiogenesis, and wound healing200,201,202,203. The biological activities of these
secreted growth factors are regulated by their interaction with two types of receptors on the cell
surface: high-affinity receptors (FGFRs) and low-affinity receptors (heparin and heparin-like
GAGs or HSGAGs)204. HSGAGs on the cell surface protect the FGFs from degradation and
essentially “hold” the proteins until they are released to bind to the FGFRs205. The FGF family
consists of 23 members in mammals. There are 18 mammalian FGFs (FGF-1 to FGF-10; FGF16 to FGF-23) that are grouped into six subfamilies based on differences in sequence
homology200. The six subfamilies are FGF-1 and FGF-2; FGF-3, 7, 10, and 22; FGF-4, 5, and 6;
FGF-8, 17, 18; FGF-9, 16, 20; FGF-19, 21, 23. FGFs-11, 12, 13, and 14 are considered FGF
homologous factors (FHFs) that have high sequence identity with the FGF family but do not
activate the FGF receptors206. These FHFs are not secreted and act intracellularly207. FGF-15 is
the mouse ortholog of human FGF-19. FGFs are considered paracrine factors, but it has been
recently shown that FGF-19, 21, and 23 function in an endocrine manner, dependent on the
presence of Klotho proteins, to regulate bile acid, cholesterol, glucose, vitamin D, and phosphate
homeostasis200. Most FGFs contain a signal peptide sequence for secretion through the
traditional endoplasmic reticulum-Golgi secretory pathway. FGF-1 and FGF-2 lack a signal
peptide sequence, are synthesized as cytosolic proteins and are exported from the cell by a nonclassical mechanism independent of the endoplasmic reticulum and Golgi apparatus208. Soluble
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secretory proteins, FGFs excluding FGF-1 and 2, are transported from the ER through the Golgi
apparatus to the cell surface. Luminal proteins are then released into the extracellular space by
fusion to the plasma membrane209. FGF-1 and 2 do, however, possess a nuclear localization
motif and have been found associated with the nucleus210. This non-classical release of FGF-1 is
an inherent protective mechanism developed to regulate the mitogenic potential and widespread
expression of FGF-1211.
The defining feature of the FGF family is the presence of a central core of 130 amino
acids that is highly homologous between the different family members, with 28 residues being
highly conserved. This core folds into 12 antiparallel β-strands (β1-β12) that together form a
cylindrical barrel closed by the more variable N- and C-terminal stretches212. It is known that 10
of these highly conserved amino acids interact with the fibroblast growth factor receptors
(FGFRs) to form functional receptor dimers213. The heparin-binding region (HBR) within the
core is composed of the β1-β2 loop and some of the region spanning β10 and β12200. The amino
acid sequence of FGF-1 can be seen below, with the HBR in bold (received from
www.uniprot.org).

MAEGEITTFTALTEKFNLPPGNYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQ
LSAESVGEVYIKSTETGQYLAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAE
KNWFVGLKKNGSCKRGPRTHYGQKAILFLPLPVSSD

The HBS of FGF-1 as well as many other HBPs have been focused on in detail for scientists to
fully understand the interaction of heparin with these proteins.
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Unlike FGF-1 that is the universal ligand and can bind to all the FGFRs, most of the
FGFs require binding to their specific receptors214. These FGFRs are members of the receptor
tyrosine kinase family (RTK). This family has 58 members and is divided into 20 subfamilies in
humans201. All members have the common overall structural composition of an extracellular
ligand-binding region, a single-pass transmembrane domain, and an intracellular tyrosine kinase
domain215. Growth factor binding to the ligand-binding region induces RTK activation and the
initiation of the intracellular signaling cascades that control vital cellular processes201. RTKs
play an important role in maintaining tissue homeostasis during the development and adult life of
organisms216,207. The extracellular domain consists of three immunoglobulin-like (Ig-like)
domains termed D1-D3 and an acidic serine-rich region between D1 and D2, termed the acid box
(Hung). The D1 domain, together with the acid box, is thought to play a role in receptor autoinhibition, whereas D2 and D3 domains constitute the FGF ligand binding site217. Eswarakumar
and coworkers have proposed that an autoinhibition “closed” conformation of FGFR exists in
equilibrium with an active “open” state ready for dimerization and autophosphorylation218. The
D3 domain dictates the specificity of ligand binding, and D2 domain contains the primary sites
of binding for both the ligand and heparin219. The D1 domain can fold back and interact with D2
in the FGF and HS binding site, functioning as a competitive auto-inhibitor in the interaction of
FGFR with FGF and HS41. In FGFR1-3, alternative splicing in D3 domain creates isoforms with
different ligand-binding specificities220. The most common variant involves an alternate exon in
the second half of the D3 domain, giving rise to the b and c isoforms221,222. The FGFR IIIb
isoforms are predominantly epithelial, and the IIIc isoforms are predominantly
mesenchymal223,224.
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FGF-FGFR Signaling
FGF-FGFR binding specificity is essential for the regulation of FGF signaling and
depends on the primary sequence differences in the 18 FGFs and 7 FGFRs105. FGF interacts
extensively with D2, D3, and the linker between the two domains within one receptor225. This
constitutes the primary binding site. Receptor signaling and stabilization of the resulting dimer
requires the presence of highly sulfated heparin/HS polysaccharide chains of HSPGs to stabilize
the FGF/FGFR/HS assembly226. HSPG consists of a proteoglycan core that binds two or three
linear polysaccharides (heparan sulfate chains). Heparin/HS binds to a positively charged cluster
of Lys and Arg residues extending across the D2 domains of the two receptors and the bound
FGF molecules215. HSPGs protect the FGF ligands from degradation as well as mediate the
complex formation between FGF and FGFR227,228. FGFs have a high affinity for HS/heparin
with dissociation constants in the nanomolar range. The binding of FGFs to FGFRs causes the
dimerization of the ternary complex of FGF-FGFR-HS229,230. The dimer is stabilized by
interactions between FGF and D2 at the secondary binding site in a second receptor. The two
FGFs in the 2:2 FGF:FGFR complex surprisingly do not make any contact with one another231.
There are two main binding models for heparin: 1) HS/heparin binds first to FGF then to FGFR;
2) HS has to bind to FGF-FGFR complex in order for signaling to occur232,225. In these
experiments, the affinity for HS/heparin of the FGF-FGFR complex is higher than that of a
monomer or dimer of FGF alone, suggesting HS binds to the FGF-FGFR complex first188. The
ternary complex formation causes receptor dimerization and autophosphorylation of specific
cytoplasmic tyrosine residues and activation of downstream signaling processes233,234. Seven
phosphorylation sites have been identified in FGFR1 (Tyr463, Tyr583, Tyr585, Tyr653, Tyr654,
Tyr730, and Tyr766)235,236. The activated receptor recruits target proteins from the signaling

27

cascade to its cytoplasmic tail and activates them by phosphorylation213. The activation of the
receptor initiates transduction via three major intracellular pathways: classic mitogen-activated
protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), phospholipase Cγ (PLCγ)
activation237. The latter two pathways are capable of activating protein kinase C (PKC) and in
turn stimulating Erk 1/2 signaling226. The FGF/HSPG interaction modulates angiogenesis by the
direct activation of PIP2 and PKC-α that eventually leads to activation of MAPKs110.
Tight regulation of FGFR activation can be achieved either at the level of extracellular
signaling complex assembly or intracellular signaling network226. Some examples of
extracellular regulatory inputs are the (i) extracellular receptor modulators, such as neural cell
adhesion molecule involved in neuronal migration and axon growth, L1, cadherin, and
neurofascin, and (ii) receptor auto-inhibitory properties238,239. One example of intracellular
regulation involves the Sprouty (Spry) protein and MAPK phosphatase family working as
negative modulators of FGF signaling through the reduction of downstream signaling240. FGF
signaling activates Spry proteins, which can then in turn inhibit FGF stimulation of the MAPK
pathway by interacting with growth factor receptor bound protein 2, SOS1 or RAF1, preventing
their binding to FRS2241,242. Spry acts as an inhibitor in a classical negative feedback loop243.
Besides the classical signaling pathways, other genes can negatively or positively regulate the
signaling of FGFs. For example, Sef interacts with FGFRs and prevents FRS2 phosphorylation
or blocks FGF signaling downstream of MAPK/ERK (extracellular-signal-regulated kinase)
kinase244,245. XFLRT3, whose expression is regulated by FGFs, is a novel transmembrane
component of the FGF signaling pathway that promotes FGF signaling through the MAPK
pathway246.
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Cytokines and Inflammation
It is necessary for immune cells to migrate and interact with each other for infections to
be fought in the immune system. Chemotactic cytokines (chemokines) are mediators of this
migration247. The main activity of chemokines in inflammation is their recruitment and
activation of leukocytes248. Like most heparin-binding proteins, these proteins bind to and
activate their cell-surface receptors, members of the G-protein-coupled receptor superfamily249.
Endothelial heparan sulfate is binds chemokines and translocates them to the surface of the
endothelium during the inflammatory process250. The binding of chemokines to heparin/HS is
thought to be the key for regulation and modulation of chemokine activity251. Once HS
immobilizes chemokines on the cell surface, leukocytes are then directed to the site of
inflammation252. A conserved stretch of residues has been observed in chemokines to be
responsible for GAG binding ability that is similar to the binding region of other HBPs.

1.8. Heparin-Binding Region of Heparin-Binding Proteins
The heparin-binding region of each of these proteins is hypothesized to be similar to that
of FGF-1, with positive residues adding to the electrostatic interactions with heparin/HS. The
first study looking at requirements for GAG-protein interactions was performed by Cardin and
Weintraub in 1989, when they compared the heparin-binding regions of four proteins:
apolipoprotein B, apolipoprotein E, vitronectin, and platelet factor 4253. This study showed that
the domains of these proteins contained a conversed sequence of XBBXBX and XBBBXXBX
(B is basic residue and X is neutral and hydrophobic residue)253. Molecular modeling results
suggested that if the XBBXBX sequence was in the β-strand conformation, the basic amino acid
residues would be aligned on one face of the strand and the hydrophobic residues would face the
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inner core of the protein. If the XBBBXXBX sequence would fold into a α-helix, the basic
residues would face one side of the helix with the other residues facing inside the core of the
protein again (Figure 1.4).

Figure 1.4 – Helical model of a XBBBXXBX motif built using the software package SYBYL
version 6.3, reproduced from Capila et al27, with permission from Angew. Chem. Int. Ed.
Sobel and co-workers used these findings to propose a new signature sequence,
XBBBXXBBBXXBBX, found in another HBP, the von Willebrand factor 254. This consensus
sequence was, however, found in every other HBP.
Spatial orientation, rather than sequence proximity, of the basic residues in signature
sequences in a protein is a major factor in determining the binding affinity of the protein to
heparin. Margalit and co-workers showed using molecular modeling techniques that a distance
of approximately 20 Å between basic amino acids is important for heparin binding255. The FGF
heparin-binding site contains a peptide backbone that loops back upon itself; three turns are
present in the loop256. This domain is described as a triangle. By looking at the structures of
FGF-1, FGF-2, and transforming growth factor β-1 (TGF β-1), a new motif was implicated:
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TXXBXXTBXXXTBB, where B is basic residue, T is a turn, and X is hydropathic residue254
(Figure 1.5).

Figure 1.5 – Turn-rich heparin-binding region in FGF-1 and FGF-2, reproduced with permission
from Capila et al27, with permission from Angew. Chem. Int. Ed.
A cyclic peptide that was designed to resemble the heparin-binding region in the real structures
of the proteins, bound more tightly to HS than the acyclic peptide of the same sequence, proving
the spatial arrangement of the basic residues is more important for better access and binding to
heparin/HS257. Capila and Linhardt looked at various libraries of a wide array of peptides and
chains of HS and heparin, and concluded that sequences rich in lysine and arginine, but not
histidine residues bound more tightly to HS/heparin27. Peptides with high affinity for HS/heparin
were rich in polar amino acids including serine258. It was also observed that known heparinbinding regions contain amino acids (glutamine and asparagine) capable of hydrogen bonding27.
Arginine binds 2.5 times more strongly than lysine257. This tight interaction of arginine results
from strong hydrogen bonding between the guanidinio group in arginine and a sulfo group in
heparin259. Bae and coworkers suggested the importance of a tyrosine residue in a synthetic
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ATIII peptide. This residue had a specific, hydrophobic interaction with the N-acetyl group in
heparin’s ATIII pentasaccharide sequence260. A single, isolated basic amino acid is commonly
found in a heparin-binding site, followed by clusters of two and three basic amino acids256,257.
Another commonality in heparin-binding sites is a single nonbasic amino acid between basic
amino acid clusters256. Although various consensus sequences in HBPs have been found, HBPs
bind to different sulfo groups in various conformations and orientations in HS and heparin,
adding another aspect to the mix of finding a perfect sequence to bind tightly to heparin.
Hileman and coworkers used all of these experimental data of synthetic peptides to develop a
new type of heparin-binding site having the following characteristics: 1) The peptide backbone
that turns back upon itself to form a cup of positive charge to interact with the negatively
charged GAG. The majority of the interacting amino acids are contained in this contiguous
region with a consensus sequence of TXXBXXTBXXXTBB; 2) Proper spacing and patterns of
basic residues partially determine affinity and specificity for GAG interaction; 3) Arginine
residues promote tighter interaction of these sites for GAGs than lysine residues. The correct
ratio of these two residues defines affinity of the site for GAGs; 4) Other polar amino acids
distributed throughout the site, in part, define the specificity and affinity for GAGs256.

1.9. Recombinant DNA Cloning and Protein Expression
The biomedical field today is largely controlled by the production of pure proteins that
have been expressed using optimized systems. There is greater need year by year for pure
proteins that can be used to test pharmaceutical drugs on before they are tested on human beings.
Pure recombinant proteins can be obtained from the use of bacterial systems, such as Escherichia
coli (E. coli), due to the ease and low cost of growth261,262. Before the protein can be isolated,
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the DNA must first be inserted into the cell of choice. Molecular cloning is the insertion of a
foreign DNA fragment into the replicating DNA of another type of cell (usually E. coli) through
the use of a vector263. The essential feature of a vector is that it can replicate autonomously in
the appropriate host32. Plasmids and bacteriophage lambda (λ phage) are choice vectors for
cloning in E. coli. Plasmids are self-replicating, extrachromosomal, closed circular, doublestranded DNA molecules that occur naturally in some bacteria. They range in size from two to
several hundred kilobases. Plasmids carry genes for antibiotic inactivation, production of toxins,
and the breakdown of natural products32. The lambda phage, a virus, can either destroy or
become part of its host264. In the lytic pathway, viral DNA and proteins are produced and
packaged into virus particles (virions), leading to host cell lysis32. In the lysogenic pathway, the
phage DNA becomes integrated into the host genome and can be replicated together for many
generations, remaining inactive265. Certain environmental factors can lead to the activation of
the phage DNA, leading to lysis of the host cell. This vector can accept larger DNA fragments
of eukaryotic DNA than a plasmid can. Yeast artificial chromosomes (YACs) and bacterial
artificial chromosomes (BACs) can hold much larger pieces of DNA. BACs can include inserts
as large as 300 kb, which means they can hold the entire genomic locus of most mammalian
genes266,267. YACs contain a centromere, an autonomously replicating sequence (ARS), a pair of
telomeres, selectable marker genes, and a cloning site32. They can hold megabase-sized genomic
inserts268. YACs are then cloned into yeast cells as the name implies. Using these vectors,
foreign DNA can be replicated into other host cells, which ultimately leads to the production of
the desired product, recombinant proteins.
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The main goal of recombinant protein expression is often to obtain a high accumulation
of soluble product in the bacterial cell269. Various strains of E. coli have remained the best
organisms to use for cloning techniques due its lack of restriction endonucleases that usually
degrade foreign DNA. It remains one of the most attractive systems for heterologous protein
production because of its ability to grow on inexpensive carbon sources, its well-characterized
genetics, and availability of increasingly large numbers of cloning vectors and mutant host
strains270,271,272. The most common strain of E. coli is BL21 because it is able to grow in
minimal media but is non-pathogenic and does not cause disease in host tissues273. This strain is
also chosen because it is deficient in both lon and ompT proteases, which interfere with protein
isolation downstream274.
The common metabolic response in some bacterial strains trying to express recombinant
proteins is the accumulation of target proteins into insoluble aggregates known as inclusion
bodies because the accumulation of target proteins may not be accepted by the host’s
metabolism275,276. The protein expression commonly saturates the cell folding machinery,
leading to formation of aggregates277,278. These entities were previously thought to be fully
misfolded and thus biologically inactive269. Recently, it has been shown that inclusion bodies
have intermolecular β-sheet secondary structure, which goes against the previous notion that they
are devoid of any molecular structure279. These partially folded molecules associate mainly by
hydrophobic interactions280. Cytoplasmic proteins fold spontaneously under normal conditions,
but aggregation prone proteins require the existence of molecular chaperones to prevent
misfolding281. Molecular chaperones interact with the polypeptide chain to prevent aggregation
during the folding process282. Aggregation could result from either a large increase in
concentration of folding intermediates coming from the ribosome or inefficient processing by
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molecular chaperones283,284. Depending on the aggregation properties of proteins, different types
of inclusion bodies can occur in E. coli285.
Additional difficulties encountered in E. coli include degradation of the protein, toxicity,
and production of nonfunctional protein, which generally occurs due to lack of correct eukaryotic
post-translational modification286. If protein exists in inclusion bodies, strong denaturants may
be used such as guanidine hydrochloride or urea in order to solubilize the protein for further
purification steps. Urea has advantages over the more harsh denaturant because of its low costs
and its ability to be used in sodium dodecylsulfate polyacrylamide gel electrophoresis (SDSPAGE) unlike guanidine hydrochloride that precipitates in the presence of SDS287. The use of
mild solubilization agents, not just high concentrations of denaturants, also helps to solubilize
aggregates without disturbing the secondary structures of the proteins288,289,290,291. Purification of
proteins in inclusion bodies has been optimized that greater than 90% purity has been
obtained292,293. These findings prove the existence of inclusion bodies is not as devastating as
previous scientists had believed. After purification, the corresponding denaturant can be
removed by dialysis and other methods in order to obtain pure refolded protein294.
Several techniques have been proposed to improve the solubility or folding of
recombinant proteins in E. coli295. These include co-expression of chaperone proteins, lowering
incubation temperature, use of weak promoters, use of richer media with phosphate buffer such
as terrific broth (TB), and the use of fusion tags to aid in the expression and purification
process296,297,298,299. The activity and expression of a number of E. coli chaperones increase at
30oC, as reported by Sorensen and Mortensen269. Co-overexpression of molecular chaperones
such as DnaK-DnaJ-GrpE and GroEL-GroES systems have proved efficient in soluble
expression and decreasing the existence of proteins in inclusion bodies300. The partial
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elimination of heat shock proteases induced under normal conditions is also a direct result of
temperature reduction301. The promoters used for transcription of heterologous genes have
remained in the lac operon family (lac-derived regulatory elements). The lac promoter and its
relative, lacUV5, are relatively weak, and are therefore seldom used for high-level production of
recombinant proteins270. They can, however, be used for expression of helper or toxic proteins,
provided that lacY mutant hosts are used and that the induction is performed with the nonhydrolyzable lactose analog, isopropyl-β-D-1-thiogalactopyranoside (IPTG)302,303. The synthetic
tac and trc promoters consist of the -35 region of the trp promoter and the -10 region of the lac
promoter. These promoters are quite strong and commonly allow the accumulation of
polypeptides to 30% of the total cell protein270. Bacterial growth and expression is controlled by
the lac operon. When enough lactose is added to the cell, it binds to repressor proteins and
causes the induction of the transcription of permease and β-galactosidase because the repressor
can no longer bind to operator DNA304. Researchers have removed these two genes and have
placed their gene of interest in their place. When lactose, or its analog IPTG, is added, the gene
of interest is produced through induction, instead of permease and β-galactosidase.
Certain fusion proteins have been constructed and expressed in E. coli for use in
purification techniques as well as better solubility of proteins in expression systems. These
proteins or tags improve the solubility of partner proteins that would otherwise form inclusion
bodies in the cytoplasm during expression. Commercially available fusion partners include
glutathione-S-transferase (GST), maltose-binding protein (MBP), thioredoxin, or poly-Histidine
tag (His-tag)305. Improved folding of passenger proteins is most likely obtained by the fusion
partner efficiently reaching its native conformation as it exits the ribosome, and promotes the
correct structure in downstream folding units by favoring on-pathway isomerization reactions270.
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For example, unfused MBP requires molecular chaperones such as DnaK-DnaJ-GrpE and
GroEL-GroES, which might recruit these molecules to the partner protein during the folding
process270. It has also been proposed that MBP might actually act as an “intramolecular
chaperone” to assist in the correct folding of the fused protein by being in close proximity during
the process306. Thioredoxins are universal oxido-reductases that reduce disulfide bonds through
thio-disulfide exchange307. TrxA is an 11.6kDa thioredoxin found in E. coli that demonstrates
high solubility in the crystallization of proteins and is used to increase expression of recombinant
proteins308. Small ubiquitin-like modifier (SUMO), when used as an N-terminal carrier protein
promotes folding, enhances solubility during expression, and structural stability during protein
expression309,310,311. In its native system, Smt3, a form of post-translational modification, plays
roles in apoptosis, nuclear-cytosolic transport, and protein activation312,313,314. These “solubility
increasers” are very useful tags during bacterial expression of recombinant proteins, but various
tags have also been developed to aid in the purification of the expressed proteins. Some tags,
like GST and MBP, have dual roles in expression and purification.

1.10. Chromatography for Protein Purification
After the fusion protein is expressed at high yield, it needs to be removed from the
millions of other proteins that are contained in the bacterial cell. The general order of obtaining
a protein of interest includes overexpression using solubility tag, lysis of the bacterial cells to
bring the proteins into the aqueous phase, and removal of contaminating proteins from the target
protein using column chromatography. This purification method employs chromatography
techniques that separate the proteins based on various characteristics. The most well-known
techniques include size-exclusion, affinity, and ion exchange, with some proteins requiring the
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mixture of two or more of these chromatography methods315. Proteins that are eluted can be
traced using UV-vis spectroscopy attached to the chromatography apparatus because most
proteins contain at least one tryptophan that absorbs light at 280 nm. Once fractions containing
eluted protein are collected, visualization of distinct proteins occurs using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie Blue staining to
determine purity of protein samples.

Ion-Exchange Chromatography
In this technique, proteins interact with charged molecules, either positive or negative,
that are bound to a stationary phase by electrostatic interactions316. The main advantage of this
technique is that it maintains the biological activity of the purified protein317. Ligand density has
a profound effect on protein binding behavior and purification efficiency, as seen in various
experiments performed318,319,320. In general, the greater ligand density, the greater binding
capacity occurred for a protein. For high ligand densities, physical characteristics of the adsorber
such as particle and pore diameter and available adsorber area, also affect elution behavior321.
This purification mode is often used as a final step of removing any last-minute contaminants
after other purification steps have been performed315.

Size-Exclusion Chromatography (SEC)
This type of chromatography that is also known as gel filtration chromatography, was
first shown in 1955 to be efficient for the separation of biomolecules, in particular the separation
of peptides from amino acids and proteins322,323. Using SEC has allowed the determination of
the molecular weight of an unknown analyte, based on a calibration curve of known
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analytes324,325. The pore size on the resin is what restricts molecules, depending on their sizes
from entering the pores. Larger molecules (larger Stokes radius) do not gain access into the
pores, so they elute first. The elution of next largest molecules occurs until the smallest ones
come out last326. A setback of SEC is that proteins vary in shape, so their Stokes radii do not
match up exactly with its actual molecular weight. This usually results in proteins of varying
shape and size actually coeluting, which gives rise to the incorrect molecular weight
estimation327. The average molecular weight of heparin has been studied using various
standards, but the mobile phase conditions affected the analysis of its accurate molecular
weight328. Even though the overall rate of SEC is fast, the desire of any scientist is for improved
resolution and separation of biomolecules. This improvement comes with decreased flow rate,
which in turn increases the analysis times for SEC. This was demonstrated by Ricker and
Sandoval, as better resolution of bovine serum albumin and ovalbumin was observed with
decreased flow rate329. SEC has become the standard for monitoring protein aggregation and
quaternary structure in the biopharmaceutical industry330,331. SEC is also used as a polishing step
for protein purification in industry, where aggregate impurities could not be removed using
previous chromatographic processes332.

Affinity Chromatography
One of the most popular methods of purification is the expression of various proteins
attached to affinity tags, which allows for a one-step purification process of proteins obtained at
high purity333,334. Yields over 90% with reduced steps are observed in affinity
chromatography335. The column consists of beads containing a material or ligand that has a high
binding affinity to a protein or small molecule. The protein of interest is attached to a peptide or
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large protein that binds in a specific fashion to an immobilized ligand that other proteins do not
have affinity for, in a fashion close to antibody-antigen interaction333. Advantages of adding an
affinity tag to a target protein include improved yield and solubility, increased sensitivity of
binding assays, and improved antigenicity336,337,338,339. Some disadvantages exist, however,
including biological activity being altered340. A few examples of affinity chromatography
partners include heparin/HBPs, glutathione/GST, nickel/His-tag.
The ligand that is trapped on the column for purifying proteins using affinity tags is of
great importance when determining what tag to use. There are many different affinity column
materials available but the most well-known include heparin-Sepharose, glutathione-Sepharose,
nickel-Sepharose, to name a few. Electrostatic interactions, as well as hydrogen bonding, are the
governing forces for the binding of proteins or affinity tags to heparin-Sepharose, with protein
eluting using varying salt conditions341,342. Due to its high negative character, heparin can also
be used as an ion exchanger315. Just like the other chromatography techniques, this method can
be used in tandem with other techniques for protein purification343,344,203.

1.11. Affinity Tags
These affinity tags used as fusion partners for target proteins are efficient tools for their
purification from crude extracts334. The affinity tags can be small peptides made up of varying
or repeating amino acids such as His-tag, or they can be larger proteins such as GST and MBP.
Whatever the tag composition is, the ultimate goal in designing or choosing a suitable fusion
partner for proteins is the purification technique of choice. A benefit of affinity tags is their
ability to hundred- or thousand-fold purification without prior steps to remove cellular
material345. The affinity-tag systems, when vying for the researchers’ attention, should share
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similar features, such as minimal steps of purification, minimal effect on the tertiary structure
and activity of proteins, specific and easy removal of tag to produce native protein, accurate
assay of the recombinant protein during purification, and versatility to different proteins346,347.
The tags used to increase solubility of proteins during expression include GST, MBP, NusA,
thioredoxin, and SUMO. The tags used solely for affinity purification include His-tag, FLAG,
Strep II, calmodulin-binding peptide (CBP), and chitin-binding domain. For well-expressed
soluble proteins, an affinity tag alone is sufficient for expression and subsequent purification348.
For poorly soluble proteins that are difficult to express, a solubility and affinity tag might be
needed. In order to increase the versatility of the tags with respect to solubility and affinity roles,
dual-tagging methods have been applied to various proteins348. Tags, such as GST and MBP,
have dual roles in expression and purification and have become a highly chosen affinity tag in
laboratories today.
The GST tag was first described in 1988 by Smith and Johnson as a 26kDa GST of
Schistoma japonicum cloned in an E. coli expression vector349. In the majority of the cases, the
fusion proteins are soluble in aqueous solutions and form dimers346. This tag helps protect
against intracellular protease cleavage and stabilize the fusion partner 350,351. GST fusion proteins
can be purified on glutathione (γ-glutamylcysteinylglycine)-Sepharose. The resin is affected by
γ-glutamyl transpeptidase activity in crude cell lysates352. This means that the glutathione resin
can only be used up to twenty times. An advantage of glutathione purification is that proteolytic
cleavage can be performed while the fusion protein is still bound to the column, which allows
fewer steps in the purification process. Glutathione chromatography depends on the proper
three-dimensional folding of GST, so insoluble fusion proteins must be refolded and the buffer
exchanged before purification is performed353. Using a GST tag allows high levels of expression
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of the fusion protein in E. coli (10-50 mg/liter culture)354. A major drawback to using GSTtagged proteins is seen in its slow binding kinetics to glutathione-Sepharose, making purification
of large cell culture volumes extremely time consuming355. The next fairly large protein
molecule used an affinity tag is the 42kDa MBP encoded by malE gene of E. coli K12356.
Vectors that facilitate the expression and purification of foreign peptides or proteins in E. coli by
MBP tags were first described in 1988 by Di Guan and coworkers357. MBP-tagged proteins bind
to immobilized amylose and are released by 10 mM maltose. This one-step purification process
using MBP tags can lead to a fusion protein of 70-90% purity358. MBP-tagged proteins have
typical yields of 10-40 mg/liter of culture359. The large size of this tag, however, may result in
aggregation of the target protein after cleavage occurs360. Another disadvantage when compared
with GST tags is that target proteins cannot be proteolytically cleaved from MBP while still
bound to the amylose resin359. The MBP tag expression system is widely used in combination
with a poly-His tag for better purification361.
Very small peptide tags are valued in purification processes due to their ability to not
interfere with the biological and structural properties of the fused protein. These small tags
include poly-arginine, FLAG, His-tag, Strep II, c-myc, and S tags, which, since so small, may
not have to be removed following purification333. The poly-arginine tag was first described in
1984 by Sassenfeld and Brewer, which consists of five or six arginine residues362. These tagged
proteins can be purified by cation exchange resin SP-Sephadex. Proteins elute at a linear sodium
chloride gradient at alkaline pH346. The downfall of using a poly-arginine tag is that proteins
also contain arginine residues, which could then affect the binding capability of the fusion
protein containing this tag363. The next small peptide tag is a commonly used affinity tag known
as His-tag, which consists of roughly six histidine residues that binds to small molecules
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immobilized on a column. The process of purifying proteins with His-tags is known as
immobilized metal-affinity chromatography (IMAC), which was described in 1975 by Porath
and coworkers364. This purification technique is based on the interaction between a transition
metal ion (Co2+, Ni2+, Cu2+, Zn2+, and recently, Fe3+) immobilized on a matrix and specific amino
acid side chains (accessible His, Ser, Cys, Glu, and Asp residues)365, 366. The electron donor
atoms in chelating compounds of the chromatographic support (histidine imidazole ring) are able
to coordinate metal ions and form metal chelates, which can be bidentate, tridentate, etc,
depending on the number of occupied coordination bonds367. In one instance, His-tag showed to
improve cell growth rates and protein expression levels in cells containing His-fusion proteins368.
Also being a short sequence, these tags do not add a significant metabolic load to the protein
expression and can easily be incorporated to the protein by simple genetic engineering at the
upstream level369. Advantages of IMAC include stability of metal chelates over a wide range of
buffer conditions and temperatures, ability to exist in denaturing conditions and high protein
loading capacities370,367. IMAC is also the leading method for purification of denatured
proteins287. Disadvantages of the His-tag include metal leaching that contaminates the protein,
adsorbent binding to other native histidine or amino acid patches resulting in low selectivity or
coelution, and altered biological and physiochemical properties of the target protein371,372,373,374.
The FLAG peptides are epitope tags, which bind to immobilized monoclonal antibodies,
such as M1375,376,377. These FLAG-tags can be located at the N- or C-terminal of a fusion
protein. The eight-residue Strep II tag binds reversibly to a modified biotin-binding pocket of
the engineered streptavidin called Strep-Tactin378. It can be released using a biotin analog, in the
absence of metal ions during purification379. This tag is proteolytically stable, biologically inert,
and can be engineered at either terminus of a protein380. The murine anti-c-myc antibody 9E10
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was developed in 1985 by Evan and coworkers, and is used as an immunochemical reagent
today381. C-myc tag is an antibody epitope tag of 11 amino acids that can be placed at either end
of the desire protein382. Tagged proteins of this nature can be purified by coupling mAB 9E10 to
divinyl sulphone-activated agarose346. This tag is commonly used to monitor expression of
proteins in a wide array of cell hosts383,384,385,386. The S-tag is a soluble 15 amino acid tag that
interacts strongly with the 103 amino-acid S-protein, both derived from RNaseA387,388.
There are, however, many other types of affinity tags that are used today but not to the
degree of His-tag, GST, and MBP tags. The CBP tag was first described in 1992 by StofkoHahn and coworkers as a 26-amino acid tag derived from the C-terminus of skeletal muscle
myosin light-chain kinase389. The CBP tag forms an α-helix, which is engulfed by the EF-hand
motif of calmodulin390. This system has high specificity to purify recombinant proteins in E.
coli because there are no endogenous proteins that interact with calmodulin in this bacterium346.
CBP-tagged proteins are released from calmodulin resin by EDTA, which chelates the calcium
ions necessary for proper folding of the EF-hand motif390. The N-terminal location may reduce
the efficiency of translation, whereas the C-terminal location can result in high expression
levels391. A novel and very innovative tag has been designed called intein-chitin binding domain
tag. This tag is the combination of a protein self-splicing element (intein, intervening proteins)
and chitin-binding domain359. The yield using this tag is roughly 0.5 to 5 mg cleaved
protein/liter bacterial culture345. Use of this affinity tag is not recommended in eukaryotic cells
because endogenous proteins can interfere with the binding affinity based on calcium392.
In the industrial and commercial aspect of choosing a good affinity tag for purification,
one must consider the ultimate desired outcome. Experiments requiring large amounts of
partially purified material in high yields at low cost may find His and GST tags attractive, but for
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small amounts of highest purity, FLAG and HPC tags might outweigh their costs and limited
capacity345. Short peptides have gained the spotlight as excellent ligands for affinity
chromatography393. Peptide ligands are much more physically and chemically stable than
antibody ligands and are more resistant to proteolytic cleavage394,395. These peptides can also be
easily modified to aid in protein elution under mild conditions. Peptides can be readily
synthesized using already established methods at lower cost396. Immobilization of these peptides
onto a resin can be achieved, and the designed matrices are more durable during protein elution
than the protein-based affinity chromatography397. Lastly, during protein expression, these
affinity peptides have low toxicity and generate low immune responses in the event of cell
leakage as compared with proteins and transition metal ligands394. No matter what affinity tag is
used, there are always advantages and disadvantages to every one (Table 1.3).
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Affinity Tag
His-tag

Size
(amino
acids)
5-15

GST

201

MBP

396

Thioredoxin

109

Advantages

Disadvantages

Low metabolic burden, inexpensive,
mild elution conditions, works under
native and denaturing conditions
Efficient translation initiation,
inexpensive, mild elution conditions
Efficient translation initiation,
inexpensive, mild elution conditions
Efficient translation initiation,
enhances solubility

Specificity of IMAC is
low
High metabolic burden,
homodimeric protein
High metabolic burden

Except few derivatives
of thioredoxin like Hispatch thioredoxin, it
does not act as affinity
tag
FLAG
8
Low metabolic burden, high specificity Expensive, harsh
elution conditions
S-tag
15
Low metabolic burden, high specificity Expensive, harsh
elution conditions, does
not enhance solubility
CBP
27
Low metabolic burden, high specificity Expensive, does not
enhance solubility
STREP II
8
Low metabolic burden, high specificity Expensive, does not
enhance solubility
BAP
51
Low metabolic burden
Expensive, does not
enhance solubility
CBD
15
No exogenous proteolytic cleavage is
Does not enhance
needed
solubility
Table 1.3 – Well-known affinity tags, their sizes, advantages, and disadvantages, modified from
Mondal et al398.
Also, various tags can be used in combination on target proteins to increase solubility and
yield399.

Cleavage of Affinity Tags
Ultimately, the native pure protein is desired after affinity chromatography is performed,
which requires the removal of the affinity tag. This process is performed by enzymatic or
chemical cleavage at the junction between the tag and the protein of interest335,400. The most
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common form of cleavage today is performed enzymatically by proteases, such as thrombin,
factor Xa, enterokinase, and tobacco etch virus (TEV) protease401,402,403,404. The chemicals most
commonly used for cleavage are cyanogen bromide (CNBr), formic acid, and hydroxylamine348.
Enzymatic cleavage is more specific and milder than chemical cleavage348. Thrombin, 37 kDa,
is the most well-known endopeptidase and recognizes the specific sequence of Leu-Val-Pro-ArgGly-Ser, where it breaks Arg and Gly bond405. Thrombin is preferred due to its low cost and
optimal physiological pH range of 6-8406. The proteases have their own cleavage site that they
recognize: thrombin (LVPR/GS), factor Xa (IEGR/), enterokinase (DDDDK/), TEV
(ENLYFQ/G)305. Various reviews go into more detail on each protease405,333,407. The downfall
of these endopeptidases, with the exception of TEV protease, is their ability to cleave at sites
other than their intended specific cleavage site408,409,410. Viral proteases like TEV protease have
more specificity for their cleavage sites, which makes TEV protease a solid choice for cleaving
affinity tags from target proteins411.

1.12. Detection of Proteins by Immunoblotting
Preparation of antibodies to detect specific proteins is an ongoing need in molecular
biology412. Immunoblotting, also known as Western blotting, originated from the other blotting
techniques, Southern for DNA and Northern for RNA413,414. WB is a diagnostic tool today for
HIV, Lyme disease, and hepatitis B415. Towbin et al established a method of transferring
proteins from polyacrylamide-urea gel onto a nitrocellulose membrane in 1979, but in 1981,
Burnette introduced adaptations to this existing method to coin the new optimized method as
Western blotting, in honor of the Southern blotting that already existed416,417,418. This Western
blotting allows proteins to be transferred from SDS-PAGE gels to nitrocellulose membranes,
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since most protein analyses are run on these types of gels not polyacrylamide-urea gels417. WB
has multiple advantages that include proteins of low abundance can be detected, small amount of
chemicals required for transfer, proteins on the membrane are easily accessible to various
ligands, and many more419,420,421. Electroblotting is the most commonly used technique for
transfer of proteins onto the membrane because it is fast and complete compared to conventional
ones (diffusion and vacuum). After transfer has occurred milk is used to block unoccupied sites
on the membrane422. After transfer has occurred, primary antibody grown against a specific
peptide sequence is then incubated with the membrane-bound proteins. After this, horseradish
peroxidase- or alkaline phosphatase-conjugated secondary antibody, grown against the primary
antibody, is incubated as well with multiple washing steps in between. These washing steps
remove any unwanted nonspecific antibody-antigen or even antibody-membrane interactions.
Most commonly, a substrate composed of nitro-blue tetrazolium (NBT) and 5-bromo-4-chloro3'-indolyphosphate (BCIP) is added after the secondary antibody is incubated, which when
reacted with the alkaline phosphatase, it creates a purple-black precipitate. Since the secondary
antibody should only attach to the primary antibody, only the protein of interest that the primary
antibody was raised against should make a colored precipitate. It has been shown that to reach a
higher sensitivity of detection, heat treatment of the nitrocellulose membrane after blotting can
be performed423. This method is very effective for detection of protein of interest with high
specificity when performed correctly, with the only major drawback of it being a qualitative not
quantitative measurement. Antibodies can also be immobilized on a matrix for the purification
of proteins by immunoaffinity chromatography424.
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Chapter 2
Use of Heparin-Binding Affinity Tag for Protein Purification
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2.1. Abstract
Recombinant proteins are useful in a variety of settings in biotechnology. These proteins
need to be purified to homogeneity, however, before they can be used for further experiments.
Affinity tags have become common avenues for protein purification. Several affinity tags
available today include GST, His-tag, MBP, and several others. Despite being commonly used,
they have multiple downfalls that include their bulky size interfering with target protein structure
and folding, aggregation, and expensive and harsh conditions needed for purification. We have
designed a 34-amino acid residue heparin-binding (HB) peptide based on structural features from
the heparin-binding region of various HBPs, which are known to naturally bind to heparin. HBpeptide has good binding affinity for heparin and HS in a two-site binding model (Kd in high nM
to low µM for both GAGs). In the presence of heparin or its analog SOS, HB-peptide gains
helical secondary structure from a random coil structure, does not undergo an extreme change in
its tertiary structure, but is perturbed in its overall backbone conformation. This peptide has also
successfully been exploited as an affinity tag for the expression and purification of three different
non-heparin-binding proteins (C2A, CAlb3, and S100A13). Using a step-wise NaCl gradient on
heparin-Sepharose, the fusion proteins were purified to homogeneity (HB-C2A elutes at 500 mM
NaCl, and HB-CAlb3 and HB-S100A13 elutes at 1 M NaCl). These mild conditions using
various pH and buffers allowed for successful purification of these fusion proteins. Following
purification, enzymatic cleavage was successful for all three proteins using thrombin and TEV
protease. Subsequent separation of the target protein from the HB-peptide was then achieved by
additional heparin-Sepharose affinity chromatography.
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2.2. Introduction
Pure recombinant proteins have become extremely important in a commercial aspect such
as therapeutics, diagnostic tools, and drug design1,2. These target proteins are expressed in large
yields in bacterial cell lines such as E. coli, and are then purified to homogeneity. Various types
of purification methods exist such as ion-exchange, size exclusion, and affinity chromatography.
Affinity chromatography has become one the most widely used methods to purify recombinant
proteins due to high yields and high purity that can be achieved3. Typically, an affinity tag of
any desired size (protein or peptide) is attached to the target protein of choice. The affinity tag
then binds to its partner that is immobilized on a resin, aiding in the efficient purification of the
desired protein. In general, affinity tags used for protein purification are expected to possess the
following properties: (a) high binding specificity during purification; (b) wide range of target
proteins as their partner; (c) no interference with the target protein’s structure or and (d) ability to
be removed from the target protein4,5,6,7,8,9. Common affinity tags include His-tag, GST, MBP,
thioredoxin, and several others10,11. The current affinity tags have some downfalls, which
include conditions or the presence of the tag interfering with the target protein’s
structure/activity, aggregation during purification, lack of purification under denaturing, and
expensive conditions of purification required12,13,14,15. Peptides, however, have become popular
in their use as affinity tags due to their stability16. Most small peptide tags added to a target
protein will not affect the protein activity17.
Numerous proteins have exhibited heparin-binding capability that are involved in
extremely diverse processes18,19,20,21,22,23. The regions called HBRs that exist in the proteins
demonstrating this binding affinity contain an expanse of positively charged residues that bind to
the negatively charged heparin molecule24. Cardin and Weintraub have shown that HBPs
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contain specific consensus sequences that are responsible for their specific interaction with
heparin, most commonly including XBBXBX, XBBBXXBX, and XBBXXBBBXXBBX, where
B is one of the three basic amino acids (arginine, lysine or histidine) and X is any of the other 17
natural amino acids25,26,27,28. Spatial arrangement of the HBR is just as important for heparinbinding capability as the sequence itself. Heparin binding is also known to increase α-helix
conformation of specifically designed short-chained peptides, increasing their stability29.
HBPs, such as FGFs, ATIII, fibronectin, cytokines, and others exhibit high binding
affinity for heparin30,31,32,33,34. Heparin-Sepharose is especially important for the purification of
these HBPs, which naturally bind to heparin-Sepharose without the aid of an affinity tag35. If a
non-heparin-binding protein needs to be purified, the addition of an affinity tag that binds to
heparin would be beneficial in order to use the mild elution conditions and simple steps that
heparin-Sepharose provides. We have fashioned a heparin-binding peptide after various
sequence and structural features in HBPs that is used as an affinity tag for the purification of
various recombinant proteins by heparin-Sepharose affinity chromatography.

2.3. Materials and Methods
Expression and Purification of GST-HB
In order to acquire large amounts of the HB-peptide, a GST-fused-HB-peptide was designed for
characterization studies. The recombinant GST-fused-HB-peptide (GST-HB) was transformed
into BL21 E. coli strain. Bacteria were grown under shaking conditions (250 rpm) at 37oC for in
Luria-Bertani (LB) broth containing ampicillin (100 mg/mL). Once the OD of 0.6 was reached
IPTG was used to induce the cells, which grew an additional 4 hours in the same environment.
The cells were later harvested at 6000 rpm at 4oC. Expression cell samples in phosphate
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buffered saline (1X PBS) (10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl), pH
7.2 were lysed (10 minutes, 10-second pulse with 10-second rest) on ice using a Microson XL
sonicator with a power setting of 15. The cell lysate was centrifuged at 20,000 rpm for 30
minutes at 4oC. The supernatant was loaded onto equilibrated glutathione-Sepharose at a flow
rate of 1 mL/minute and eluted using 10 mM reduced glutathione (GSH) in 1X PBS. Protein
elution was monitored at 280 nm using a BioRad UV-visible detector. The eluted protein was
dialyzed against 1X PBS, pH 7.2 to be used for further experiments. The GST affinity tag was
cleaved from the HB-peptide using thrombin (1 unit thrombin/250 µg GST-HB for 16 hours at
25oC) while gently rocking. The HB-peptide was removed from GST using heat treatment
method established by the Kumar lab (data not published yet). The supernatant from this method
was HB-peptide, which was then desalted using precipitation by isopropyl alcohol (IPA).
Varying amounts (percentage) of IPA was added to the HB-peptide solution, which was then
incubated at -20oC for 4 hours. This mixture was then centrifuged at 13,000 rpm for 10 minutes,
and the resulting pellet (HB-peptide) was dried with nitrogen and heated if IPA was still present.

Isothermal Titration Calorimetry of HB-peptide
Isothermal titration calorimetry (ITC) measurements were performed using iTC200 (MicroCal
Inc., Northampton, MA) at 25°C. The concentration of HB-peptide was maintained at 1:10 the
concentration of LMWH and HS in 10 mM phosphate buffer, 100 mM NaCl, pH 7.2. All
samples were centrifuged at 13,000 rpm to remove particulates and later degassed under vacuum.
The corresponding GAG was titrated into HB-peptide at 1.3 µL injections with 12 sec intervals.
The raw data was fit using binding models in the Origin Version 7.0 software supplied by
MicroCal Inc. The accuracy of the fitting was assessed using the given Χ2 values.
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Far UV Circular Dichroism of HB-peptide
All circular dichroism (CD) measurements were performed on a Jasco-720 spectropolarimeter at
25oC in Milli-Q H2O. The concentration of HB-peptide was 100 µM, with LMWH and SOS of
500 µM. Wavelength scans were from 190-250 nm in a 0.02 cm path length cuvette. CD spectra
are average of 10 scans at a scan speed of 50 nm/minute.

Intrinsic Fluorescence of HB-peptide
All intrinsic fluorescence measurements were performed on a Hitachi F2500 fluorimeter using a
1.0 cm path length cuvette. Concentration of HB-peptide was 25 µM, whereas LMWH and SOS
were 250 µM. The excitation wavelength was 280 nm with acquisition of 300-450 nm.

NMR Spectroscopy of HB-peptide
1

H-15N heteronuclear single quantum coherence spectroscopy (HSQC) measurements were

performed on Bruker Avance 500 MHz nuclear magnetic resonance (NMR) at 25oC.
Concentration of HB-peptide was 500 µM and heparin was 2.5 mM in 10 mM phosphate buffer,
100 mM NaCl, pH 7.2 (90% H2O + 10% D2O). All 1H data were referenced to the resonance
frequency of H2O (~ 4.7-4.8 ppm)

Expression and Purification of the First HB-fusion Protein (HB-C2A)
The previously obtained recombinant pET-28a-HB fusion construct (HB-C2A) was transformed
into BL21* E. coli strain. In short, the C2A domain of mouse synaptotagmin-1 was cloned into
the pET-28a-HB vector. Bacteria were grown under shaking conditions (250 rpm) at 37oC in LB
and TB containing kanamycin (50 µg/mL) for HB-C2A and both ampicillin (100 µg/mL) and
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chloramphenicol (35 µg/mL) for HB-S100A13 and HB-CAlb3. Once the OD of 0.6 was
reached, IPTG was used to induce the cells, which grew an additional 4 hours in the same
environment. The cells were later harvested by centrifugation at 4oC at 6000 rpm. For 15Nlabeled HB-C2A, M9 minimal medium with15NH4Cl as the sole source of nitrogen was used.

Expression samples in 10 mM Tris-HCl, pH 8 were lysed (10 minutes, 10-second pulse, 10second rest) on ice using a Microson XL sonicator with a power setting of 15. The cell lysate
was centrifuged at 20,000 rpm for 30 minutes at 4oC. The supernatant was loaded onto
equilibrated heparin-Sepharose (6% highly cross linked spherical agarose) at a flow rate of 1
mL/minute and eluted using a salt gradient of 100 mM to 500 mM NaCl in 10 mM Tris-HCl.
Protein elution was monitored at 280 nm using a BioRad UV-visible detector. Purifications were
also performed in 10 mM Tris-HCl, pH 7.2 and 10 mM phosphate buffer, pH 6.5, pH 7.2, and
pH 8. The purity of each eluted protein was assessed on a 15% SDS-PAGE gel. All protein
concentrations were measured using an Agilent spectrophotometer at 280 nm in 10 mM TrisHCl, pH 8.

Cloning, Expression, and Purification of Other HB-fusion Proteins
Mouse S100A13, heparin-affinity tag vector, and the C-terminal domain of Albino-3 from
Arabdopsis thaliana (CAlb3) were each transformed into DH5α cells using ampicillin as the
antibiotic of choice. A colony from each transformed product was inoculated 16 hours, and
plasmid isolation was performed using Qiagen Miniprep Plasmid Purification kit. Primers of 30
bp in length were designed that contained restriction site bases for BamH1 and XhoI.
Preparative PCR was then performed using the designed primers, Phusion Mastermix, and
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dimethyl sulfoxide (DMSO). Double digestion of the inserts and the affinity tag vector was
performed using BamH1 and XhoI as the restriction enzymes after gel extraction was performed
using Qiagen Gel Extraction kit. Antarctic phosphatase was added to the affinity tag vector for
dephosphorylation before ligation occurred. HB-vector and target inserts were ligated using T4
ligase at 22oC for 20 minutes. The ligation product was transformed into DH5α cells with
ampicillin as the antibiotic of choice. Colony PCR was performed using Taq polymerase.
Double digestion using BamH1 and XhoI was performed on the ligated product to ensure
successful ligation. The pET-22b-HB fusion constructs were transformed into BL21 (DE3) E.
coli strain for S100A13 and Rosetta DE3 E. coli strain for CAlb3. Expression was performed in
a similar fashion as HB-C2A.

Expression samples in 10 mM Tris-HCl, pH 8 were lysed (10 minutes, 10-second pulse with 10second rest) on ice using a Microson XL sonicator with a power setting of 15. The cell lysate
was centrifuged at 20,000 rpm for 30 minutes at 4oC. The supernatant was loaded onto
equilibrated heparin-Sepharose at a flow rate of 1 mL/min and eluted using a salt gradient of 100
mM to 2 M NaCl in 10 mM Tris-HCl. Protein elution was monitored at 280 nm using a BioRad
UV-visible detector. The purity of each eluted protein was assessed on a 15% SDS-PAGE gel.

Purification of Denatured HB-fusion Proteins
The expression samples in 10 mM Tris-HCl, pH 8 containing either 8 M urea or 6 M guanidine
hydrochloride were lysed (10 minutes, 10-second pulse with 10-second rest) on ice using a
Microson XL sonicator with a power setting of 15. The cell lysate was centrifuged at 20,000
rpm for 30 minutes at 4oC. The supernatant was loaded onto heparin-Sepharose at a flow rate of
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1 mL/min, and protein was eluted using a salt gradient of 100 mM to 2 M NaCl in 10 mM TrisHCl containing corresponding denaturant. Protein elution was monitored at 280 nm using a
BioRad UV-visible detector.

Proteolytic Cleavage of HB-Fusion Proteins
Dialysis (10 mM Tris-HCl, 100 mM NaCl, pH 8) was performed immediately following elution.
The sample was concentrated down to 5 mL (Macrosep Advance Centrifugal Device, MWCO
10K), and the amount of protein present was determined using Agilent spectrophotometer at 280
nm. Thrombin cleavage then occurred for HB-C2A (1 unit thrombin/25 ug HB-C2A for 20-24
hours at 37oC) and HB-CAlb3 (1 unit thrombin/10 ug HB-CAlb3 for 24 hours at 37oC). ProTEV
Plus was used for cleavage of HB-S100A13 (1 unit ProTEV Plus/200 ug HB-S100A13 for 18
hours at 30oC in presence of 1 mM DTT in 1X ProTEV Plus buffer). Recombinant TEV
protease was used under similar conditions (1 µL TEV/2 µg HB-S100A13 for 9 hours).
Phenylmethylsulfonylfluoride (PMSF) was used to inhibit thrombin cleavage, and trichloracetic
acid (TCA) for TEV protease cleavage. The cleaved sample of HB-C2A was passed onto
heparin-Sepharose using the salt gradient of 100 mM to 2 M NaCl in 10 mM Tris-HCl, pH 8 to
separate the target protein from the HB-peptide. Cleavage of HB-C2A was also performed in 10
mM Tris-HCl, pH 7.2 and 10 mM phosphate buffer, pH 6.5, pH 7.2, and pH 8.

NMR Spectroscopy of Target Protein (C2A)
1

H-15N HSQC measurements were performed on Bruker Avance 500 MHz NMR at 25oC.

Concentration of C2A was 320 µM in 1X PBS, pH 7.2 (90% H2O, 10% D2O). All 1H data were
referenced to the resonance frequency of H2O (~ 4.7-4.8 ppm).
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Comparison of Affinity Tags
Two simultaneous transformations into BL21 cells, followed with over-expression of 1L culture
in LB broth were performed for both HB-C2A and GST-C2A. The expression pellet of HB-C2A
was resuspended in 10 mM Tris-HCl, pH 8, whereas GST-C2A was in 1X PBS, pH 7.2. Both
cell samples were lysed (10 minutes, 10-second pulse with 10-second rest) on ice using a
Microson XL sonicator with a power setting of 15. Both cell lysates were centrifuged at 20,000
rpm for 30 minutes at 4oC. The supernatant was loaded onto heparin-Sepharose column for HBC2A and a GSH-Sepharose column for GST-C2A.

2.4. Results and Discussion
HB-peptide is designed to contain similar features as HBPs: Consensus sequences discovered
in the HBR of HBPs are responsible for their binding affinity for heparin. In helical wheel plots
of these motifs, the positively-charged amino acid residues (mainly Lys and Arg) face the
outside of the protein in order to interact in a mainly electrostatic manner with the negativelycharged heparin molecule. Another important factor responsible for heparin-binding capability
is the protein’s ability to hydrogen bond (mainly Gln and Asn). The ability for the designed HBpeptide to form a helix and have the positively-charged residues face the outside of the helix
enables the peptide to bind strongly to heparin (Figure 2.1).
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Figure 2.1 – Helical wheel plot of HB-peptide. As seen here, positively-charged lysine residues
face the outside of the helix to interact with heparin.
Good yield of HB-peptide is achieved from purification of GST-HB: Characterization of the
peptide in the present of heparin, such as its binding affinity for heparin, needs to be established
before it is used as an affinity tag by heparin-Sepharose chromatography. In order to obtain high
yields of the peptide, a GST affinity tag was attached to the N-terminal end of the peptide. Since
the thrombin cleavage site would then be on the N-terminal end of the peptide, once cleavage has
occurred, only the amino acids glycine and serine would be present on the peptide. These two
residues are not expected to interfere with heparin-binding capability since it is only two
residues. GST-HB contains 256 amino acid residues with ~ 30 kDa molecular weight (Figure
2.2).
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Figure 2.2 – Amino acid sequence of GST-HB (256 residues, 30 kDa). HB-peptide portion is in
red, and thrombin cleavage site is in green.
Large yields of GST-HB (as high as 40 mg) can be expressed and further purified by
Glutathione-Sepharose affinity chromatography (Figure 2.3). Due to the large amount of GSTHB expressed, some of the protein is aggregated on the column (lane 6). In this circumstance, it
is not a problem because good yield of protein is still acquired for experiments.
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Figure 2.3 – Expression (Panel-A) and purification (Panel-B) of GST-HB by glutathioneSepharose affinity chromatography. Panel-A: Lane 1, uninduced; Lane 2, induced; Lane 3,
GST-HB (positive control, 30 kDa). Panel-B: Lane 1, protein marker; Lane 2, post-sonication
pellet; Lane 3, clear cell lysate; Lane 4, 1X PBS flow-through; Lane 5, 10 mM GSH (eluted
GST-HB); Lane 6, 6 M guanidine hydrochloride.
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This is a bottleneck to be avoided for other target proteins attached to GST tag. On occasion,
impurities are seen after purification, but these are removed when separation by heat treatment is
performed.
The Kumar lab has optimized separation of target proteins from GST affinity tag by heat
treatment (data not published). This approach proved to be beneficial for the peptide since the
molecular weight cutoff for the heat treatment procedure is 10 kDa or less. Even though a small
portion of the peptide is lost in the heat treatment technique, the most important aspect is the
purity of the peptide (Figure 2.4). As seen in lane 9, no GST is present in the heat treatment
supernatant. Consistently, 5 mg of HB-peptide is obtained from 2 L culture.
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Figure 2.4 – Thrombin cleavage of GST-HB followed by the heat treatment at 65oC to obtain the
HB-peptide separated from GST tag. Lane 1, protein marker; Lane 2, GST-HB; Lane 3, cleaved
GST-HB; Lane 4, heat treatment pellet (GST); Lane 5, heat treatment supernatant (HB-peptide).
In order to obtain concentrated peptide, lyophilization was employed in the beginning, but this
posed a problem when the lyophilized peptide needed to be in a different buffer than before. The
desalting method by IPA (at least 80% v/v) was previously optimized in the Kumar lab
(unpublished data), where a peptide or protein can be precipitated free from buffer. The pellet
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can then be dissolved in any volume of the buffer of choice when needed. As the amount of IPA
is increased to 95%, there is no increase in yield of peptide because all of the peptide gets
precipitated at 80% IPA (Figure 2.5). Therefore, 80% IPA has been established as the condition
of choice when a peptide or protein needs to be desalted and concentrated without using
centrifugal filter/membrane units.
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Figure 2.5 – Precipitation of HB-peptide using varying amounts of isopropyl alcohol at -20oC to
obtain the desalted and concentrated HB-peptide. Lane 1, protein marker; Lane 2, untreated HBpeptide; Lane 3, 80%-pellet; Lane 4, 80%-supernatant; Lane 5, 85%-pellet; Lane 6, 85%supernatant; Lane 7, 90%-pellet; Lane 8, 90%-supernatant; Lane 9, 95%-pellet; Lane 10, 95%supernatant.
This method also saves on time and reagents compared to dialysis or concentration. Peptides are
also very susceptible to degradation due to their residues being readily accessibly to proteases
and other enzymes, so stable storage includes lyophilization and not freezing. This method of
precipitation allows for the desired storage without using an expensive lyophilizing instrument.

HB-peptide exhibits good heparin-binding affinity: Since the peptide was fashioned after the
heparin-binding region of FGF-1 that exhibits good binding affinity for heparin, it is expected
that the peptide should also have good binding affinity for heparin. ITC is a beneficial
96

technique, used for the measurement of the binding affinity for protein-ligand interactions36,37.
The binding affinities of the HB-peptide for heparin and HS were measured using ITC. HS was
used in this study as well because it is the universal ligand that exists on every cell surface, on
which it is the ligand of choice for growth factors and other HBPs38. In order to determine if the
peptide functions in a similar fashion as the HBR of other HBPs, the cell surface HS was chosen
as the ligand for this peptide before heparin was introduced. The isothermograms representing
the interaction of HB-peptide with HS and heparin are exothermic and sigmoidal (Figure 2.6).
HB-peptide binds to both ligands in a 1:2 stoichiometry. The binding affinities for HS are 0.15
and 3.3 µM, whereas for heparin, the affinities are 176 and 14 nM.
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Figure 2.6 – Isothermograms for the titrations of HB-peptide with heparan sulfate (Panel-A) and
heparin (Panel-B). The top panel is the raw data, whereas the bottom panel is the integrated data
from the raw data. The peptide binds to both GAGs in a 1:2 binding fashion and has good
binding affinity for heparan sulfate (Kd ~ 0.15 and 3.3 µM) and heparin (176 and 14 nM).
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Heparin does show slightly better binding affinity for this peptide, which is promising for the
subsequent purification of proteins by the binding of this peptide to heparin-Sepharose. The
binding the peptide for heparin is crucial for other heparin-binding applications. Due to this
good binding affinity, the peptide shows promise for use in downstream heparin-related
applications. In order for the peptide to have selective affinity for heparin over the other GAGs,
future mutations need to be performed on the peptide.

Secondary structure changes when bound to heparin/SOS: FGF-1 and other HBPs undergo a
conformational change when binding to heparin occurs. This change is expected for the peptide
due to its ability to bind to heparin with good affinity. Far-UV CD is a useful tool for
determining the overall secondary structure of proteins and peptides39. The spectra of HBpeptide in the presence and absence of heparin and SOS, a functional mimic of heparin used for
binding studies, are in Figure 2.7. SOS is used occasionally in the place of heparin because it
has been shown to interact with heparin-binding growth factors in a similar fashion as heparin40.
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Figure 2.7 – Overlay of the far-UV circular dichroism spectra of HB-peptide in the absence
(black) and presence of heparin (red) and SOS (blue). The peptide adopts an alpha helical nature
upon binding to heparin/SOS.
In the absence of heparin/SOS, the peptide adopts a random coil-like structure, which is seen by
the negative band around 200 nm, but the corresponding positive band at 212 nm is not present.
The peptide could adopt a slight overall structure that is more similar to random coil than the
other two secondary structures. Peptides are short chains of amino acid residues, which usually
are not long enough to adopt any significant secondary or tertiary structure like larger proteins.
This is seen in the spectrum for the peptide not bound to any molecule. In the presence of
heparin/SOS, the peptide then becomes more alpha helical in nature with the negative bands at
208 nm and 222 nm, characteristic of an alpha helix. Heparin gives a more pronounced shift in
conformation due to its character being more alpha helical than SOS.
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Subtle tertiary structural changes are seen when bound to heparin/SOS: Changes in structural
changes at the tertiary level can be monitored by intrinsic fluorescence spectroscopy41.
Tryptophan residues in proteins are studied because their quantum yields are high, and they give
an efficient fluorescence signal. Changes in the emission of tryptophan residues monitor protein
folding because their quantum yields are sensitive to their microenvironment42. The peptide is in
the unfolded state, as seen by the emission maximum at 355 nm. In this instance, the tryptophan
is completely solvent exposed. When bound to heparin/SOS, it gains some structure, as seen by
the increase in relative fluorescence intensity, but the peptide does not become fully folded
(Figure 2.8). If the peptide became fully folded, the tryptophan would now be on the interior of
the fold in a hydrophobic environment, which would be accompanied by a blue shift to shorter
wavelengths. Since the tryptophan would not be completely buried, a shift of emission

Relative fluorescence intensity

maximum would not be expected.

Wavelength
Figure 2.8 – Intrinsic tryptophan fluorescence spectra of the peptide (black) and upon binding to
heparin (red) and SOS (blue). Only a minor conformational change in the tertiary structure is
seen by the slight intensity increase.
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Interaction with heparin causes chemical shift perturbation: Two-dimensional 1H-15N HSQC
spectroscopy provides useful information about the backbone conformation of a protein or
peptide. Each crosspeak represents an amino acid residue that is in a specific backbone
conformation of the protein43. When structural changes occur, the conformation of the backbone
is perturbed, leading to shifts in the corresponding crosspeaks or particular amino acids affected
by the structural change44. The conformational change of the backbone for the peptide was
studied upon the binding of heparin by the chemical shifts of the crosspeaks. The peptide is not
well structured, as indicated by the clustering of peaks in the spectrum (Figure 2.9). Wellstructured proteins have crosspeaks that are spread out in the spectrum normally. Once the
peptide is bound to heparin, a significant shift in almost every crosspeak is observed, proving
that a structural change has occurred. The binding of heparin probably changes the conformation
of the individual amino acids but does not completely fold the peptide, since the intrinsic
tryptophan fluorescence does not show a red shift. This hypothesis is also confirmed by the
continued clustering of crosspeaks in the 1H-15N HSQC spectrum even upon the binding to
heparin.
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Figure 2.9 – 1H-15N HSQC spectrum of the peptide bound to heparin (red) overlaid on the
peptide (blue). There is a shift in the cross peaks upon binding to heparin, showing a
conformational change occurs.
HB-fusion proteins are expressed and purified in good yields: Once HB-C2A is successfully
cloned into pET-28a, the fusion protein is successfully expressed in the soluble form at good
yield in LB broth. The amino acid sequence of this fusion protein shows the HB-peptide in the
N-terminal position, followed by the thrombin cleavage site (LVPRGS), the C2A portion, ending
with a C-terminal His-tag (Figure 2.10). The strong band around 20 kDa in the induced lane
(lane 3) and supernatant lane (lane 5) after sonication occurs is indicative of a successful
expression of this fusion protein (Figure 2.11).
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Figure 2.10 – Amino acid sequence of HB-C2A (175 residues, 20 kDa). HB-peptide portion is
in red, and thrombin cleavage site is in green.

1

2

3

4

5

80
58
46

30
25

17

Figure 2.11 – Overexpression and sonication of HB-C2A. Lane 1, protein marker; Lane 2,
uninduced; Lane 3, induced; Lane 4, post-sonication pellet; Lane 5, post-sonication
supernatant/cell lysate.
This protein is then purified to homogeneity in Tris buffers within the acceptable pH values
using one-step heparin-Sepharose affinity chromatography (Figure 2.12). Tris-HCl buffer has a
pKa of 8.1, which means the buffering capacity is from pH 7-9. HB-C2A has a pI of 9.44, which
means the pH needs to be 8.4 or 10.4. Since pH 10.4 is outside the range of Tris buffer, the pH
of 8 was chosen. The majority of HB-C2A elutes in 500 mM NaCl (lane 7) extremely pure
every time, even at both pH conditions. Even though this protein does not bind to heparin as
tightly as FGF-1 (this protein elutes at 1.5 M NaCl), at 500 mM NaCl, the majority of
contaminants are already removed.
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Figure 2.12 – Purification of HB-C2A in 10 mM Tris, pH 7.2 (Panel-A) and pH 8 (Panel-B)
with step-wise NaCl gradient using heparin-Sepharose affinity chromatography. Lane 1, protein
marker; Lane 2, post-sonication pellet; Lane 3, clear cell lysate; Lane 4, 0 mM NaCl; Lane 5,
100 mM NaCl; Lane 6, 350 mM NaCl; Lane 7, 500 mM NaCl (eluted HB-C2A).
Oftentimes, GST-tagged proteins have a tendency to aggregate on the glutathione-Sepharose
resin, leading to a loss of protein, but this does not occur using the HB-affinity tag. Normally, 20
mg of HB-C2A is obtained from 1 L culture. This high yield leads the target protein, C2A, to be
in high yield as well since the small HB-peptide does not add any significant portion to the
overall yield. Other buffer conditions are employed in order to determine the efficacy of the HBtag in various environments (Figure 2.13). Sodium phosphate buffer is also used at pH 6.5-8
because the pKa of this buffer is 6.8, which means its buffering capacity is from pH 5.8 to pH
7.8. Again, HB-C2A is eluted at 500 mM NaCl (lane 7), although some protein is lost in the
lower salt concentrations, due to overloading the column. A larger column can be used for more
accumulation of fusion protein in the future.
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Figure 2.13 – Purification of HB-C2A in 10 mM sodium phosphate buffer, pH 6.5 (Panel-A),
pH 7.2 (Panel-B), and 8 (Panel-C) with step-wise NaCl gradient using heparin-Sepharose affinity
chromatography. Lane 1, protein marker; Lane 2, post-sonication pellet; Lane 3, clear cell
lysate; Lane 4, 0 mM NaCl; Lane 5, 100 mM NaCl; Lane 6, 350 mM NaCl; Lane 7, 500 mM
NaCl (eluted HB-C2A).
Since this peptide has acted as a successful affinity tag, other non-heparin-binding proteins
(CAlb3 and S100A13) have been selected and ligated successfully into the HB-vector. The
inserts are first amplified by PCR, followed by the double digestion of the inserts and HB-vector
(Figure 2.14).
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Figure 2.14 – Amplification of inserts, CAlb3 and S100A13 (Panel-A) and double digestion of
inserts and HB-vector (Panel-B). Panel-A: Lane 1, DNA marker; Lane 2, CAlb3 PCR product
(375 bp); Lane 3, S100A13 PCR product (294 bp). Panel-B: Lane 1, DNA marker; Lane 2,
digested HB-vector; Lane 3, DNA marker; Lane 4, digested CAlb3; Lane 5, digested S100A13.
The digested components are then combined in a ligation reaction that has to be determined if the
reaction is successful. Once ligation has occurred, colony PCR of the ligation products are
performed in order to determine which colonies are positive ligation products (Figure 2.15).
Since PCR only amplifies the inserts in the vector, a band at approximately 400 Da (CAlb3) and
300 Da (S100A13) is seen, proving the insert is present as the plasmid is transformed into DH5α
cells and had antibiotic resistance. Only the vector has antibiotic resistant, so since the insert
band is seen from a grown colony (lanes 1, 2, and 4), it can be concluded that the insert is
actually ligated into the vector.
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Figure 2.15 – Colony PCR of HB-S100A13 (Panel-A) and HB-CAlb3 (Panel-B) after ligation
occurred. Lane 1, colony 1; Lane 2, colony 2; Lane 3, colony 3; Lane 4, colony 4; Lane 5, DNA
marker.
In order to be completely assured, double digestion proves the ligation is successful (Figure
2.16).
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Figure 2.16 – Double digestion of ligated HB-S100A13 (Panel-A) and HB-CAlb3 (Panel-B).
Panel-A: Lane 1, digested HB-S100A13; Lane 2, DNA marker. Panel-B: Lane 1, DNA marker;
Lane 2, digested HB-CAlb3.
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The amino acid sequence of HB-S100A13 (Figure 2.17) and HB-CAlb3 (Figure 2.18) has similar
order as HB-C2A, except HB-S100A13 has TEV protease cleavage site (ENLYFQG) instead of
thrombin cleavage site. They also do not contain a His-tag like HB-C2A.
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Figure 2.17 – Amino acid sequence of HB-S100A13 (140 residues, 16 kDa). HB-peptide is in
red, and the TEV protease cleavage site is in blue.
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Figure 2.18 – Amino acid sequence of HB-CAlb3 (163 residues, 18 kDa). HB-peptide is in red,
and the thrombin cleavage site is in green.
These clones are successfully expressed in LB broth (Figure 2.19), as seen by the bands of
appropriate molecular weight in the induced lane, lane 2 (HB-CAlb3 ~ 18 kDa; HB-S100A13 ~
16 kDa) indicated by arrows. Interestingly enough, HB-CAlb3 is always seen to migrate lower
than its expected molecular weight (right below the 17 kDa band in the protein marker) on 15%
SDS-PAGE. HB antibodies bind to this protein in Western blotting, proving this protein band
indeed belongs to HB-CAlb3. The lower migration is likely due to the positively charged protein
binding more negatively charged SDS molecules, leading to faster migration through the gel.
108

1

2

3

4

5

80
58
46
30
25

17

Figure 2.19 – Expression of HB-CAlb3 and HB-S100A13 in LB broth. Lane 1, protein marker;
Lane 2, uninduced HB-CAlb3; Lane 3, induced HB-CAlb3; Lane 4, uninduced HB-S100A13;
Lane 5, induced HB-S100A13.
The Kumar lab has been unsuccessful in expressing CAlb3 using solely a His or GST tag, so it is
rewarding that by the use of the HB-tag, this protein can be expressed. CAlb3 being a difficult
protein, it is not surprising that the overall yield of HB-CAlb3 is much lower than C2A and
S100A13.

Other HB-fusion proteins can be purified to homogeneity using heparin-Sepharose affinity
chromatography: Since HB-peptide is an effective affinity tag for C2A, its reputation continues
by aiding in the purification of CAlb3 and S100A13, two more non-heparin-binding proteins.
The fusion proteins elute at 1 M NaCl, as indicated in lane 8 by the arrows, as compared to 500
mM NaCl for HB-C2A (Figure 2.20). HB-CAlb3 and HB-S100A13 have pI values of 10.3 and
9.6-9.7, respectively, compared to that of HB-C2A of 9.4. These greater pI values could
contribute to the greater binding affinity for heparin-Sepharose because the positively charged
residues could be in a better orientation for interaction with the negatively charged heparin
molecule. The linear amino acid sequence does not play as much of a role in binding capability
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as does the overall fold of the protein, as seen by the consensus sequences in heparin-binding
proteins. Target proteins are also known at times to contribute to the binding capability of the
affinity tag45,46.
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Figure 2.20 – Purification of HB-CAlb3 (Panel-A) and HB-S100A13 (Panel-B) by heparinSepharose affinity chromatography. Lane 1, protein marker; Lane 2, post-sonication pellet; Lane
3, clear cell lysate; Lane 4, 0 mM NaCl; Lane 5, 100 mM NaCl; Lane 6, 350 mM NaCl; Lane 7,
500 mM NaCl; Lane 8, 1 M NaCl.
At times, HB-CAlb3 does elute around 1 M to 2 M NaCl, but still in a pure state. The majority
of the fusion protein elutes at 1 M NaCl but there is residual protein at 2 M NaCl. Both fractions
are normally combined for further experiments if enough protein is observed in the 2 M NaCl
fraction. The yield of HB-CAlb3 is approximately 2 mg protein/L culture, whereas HBS100A13 is 3-4 mg protein/L culture. CAlb3 has also not been purified to homogeneity
successfully in the past attempts in the Kumar lab, so being able to purify this protein by means
of HB-affinity tag is quite gratifying. In the future, it would be interesting to investigate the
efficacy of HB-affinity tag with other proteins that do not possess as high of a pI value as these
proteins to determine their effect on binding capability to heparin-Sepharose.
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HB-fusion proteins can be purified in a mild denatured state: On occasion, it is reported that
certain proteins are expressed in insoluble form, which are known as inclusion bodies47,48,49.
Denaturants are needed to isolate proteins from inclusion bodies in order to perform their
purification effectively. Urea, unlike guanindine hydrochloride, is a non-ionic denaturant
commonly used in purification50,51,52. HB-C2A and HB-S100A13 are successfully purified in 8
M urea (Figure 2.21).
A.

B.
1

2

3

4

5

6

7

1

80
58
46

80
58
46

30

30

25

2

3

4

5

6

7

8

25
17

17

Figure 2.21 – Purification of HB-C2A (Panel-A) and HB-S100A13 (Panel-B) in 8 M urea.
Panel-A: Lane 1, protein marker; Lane 2, post-sonication pellet; Lane 3, clear cell lysate; Lane 4,
0 mM NaCl; Lane 5, 100 mM NaCl; Lane 6, 350 mM NaCl; Lane 7, 500 mM NaCl (eluted HBC2A). Panel-B: Lane 1, protein marker; Lane 2, post-sonication pellet; Lane 3, clear cell lysate;
Lane 4, 0 mM NaCl; Lane 5, 100 mM NaCl; Lane 6, 350 mM NaCl; Lane 7, 500 mM NaCl;
Lane 8, 1 M NaCl (eluted HB-S100A13).
There is some HB-C2A that is present in the flow-through (lane 4), probably resulting from an
overloaded resin. This is likely because the majority, if not all, of HB-S100A13 is present in 1
M NaCl, not the flow-through, and this fusion protein gives less yield than HB-C2A. The HBaffinity tag cannot, however, be used in 6 M guanidine hydrochloride (Figure 2.22). All of the
HB-C2A is eluted in 0 mM NaCl (lane 3), as seen by the band at the same molecular weight as
the positive control (HB-C2A, 20 kDa) with arrow. This is expected because guanidine
hydrochloride is an ionic denaturant that breaks all electrostatic interactions present. HB-peptide
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and heparin bind to each other based mainly on electrostatic interactions, which are completely
interrupted by this denaturant.
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Figure 2.22 – Purification of HB-C2A in 6 M guanindine hydrochloride using heparinSepharose affinity chromatography. Lane 1, post-sonication pellet; Lane 2, clear cell lysate;
Lane 3, 0 mM NaCl (eluted HB-C2A); Lane 4, 100 mM NaCl; Lane 5, 350 mM NaCl; Lane 6,
500 mM NaCl; Lane 7, HB-C2A (positive control).
If HB-fusion proteins need to be purified using a denaturant, a non-ionic one is preferred for
efficient purification by heparin-Sepharose. Proteins that generally express as inclusion bodies
can be attached to the HB-affinity tag, solubilized in urea, and purified by heparin-Sepharose
affinity chromatography in the future.

Target protein can be obtained from HB-fusion proteins through proteolytic cleavage:
Enzymatic cleavage is a useful tool to remove target proteins from their corresponding affinity
tags. In this case, thrombin and TEV protease sites were added to the HB-fusion clones, in order
to later detach C2A, CAlb3, and S100A13 from the HB-affinity tag. The cleavage reaction is
optimized, and the corresponding target protein can be removed from the peptide via another
round of heparin-Sepharose affinity chromatography. Once cleaved, the target protein contains
the last two residues of the thrombin or TEV protease cleavage site, which should not interfere
with the activity or structure of the target protein. The best cleavage conditions for HB-C2A
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include 1 unit thrombin per 25 µg protein overnight at 37oC. The cleavage reaction is complete
after 20 hours, but the reaction was let go 24 hours for feasible wait times in the lab (Figure
2.23). Even at longer times such as 24 hours, no additional cleavage products/degradation of
C2A is observed (only two product bands are seen in lane 3). The HB-peptide (~ 4 kDa) is
indicated by the red arrow. If less thrombin is preferred, the incubation time needs to be
increased to approximately 48 hours.
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Figure 2.23 – Thrombin cleavage of HB-C2A using 25 µg (Panel-A) and 50 µg (Panel-B) of
fusion protein. Lane 1, protein marker; Lane 2, HB-C2A; Lane 3, thrombin-cleaved HB-C2A.
The cleavage reaction of HB-C2A, like the purification, has also been optimized for other buffer
conditions (Figure 2.24). Sometimes, HB-peptide is not in high yield so a strong band is not
observed on the gel, but its position is indicated by the red arrow. In order to stabilize thrombin,
calcium ions are normally used during thrombin cleavage reactions. It has been shown in the
Kumar lab that 2.5 mM calcium chloride is a good condition for efficient thrombin cleavage to
occur. Interestingly enough, for HB-C2A, calcium chloride is not required for suitable cleavage
to happen. As seen in lanes 2 and 3, both with and without the calcium ions work for good
cleavage of HB-C2A. The downside of using phosphate buffer is that calcium chloride cannot
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be used in this buffer because the negatively charged phosphate groups do a double displacement
reaction with chloride ions to produce calcium phosphate, instead of free calcium ions. Calcium
phosphate, the product of calcium chloride in phosphate buffer, precipitates out of solution as
well, which is extremely undesirable. Only Tris buffer should be used in this instance.
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Figure 2.24 – Thrombin cleavage of HB-C2A in 10 mM phosphate buffer (Panel-A) and 10 mM
Tris-HCl (Panel-B) with and without CaCl2 (Panel-C) for 24 hr. Panel-A: Lane 1, protein
marker; Lane 2, HB-C2A (20 kDa); Lane 3, cleaved at pH 6.5; Lane 4, HB-C2A; Lane 5,
cleaved at pH 7.2; Lane 6, HB-C2A; Lane 7, cleaved at pH 8; Lane 8, C2A (16 kDa). Panel-B:
Lane 1, protein marker; Lane 2, HB-C2A; Lane 3, cleaved at pH 7.2; Lane 4, HB-C2A; Lane 5,
cleaved at pH 8. Panel-C: Lane 1, HB-C2A; Lane 2, cleaved without CaCl2; Lane 3, cleaved
with CaCl2.
HB-CAlb3 is also cleaved with thrombin, but the greater number of positively charged residues
makes the cleavage reaction not as efficient using similar conditions as HB-C2A (Figure 2.25).
A ratio of 1 unit thrombin per 25 µg HB-CAlb3 is used for 48 hours, and calcium chloride is
essential, unlike HB-C2A, for this cleavage reaction to successfully transpire. Since calcium
chloride is required for this cleavage reaction, phosphate buffer cannot be used in this instance.
HB-peptide is not in high yield so only a faint band is observed on the gel, as indicated by the
red arrow.
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Figure 2.25 – Optimization of thrombin cleavage of HB-CAlb3. Lane 1, HB-CAlb3; Lane 2,
1/5-24 hours; Lane 3, 1/5-48 hours; Lane 4, 1/10-24 hours; Lane 5, 1/10-48 hours; Lane 6, 1/2024 hours; Lane 7, 1/20-48 hours; Lane 8, 1/25-24 hours; Lane 9, 1/25-48 hours; Lane 10, 1/50-24
hours; Lane 11, 1/50-48 hours.
TEV protease is a more stringent protease than thrombin and the others, which means it is more
specific to its cleavage site, resulting in less nonspecific cleavage products sometimes seen from
thrombin or chymotrypsin53,54,55. For this reason, a TEV protease cleavage site is added to HBS100A13, but also to determine the efficacy of HB-affinity tag when other proteases are used.
The cleavage reaction has been optimized for HB-S100A13 using the protocol given by the
ProTEV Plus provider (Promega Corp.). The Kumar lab has been successful in purifying
recombinant TEV protease, so its activity is compared to that of ProTEV Plus in a small-scale
reaction in the presence and absence of dithiothreitol (DTT) (Figure 2.26). DTT is used as a
reducing agent to protect the cysteine residues in TEV protease from being oxidized, thus
reducing the enzyme activity. However, ProTEV Plus works to cleave HB-S100A13 even in
absence of DTT, whereas the recombinant TEV protease does not start partially cleaving until 6
hours of incubation with a 1 µL TEV/10 µg protein ratio only in the presence of DTT (lane 9).
The very lowest band is HB-peptide, as indicated by the red arrow.
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Figure 2.26 – Small-scale cleavage of HB-S100A13 by ProTEV Plus (PT) and recombinant
TEV protease (RT) in the presence (Panel-A) and absence (Panel-B) of 1 mM DTT. Panel-A:
Lane 1, 0 hour; Lane 2, PT-1 hour; Lane 3, PT-2 hours; Lane 4, PT-4 hours; Lane 5, PT-6 hours;
Lane 6, RT-1 hour; Lane 7, RT-2 hours; Lane 8, RT-4 hours; Lane 9, RT-6 hours. Panel-B: Lane
1, PT-1 hour; Lane 2, PT-2 hous; Lane 3, PT-4 hours; Lane 4, PT-6 hours; Lane 5, RT-1 hours;
Lane 6, RT-2 hours; Lane 7, RT-4 hours; Lane 8, RT-6 hours.
The large-scale reaction of cleavage of HB-S10013 is successful using ProTEV Plus in a greater
ratio than the manufacturer suggests (1 unit ProTEV Plus/100 µg protein), allowing less enzyme
to be wasted on one reaction (Figure 2.27). Longer incubation time is required for this new ratio,
but it is the same time as HB-C2A. HB-peptide is indicated with the red arrow. The upper-most
band in lane is ProTEV Plus (48 kDa molecular weight on SDS-PAGE, information from
Promega Corp.).
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2

Figure 2.27 – Large-scale cleavage of HB-S100A13 by ProTEV Plus at 30oC. Lane 1, HBS100A13; Lane 2, 20-hour cleaved HB-S100A13.
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A more in-depth examination of the recombinant TEV protease reveals that cleavage is
successful after 9 hours when a 1 µL TEV/2 µg protein ratio is applied (Figure 2.28). The red
arrow again indicates HB-peptide. This ratio is not cost-effective so longer incubation time
could allow for lower amount of TEV protease to be used.
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Figure 2.28 – Optimization of cleavage of HB-S100A13 by recombinant TEV protease at 30oC.
Lane 1, HB-S100A13; Lane 2, 6 hours; Lane 3, 9 hours; Lane 4, 15 hours; Lane 5, 18 hours;
Lane 6, 21 hours; Lane 7, 24 hours.
Expressing and purifying the recombinant TEV protease seems more cost-effective due to its
endless supply and lack of dependence on supplier. The purified TEV protease produced in the
Kumar lab is currently being used as the protease of choice by designing clones with a TEV
protease cleavage site instead of thrombin.

Target protein can be removed from HB-affinity tag by heparin-Sepharose: The target protein,
once cleaved from HB-peptide, is not a heparin-binding protein, so it does not bind with as high
affinity to heparin-Sepharose as HB-peptide. Thrombin, however, is an HBP, which means it
should bind tightly to heparin-Sepharose, only eluting with very high concentrations of NaCl.
The target protein would have already eluted before this stage. The target protein is seen eluted
at low NaCl concentration (100 mM NaCl), completely separated from the peptide and thrombin
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(Figure 2.29). The HB-peptide is indicated by the red arrow. The upper-most band in lanes 1
and 2 are more than likely an oligomer of C2A and not thrombin because thrombin is 37 kDa,
and this band is a little lower than the 30-kDa band in the protein marker. Since thrombin is
supposed to elute at greater NaCl concentration than HB-peptide, it is highly unlikely it would
elute at such an early stage as 100 mM NaCl.
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Figure 2.29 – Separation of C2A from HB-peptide by heparin-Sepharose affinity
chromatography. Lane 1, cleaved HB-C2A; Lane 2, 100 mM NaCl; Lane 3, protein marker;
Lane 4, 250 mM NaCl; Lane 5, 350 mM NaCl; Lane 6, 500 mM NaCl.
TEV protease on the other hand, does not bind to heparin, so this enzyme can be removed by
metal affinity chromatography, which can then be followed by passing the cleaved sample (HB
and S100A13) onto heparin-Sepharose. The target protein would then elute at low NaCl (0 mM
and 100 mM) concentration, whereas HB-peptide would elute at 500 mM NaCl.

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF)
provides useful information on molecular weights of proteins and peptides. After separation on
heparin-Sepharose, C2A and HB-peptide individually show purity at the relatively accurate
molecular weights (Figure 2.30). The molecular weights of HB-peptide and C2A are
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approximately 4 kDa and 16 kDa, respectively. The peak given around 8 kDa is the [M-H]2+,
basically m/z where z=2. The separation of HB-peptide from C2A results in C2A in the absence
of any residual HB-peptide.

A.

B.

Figure 2.30 – Mass spectra of C2A (Panel-A) and HB-peptide (Panel-B) after thrombin cleavage
and separation by heparin-Sepharose affinity chromatography.
Target protein, once cleaved from HB-affinity tag, retains its overall backbone conformation:
Two-dimensional 1H-15N heteronuclear single quantum coherence spectroscopy (HSQC) is a
useful tool for the backbone conformation of proteins56,57. Each peak corresponds to a particular
amino acid residue in the protein sequence. Previously, the spectrum of C2A, after cleavage
from its GST affinity tag, was obtained, and each peak was assigned, giving a “standard” for
comparison of this C2A to the one from HB-affinity tag58,59. A well-folded native protein has a
well-dispersed spectrum, which is what is seen on the spectrum of C2A after cleavage from HBpeptide (Figure 2.31). The overall spatial pattern of the peaks on this spectrum is in agreement
with the published spectrum from Rajalingam et al59 (Figure 2.32). The small size of the HB-
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affinity tag was promising for no interference with the target protein’s native structure, as seen
with some other affinity tags.

Figure 2.31 – 1H-15N HSQC spectrum of C2A after thrombin cleavage and separation from the
HB-peptide.
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Figure 2.32 – 1H-15N HSQC spectrum of C2A after cleavage from GST, reproduced from
Rajalingam et al, with permission from Biochemistry59. Red peaks correspond to C2A in pH 3.4,
whereas black peaks are in pH 6.
The black peaks are for C2A that is in its native conformation at a more neutral pH, which is
similar to the conditions used for C2A from HB-peptide (pH 7.2). As the pH drops to 3.4, there
is some perturbation seen in the peaks, leading to partially unfolded state.

This HB-peptide is successfully used as an affinity tag for recombinant proteins using heparinSepharose. In the future, proteins of biological importance can be used in conjunction with HBaffinity in the future to determine if their cleavage from HB-peptide interferes with their
biological activity. It is not expected that this peptide would interfere at all with protein
function, structure, or folding capability. Work involving the HB-peptide has been published as
a patent and manuscript60,61.
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Chapter 3
Detection of HB-Fusion Proteins Using Polyclonal Antibodies
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3.1. Abstract
Recombinant protein production is an important field for biotechnology and
pharmaceutical research. In order to determine if the appropriate proteins are expressed and
purified, antibodies are used for detection of these recombinant proteins. In our study, the use of
HB-peptide as an affinity tag has caused the need for specific detection of the HB-fusion
proteins. The detection method of choice for most laboratories is protein immunoblotting or
Western blotting. This method involves the resolution of the proteins on a SDS-PAGE gel,
electrophoretic transfer to a nitrocellulose, and detection using primary and secondary
antibodies. The primary antibodies that were used in this chapter were generated against a
specific sequence (first 12 amino acid residues) in the HB-peptide. They are, however,
polyclonal antibodies, which recognize multiple epitopes in an antigen, resulting in less specific
interactions. These antibodies are advantageous for amplifying signals of target proteins,
tolerance to changes in the protein conformation or denaturation, and more efficient detection
across cell types.

3.2. Introduction
Recombinant protein expression and purification are traced by separating proteins based
on molecular weight using gel electrophoresis. In some cases, recombinant proteins do not
express in high yields and are usually difficult to visualize on a SDS-PAGE gel1. In other cases,
proteins with similar molecular weights as the protein of interest may co-elute with the desired
protein during purification, causing ambiguity regarding the identity of the target protein of
interest2. Gel electrophoresis is not sufficient for all instances to detect proteins of interest.
Protein immunoblotting or Western blotting, first discovered in 1979, helps circumvent these
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problems in protein chemistry3. This simple, sensitive, and effective biochemical technique has
been modified and optimized to remain as a key method in biotechnology4. It is useful for the
detection of proteins with specific sequences that antibodies are raised against, particularly
proteins of low abundance5. It is also possible to characterize new proteins with unknown
biological activity by their reaction with specific antibodies6. Western blotting has been used for
a wide array of applications, such as a diagnostic tool for prion diseases, yeast infections,
parasitic infections, viral infections, diseases, cancer progression, and several others7,8,9,10,11,12,13.
The most well-known application is the detection of anti-HIV antibody in human serum
samples14.
Macromolecules are resolved on an electrophoresis gel, which are then
electrophoretically transferred to either a nitrocellulose or polyvinylidine difluoride (PVD)
membrane. It is hypothesized that proteins interact with the membranes in mainly a hydrophobic
manner, as observed by the elution of bound proteins when nonionic detergents are used15. The
membrane is then blocked to prevent any nonspecific antibody binding to the membrane.
Bovine serum albumin or non-fat milk is the blocking agent of choice because the protein binds
to areas on the membrane where the target protein is not found. This leads to less likelihood that
the primary antibody would bind to open areas on the membrane, leading to less background
noise. Polyoxyethylenesorbitan monolaureate (Tween 20) is also used in the wash buffer to
continually remove nonspecific antibody binding16. A primary antibody binds to the target
protein that contains the epitope to which it was raised against in an animal of choice. A
secondary antibody that is generated against the animal of choice, in which the primary antibody
was raised, is modified with a reporter enzyme such as alkaline phosphatase or horseradish
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peroxidase. The enzyme, upon exposure to its substrate, produces a colorimetric response of
insoluble dye, indicative of the target protein17.
Antibodies, or immunoglobulins, are naturally occurring molecules that are produced
from specialized B lymphocytes called plasma cells when a foreign molecule (i.e. bacterial
toxins) invades the body, to which the antibody will specifically bind18,19. In 1890, Emil von
Behring applied his finding (when rabbits were injected with tetanus toxin, they produced tetanus
antibodies) to treat diphtheria in children20. Researchers have produced antibodies from either
multiple B cell clones (polyclonal antibodies) or a single clone (monoclonal antibodies)20.
Monoclonal antibodies result from splenic B cells being fused with myeloma cells to form
hybridomas, each one producing a unique antibody21. These antibodies recognize only one
epitope on each antigen, making the antigen-antibody interaction more specific. Polyclonal
antibodies do recognize more than one epitope, resulting in more nonspecific interactions, but
these are less expensive and more tolerant of changes in protein structure such as denaturation
required in SDS-PAGE22. We have used this method for the specific detection of HB-fusion
proteins by anti-HB polyclonal antibodies.

3.3. Materials and Methods
Western blotting of HB-fusion proteins
HB-antibodies (HB-Ab) were generated by Genescript, NJ, USA using our specifications. The
segment of the HB-peptide possessing the highest antigenicity was designed using the Optimum
Antigen design program at the vendor site (http://www.genscript.com/PolyExpress.html). HBAb was raised in rabbit against the first 14 amino acids in the HB-peptide
(QKAQKAQAKQAKQA). A cysteine residue was added to the C-terminal end of the peptide to
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couple the N-terminus amino group of the carrier protein like thyroglobulin or Keyhole limpet
hemocyanin (KLH) to the thiol group of the peptide using m-maleimidobenzoyl-Nhydroxysuccinimide ester (MBS) as a cross linking agent. This residue is also known to increase
immunogenicity. The detailed protocol for the generation of HB-Ab can be obtained at the
vendor website (http://www.genscript.com/PolyExpress.html).

Western blotting for all experiments was performed by making adaptations of the protocol from
Burnette et al23. Proteins were resolved on a 15% SDS-PAGE gel and were then transferred to a
nitrocellulose membrane for 2 hours at 150 V and 75 mA. The nitrocellulose membrane was
blocked using 5% skim milk in Tris buffered saline with Tween 20 (1X TBS-T) (10 mM Tris,
150 mM NaCl, 0.05% Tween-20, pH 7.4) at 25oC for 30 minutes. The membrane was then
washed with 0.2% bovine serum albumin (BSA) in 1X TBS-T and the primary antibody, raised
in rabbit against the HB-peptide, was added at 1:2500 dilution and incubated for 16 hours at
25oC. Three washes of the membrane were performed using 1X TBS-T* (varying NaCl
concentrations of 150 mM, 500 mM, and 750 mM NaCl). Alkaline phosphatase-conjugated
secondary antibody was added to the membrane at 1:2500 dilution and incubated for 2 hours at
25oC. Nitrocellulose-immobilized protein was detected using the NBT/BCIP substrate.

Limit of Detection of HB-C2A Using Dot Blotting
Dot blotting was performed similarly to Western blotting without the use of electrophoretic
transfer. Varying amounts of fusion protein (1 ug to 0.5 ng) were spotted on the nitrocellulose
membrane. For the dot blot washed with 150 mM NaCl, the negative control was BSA in
varying amounts of protein as well. Antibody response was calculated by imaging densitometry
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using UN-SCAN-IT Gel Analysis Software (Silk Scientific, Orem, UT). Appropriate
background subtractions were made.

Western Blotting to Detect and Monitor Protein Expression and Purification
The expressed cell pellets were resuspended in 5 mL of 10 mM Tris-HCl, pH 8. All three HBfusion cell samples were sonicated (10 minutes, 10-second pulse with 10-second rest) on ice
using a Microson XL unit with power setting at 15. The cell lysate was centrifuged at 20,000
rpm for 30 minutes at 4oC to remove cell debris. These samples were resolved on a 15% SDSPAGE gel, and were then transferred electrophoretically to a nitrocellulose membrane. Normal
Western blotting was performed as described previously using varying concentrations of NaCl
(150 mM, 500 mM, 750 mM) in TBS-T* for secondary antibody incubation. Each eluted protein
sample from the heparin-Sepharose purification of the HB-fusion proteins was also TCA
precipitated as previously described, and Western blotting occurred. During this technique, 750
mM NaCl in the TBS-T* was used for secondary antibody incubation. Another Western blotting
was performed on the pure HB-fusion proteins using the same procedure.

Western Blotting of GST-HB and HB-S100A13 Cleavage Products
GST-HB was cleaved, and after separation of GST from HB-peptide by the established heat
treatment method, the samples resolved on a tricine gel. HB-S100A13 underwent cleavage by
TEV protease, and these cleaved samples were resolved on a 15% SDS-PAGE gel. They were
then transferred to a nitrocellulose membrane for 3 hours at 150 V and 100 mA for tricine gel
and 2 hours at 150 V and 80 mA for SDS-PAGE gel. The Western blotting protocol stated
above was performed.
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Spiking of HB-C2A in Different Cell Lines
Mus musculus NIH-3T3 cells, Pichia pastoris KM71H cells, and E. coli Rosetta (DE3) cells
were resuspended in small volume of 1X PBS. These samples were sonicated for 45 seconds (5
second-pulse with 5-second rest) on ice and centrifuged at 13,000 rpm for 5 minutes. The total
protein present in the supernatant was estimated using Bradford assay at 595 nm. The total cell
sample required was 100 µg, to which 10 µg HB-C2A was added. The cell samples were spotted
on the nitrocellulose membrane in order to have 160 ng HB-C2A present. Varying NaCl
concentrations in the TBS-T (150 mM, 500 mM, and 750 mM NaCl) were used. Similar dot
blotting technique was used as stated above to detect the HB-C2A in the crude mixture before
Western blotting occurred. Antibody response was calculated by imaging densitometry using
UN-SCAN-IT Gel Analysis Software (Silk Scientific, Orem, UT). Appropriate background
subtractions were made. The cell samples (1.25 µg HB-C2A) were then TCA precipitated and
resolved on a 15% SDS-PAGE gel, from which Western blotting occurred as previously stated.

3.4. Results and Discussion
HB-C2A is detected at nanogram levels using polyclonal antibodies: Optimization of the use of
these antibodies needs to be established before they can be used efficiently in a commercial
setting. These antibodies should recognize a specific sequence in the HB-peptide (first 12 amino
acids), which in turn should give a fairly specific response on the nitrocellulose membrane. In
order to detect proteins containing the HB-affinity tag, their limit of detection needs to be
established first. Dot blotting is a technique useful for determination of the presence of a protein
to conclude if Western blotting is required. If low amounts of protein/antigen are present, it
might not be transferred efficiently to the nitrocellulose membrane, which results in a blank
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membrane. Another use of dot blotting is for establishing if the amount of protein required for
adequate antibody binding is at an acceptable level for experimental purposes. If the amount
required were too high, it would not be feasible to use these antibodies for Western blotting.
Varying amounts of NaCl were used in the dot blotting to determine if this affects the antibodyantigen interaction (Figure 3.1). HB-C2A can be detected as low as 10 ng in 150 mM NaCl,
which is a promising result for commercial use of these antibodies (A). BSA is used as a
negative standard because it is a protein that is not similar to the HB-peptide, not a heparinbinding protein. This protein should not exhibit any binding affinity to antibodies. No antibody
response is observed on the membrane (circles 9-13). When 500 mM NaCl (B) and 750 mM
NaCl (C) are used, HB-C2A is detected down to only 50 ng instead of 10 ng. The increase in
salt concentration slightly disrupts the interaction between HB-peptide and the antibodies. The
level is still in the nanogram range, which means the antibodies can be used for detection in lowlevel protein production.

A.

B.

C.

Figure 3.1 – Dot blot analysis of HB-C2A in TBS-T containing 150 mM NaCl (Panel-A), 500
mM NaCl (Panel-B), and 750 mM NaCl (Panel-C). Circles 1-8 are HB-C2A; Circles 9-13 are
BSA in the same amounts as circles 1-5. Circle 1, 1 µg; Circle 2, 500 ng; Circle 3, 100 ng;
Circle 4, 50 ng; Circle 5, 10 ng; Circle 6, 5 ng; Circle 7, 1 ng; Circle 8, 0.5 ng.
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Densitometry shows the increase in antibody response as the amount of HB-C2A blotted is
increased for all three conditions (Figure 3.2). This is expected because more antigen (more
epitopes) is present for the antibodies to bind to, leading to greater detection.
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Figure 3.2 – Plot of densitometric scan of dot blot analysis of HB-C2A. The blue curve
represents 150 mM NaCl, green is 500 mM NaCl, and red is 750 mM NaCl.
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The pure fusion proteins were then transferred to a nitrocellulose membrane and detected using
Western blotting (Figure 3.3). The fusion protein HB-S100A13 migrated slightly higher than
what its expected molecular weight is (~ 16 kDa), but it is still detected using the polyclonal
antibodies.

135

1

2

3

4

58
46
30
25

17
7

Figure 3.3 – Western blot analysis of pure HB-fusion proteins. Lane 1, protein marker; Lane 2,
HB-C2A; Lane 3, HB-CAlb3; Lane 4, HB-S100A13.
HB-antibodies detect fusion proteins in crude cell samples and during purification: Even
though the antibodies bind to HB-C2A when in pure form during dot blotting, one must examine
their specificity for the fusion proteins in the presence of other proteins. When proteins are not
expressed in high yields, bands normally do not appear on SDS-PAGE gels in cell lysates where
hundreds of other E. coli proteins are present. There is also a chance of other proteins that are
relatively the same size as the protein of interest at higher yield than the protein of interest,
which could result in false positives on the gels occurring. There is a need for sensitive and
specific detection in cell lysates before further purification is performed. Western blotting is a
highly specific technique that can be used for low-level detection of antigens using specific
antibodies grown against a specific sequence. Since the antibodies were grown against the
specific sequence in HB-peptide, which was specially designed and expressed in much higher
yield than E. coli proteins, it is likely that the antibodies would bind to proteins that contain the
HB-affinity tag. In order to test this hypothesis, Western blotting is performed on lysed cells that
contain the proteins of interest, HB-fusion proteins (Figure 3.4).
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Figure 3.4 – Western blot analysis of crude cell samples in TBS-T containing 150 mM NaCl
(Panel-A), 500 mM NaCl (Panel-B), and 750 mM NaCl (Panel-C) after SDS-PAGE is performed
(Panel-D). Lane 1, protein marker; Lane 2, HB-CAlb3-clear cell lysate; Lane 3, HB-CAlb3post-sonication pellet; Lane 4, HB-C2A-clear cell lysate; Lane 5, HB-C2A-post-sonication
pellet; Lane 6, HB-S100A13-clear cell lysate; Lane 7, HB-S100A13-post-sonication pellet.
It is more advantageous to use secondary antibodies that are conjugated with alkaline
phosphatase instead of horseradish peroxidase because this commercially available enzyme
(alkaline phosphatase) exists in high purity24. In 150 mM NaCl, the HB-fusion proteins are
detected extremely well in the lysate and pellet, as seen by the darker bands on the membrane
(Panel-A). There are, however, other proteins that are detected as well, which is probably due to
the nonspecific manner of binding of the secondary antibodies. In addition, polyclonal
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antibodies are known to be less specific and more variable than monoclonal, so there is that risk
of cross-reactivity when using these antibodies for Western blotting25. Polyclonal antibodies
recognize more than one epitope on an antigen, but can also recognize other proteins that have
high homology with the HB-fusion proteins26. This finding could plausibly explain the presence
of other protein bands along with the HB-fusion proteins on the membrane. Since the HB-fusion
proteins are expressed in higher yield than the other E. coli proteins, antibodies should give a
greater response when bound to these concentrated HB-proteins. In this context, the salt
concentration was increased to 500 mM NaCl to remove nonspecific interactions, which aids in
the removal of other protein bands (Panel-B). Still, other protein bands are present, so 750 mM
NaCl is preferred because it removes the majority of the nonspecific interactions (Panel-C).
Multimers of various proteins can be observed as well, which would contain the epitope of
interest that the antibodies bind to. This could result in other proteins being detected on the
membrane. The HB-peptide is composed of a repeating sequence of the epitope that was used in
raising the antibodies, which means the interaction between antibodies and HB-fusion proteins is
strong and amplified. When proteins do not express in large amounts and high sensitivity is
required, polyclonal over monoclonal antibodies are preferred.

Once the salt concentration for specific detection is optimized, Western blotting of the
purification fractions is performed. Using 750 mM NaCl, only the bands corresponding to the
HB-fusion proteins HB-C2A (Figure 3.5), HB-CAlb3 (Figure 3.6), and HB-S100A13 (Figure
3.7) appear on the membrane. Even in the presence of contaminants, such as in 0 mM to 350
mM NaCl fractions, a pure band of interest is observed. From these results, it is clear that the
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antibodies are specific to HB-fusion proteins, as the bands align with the marker at their known
molecular weights (HB-C2A is 20 kDa, HB-CAlb3 is 18 kDa, HB-S100A13 is 16 kDa).
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Figure 3.5 – SDS-PAGE (Panel-A) and Western blot analysis (Panel-B) of fractions collected
from the purification of HB-C2A using heparin-Sepharose affinity chromatography. Lane 1,
protein marker; Lane 2, post-sonication pellet; Lane 3, clear cell lysate; Lane 4, 0 mM NaCl;
Lane 5, 100 mM NaCl; Lane 6, 350 mM NaCl; Lane 7, 500 mM NaCl.
Despite being polyclonal antibodies, they show specific interaction with the fusion proteins
containing the HB-sequence when 750 mM NaCl is used.

139

A.

B.
1

2

3

4

5

6

7

1

8

80
58
46

80
58
46

30

30

25

25

17

17

2

3

4

5

6

7

8

Figure 3.6 – SDS-PAGE (Panel-A) and Western blot analysis (Panel-B) of fractions collected
from the purification of HB-CAlb3 using heparin-Sepharose affinity chromatography. Lane 1,
protein marker; Lane 2, post-sonication pellet; Lane 3, clear cell lysate; Lane 4, 0 mM NaCl;
Lane 5, 100 mM NaCl; Lane 6, 350 mM NaCl; Lane 7, 1 M NaCl; Lane 8, 2 M NaCl.
HB-CAlb3, however, migrates at a slightly lower molecular weight compared to the marker, as
seen by its band migrating near the 17-kDa band. This is possibly due the protein not being fully
reduced by β-mercaptoethanol, which in turn does not reduce all disulfide bonds causing the
protein to migrate faster on the gel. In other instances, HB-CAlb3 migrates near the 17-kDa
marker band, but other times migrates faster. If a protein does not have its structure completely
disrupted by reducing agents, the resolving rate is skewed. Since the antibodies do bind to this
protein alone on the membrane, it can be inferred that it is indeed HB-CAlb3 regardless of how it
resolves on the gel. As the amount of contaminants are decreased in each fraction, the signal on
the membrane corresponding to the fusion protein increases. Another positive finding is that
even in low yield, proteins of interest (HB-fusion proteins) can be detected via Western blotting
using these antibodies. In the future, if higher specificity is required, anti-HB monoclonal
antibodies need to be generated. However, to circumvent the use of expensive monoclonal
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antibodies, the salt conditions for immunoblotting have been successfully optimized to reduce
any nonspecific interactions and cross reactivity.
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Figure 3.7 – SDS-PAGE (Panel-A) and Western blot analysis (Panel-B) of fractions collected
from the purification of HB-S100A13 using heparin-Sepharose affinity chromatography. Lane
1, protein marker; Lane 2, post-sonication pellet; Lane 3, clear cell lysate; Lane 4, 0 mM NaCl;
Lane 5, 100 mM NaCl; Lane 6, 350 mM NaCl; Lane 7, 1 M NaCl.
HB-peptide, not the target protein, contributes to antibody response: Antibodies are specific to
HB-fusion proteins, but should only bind to the epitope present in the peptide and not the partner
protein. HB-peptide is fused to GST, which is a 26 kDa protein that is not known to be a
heparin-binding protein, and therefore should not contain the specific epitope that is recognized
by the antibodies27. It is therefore expected that GST should not contribute to antibody response.
In order to examine this possibility, GST-HB, GST, and HB-peptide were analyzed by SDSPAGE and Western blotting (Figure 3.8). Only the fusion protein (lane 1) and HB-peptide (lane
3) are detected on the membrane, which demonstrates the antibodies are specific to only HBpeptide and proteins that contain this affinity tag. The large molecular weight of GST does not
contribute to the antibody response elicited on the membrane.
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Figure 3.8 – SDS-PAGE (Panel-A) and Western blot analysis (Panel-B) of GST-HB cleavage
samples. Lane 1, HB-peptide; Lane 2, GST; Lane 3, GST-HB.
Cleaved HB-S100A13 has a similar result, in which only the HB-peptide is detected on the
membrane (Figure 3.9). The target protein does not contain any structural similarities (heparinbinding capability), which removes any possibility of it binding to the antibodies. These
antibodies can be used to detect fusion proteins that contain the HB-affinity tag.
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Figure 3.9 – SDS-PAGE (Panel-A) and Western blot analysis (Panel-B) of cleaved HBS100A13. Lane 1, HB-S100A13; Lane 2, 6-hour cleavage; Lane 3, 9-hour cleavage; Lane 4, 15hour cleavage; Lane 5, 18-hour cleavage.
In the previous Western blotting of the expression clones (Figure 3.4), the contaminating
proteins that interacted with HB-antibodies are possibly other proteins that have similar
sequences as HB-peptide, perhaps even heparin-binding proteins present in the bacterial cells.
Since the S100A13 and GST are not considered heparin-binding proteins, they would not contain
epitopes similar to HB-peptide, which shows that the detected proteins have to, in fact, be similar
to HB-peptide. Proteins that do not exhibit heparin-binding qualities would not bind to the
antibodies.

HB-antibodies can interact with fusion proteins in other cell lines: Many eukaryotic proteins
do not fold properly during expression in bacteria, which calls for their expression in other cells,
such as yeast or mammal. When expression occurs, post-translational modification occurs that is
not found in bacterial expression systems28. These modifications change the structural features
of the target protein in these cell lines, resulting in the original epitope being altered. Once the
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epitope changes, monoclonal antibodies cannot bind to the target protein of interest. This is due
to monoclonal antibodies only recognizing one epitope on an antigen, which is too specific for
fusion proteins expressed in other cell lines. Polyclonal antibodies are more tolerant to changes
across cell lines, which is beneficial for proteins that are expressed in other cell lines. However,
cross reactivity of polyclonal antibodies occurs on occasion, with the antibodies binding to other
cell host proteins, as stated previously. This spiking experiment is to determine the efficacy of
the antibodies binding to HB-fusion proteins in any host of choice. Dot blotting shows the
detection of the fusion protein is successful in crude cell samples (Figure 3.10). The various salt
concentrations are used in order to reduce the nonspecific interactions that occur as previously
stated in crude cell samples. Even in 750 mM NaCl, the antibodies still bind to the fusion
protein in all the cell lines. The presence of different non-heparin-binding proteins produced in
the host cells do not appear to interfere with the antibody-antigen response generated on the
membrane.
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Figure 3.10 – Dot blot analysis of HB-C2A spiked in bacterial, mammalian, and yeast cell lines
in TBS-T containing 150 mM NaCl (Panel-A), 500 mM NaCl (Panel-B), and 750 mM NaCl
(Panel-C). Circle 1, bacteria; Circle 2, mammal; Circle 3, yeast.
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Quantification by densitometry shows a decrease in antibody response (expressed as a
percentage) from 150 mM to 750 mM NaCl (Figure 3.11). This salt concentration was set to
100% because this is the normal blotting condition. No interference of antibody binding should
occur using this concentration. There is not a large decrease in antibody response for bacterial
and mammalian cells when the salt concentration is increased from 150 mM NaCl. Similar to
the expression clones, 750 mM NaCl was the salt concentration of choice used for the
subsequent Western blotting of the spiking experiment.
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Figure 3.11 – Plot of densitometric scan of dot blot analysis of HB-C2A spiked in bacterial
(blue), mammalian (red), and yeast (green) cell lines.
All three cell samples, after undergoing TCA precipitation, were resolved on SDS-PAGE and
transferred to nitrocellulose membrane (Figure 3.12). Even in the cell lysates, in which many
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other contaminating proteins are present, the antibodies are still specific to HB-C2A. Bacteria
produce much higher amounts of protein during expression, which can then “drown out” the
presence of HB-C2A. For Western blotting, TCA precipitation is required of the cell lysate,
which for the bacteria sample produced an extremely large pellet. The use of urea did not
completely dissolve the bacterial pellet due to its large size, compared to the yeast and
mammalian cell pellets. Some of the HB-C2A could have been lost in this pellet and not been
resolved on the SDS-PAGE gel. This can then lead to a decrease in signal on the membrane. In
dot blotting, however, no precipitation of the cell lysate was required, leading to the full,
uninterrupted interaction between the antibodies and HB-C2A. Based on this experiment, these
polyclonal antibodies prove, once again, to be beneficial for the detection of HB-fusion proteins.
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Figure 3.12 – SDS-PAGE (Panel-A) and Western blot analysis (Panel-B) of HB-C2A spiked in
different cell lines. Lane 1, HB-C2A; Lane 2, bacterial cells; Lane 3, mammalian cells; Lane 4,
yeast cells.

146

The use of polyclonal antibodies that are generated against HB-affinity peptide has shown great
promise for the detection of HB-fusion proteins. The cell line does not play a large role in the
binding capability of the antibodies to their target protein of interest. Even though polyclonal
antibodies have been shown to bind in a nonspecific manner at times, increasing the salt
concentration during the washing steps decreases these nonspecific interactions. These
antibodies can be used commercially to detect any protein that contains the HB-affinity tag no
matter the cell of choice. Some work in this chapter has been published as a manuscipt29.
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Chapter 4
Separation of Glycosaminoglycans by HB-Affinity Column
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4.1. Abstract
Heparin is an important drug used for the treatment and cure of blood clots. In 2008,
molecules that are similar to heparin (OSCS and DS) were detected in batches of heparin that
resulted in numerous deaths worldwide. The contamination of heparin in 2008 has spurred on a
global approach to develop pure heparin either from existing animal sources or synthesize
oligosaccharides that have anticoagulation activity. We have designed a heparin-binding (HB)
peptide that has shown to bind with greater binding affinity to heparin than to dermatan sulfate,
chondroitin sulfate, and hyaluronic acid. Based on this finding, the HB-peptide was then
coupled onto NHS-Sepharose, which is a resin commonly used for the immobilization of
peptides and antibodies. The HB-coupled affinity column was applied in a similar fashion as
heparin-Sepharose is used to purify heparin-binding proteins, such as fibroblast growth factors.
A mixture of GAGs that included heparin, DS, and CS was applied to the HB-affinity column.
Using a step-wise NaCl gradient, fractions of GAGs were collected. The 1H NMR spectrum of
each fraction was analyzed and compared to standard GAG samples, and using this, we
discovered that heparin can in fact be separated from the majority of the other GAGs. Some
“impurities”, however, still remained when heparin was eluted, in higher salt concentrations.
Based on this result, we concluded that the “impurity” peak actually belonged to DS because
chondroitin sulfate did not show significant binding affinity to the peptide to stay bound to the
column for this long. These results are very promising for the preliminary use of this peptide for
the isolation of GAGs. We have also successfully isolated GAGs from chicken intestines on a
small-scale level using a simple method of enzymatic treatment. Azure A assay was used to
show close to 5 µg of GAGs was obtained, which was not enough to purify using the HB-affinity
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column. The HB-peptide is a very promising molecule, when future modifications are
implemented, for the commercial application of the isolation of heparin.

4.2. Introduction
Heparin, a glycosaminoglycan, was discovered in 1916 by McLean and Howell, but first
used as an anticoagulant in 1935 in clinical trials1. Heparin has also shown promise in therapy
for rheumatoid arthritis (RA). It works by reducing angiogenesis by HBPs, which promotes the
destruction of cartilage and bone in the course of RA2. This remarkable drug is normally
isolated in high yields (tons) from porcine intestines, but in 2008, contaminants of OSCS and DS
were present in the isolated batch. This oversight caused over 200 deaths3. Anaphylactic shock
and vasodilation were the results of the activation of the kinin-kallikrein and complementary
cascade4,5,6. OSCS is a semisynthetic molecule containing four sulfate groups per one building
block, not normally present in animal tissue7.
The major challenge in the analysis of adulterated heparin samples is the detection and
identification of the structurally similar impurities3. GAGs are extremely similar in structure but
there are certain aspects of each one that is unique from the others. For example, each GAG has
a unique NMR fingerprint that can be used for its detection and separation from the other
GAGs8,9,10. Heparin and contaminated heparin have different NMR spectra, due to the presence
of DS and OSCS3. These impurities actually have their own unique proton signals in NMR11,12.
Proton NMR has been established as the major analytical method to detect contaminants in
adulterated heparin samples13,14,15,16. Despite these analytical procedures for the identification of
contaminated heparin samples, there is still a need for pure heparin samples for use in medicine.
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Synthetic pathways have been proposed for the production of pure heparin, but these
processes have not shown to be efficient. The main bottleneck of this method is the poor yield
(milligram scale) obtained of the desired product as well the incessantly large amounts of
synthesis steps and cost17. A chemoenzymatically prepared alternative to heparin has been made
by using enzymes and substrates found in the biosynthetic pathway in the body. In 2013, the
number of steps required to obtain fondaparinux was decreased from the 50 steps to 36 steps18.
Another pentasaccharide of heparin called Idraparinux was synthesized in a total of 51 steps with
only 4% overall yield from D-glucose and α-D-glucopyranoside19. In addition, although the risk
of thromboembolism is reduced from that of heparin, the costly and increased number of steps
outweighs the benefit of synthesis. The biosynthesis of heparin in nature produces the most
accurate molecules for anticoagulation, whereas you run the risk of not enough or incorrect
sulfation patterns on the synthesized heparin oligosaccharides. Bhaskar et al recently have
proposed a bioengineered approach to the synthesis of heparin from recombinant heparosan in E.
coli, which resembles a non-sulfated heparin backbone20. The synthesis needs to be optimized
further for low cost and efficient yield. Other groups have proposed a similar process to the
isolation from porcine and bovine intestine in other animal sources. Saravanan et al have
isolated a LMWH of 6500-7500 Da from Marine Mollusc Amussium pleuronectus in decent
yield that showed good anticoagulation activity. This analog is sulfated like porcine heparin and
contains equivalent uronic acid and hexosamine21. The most cost and time effective method for
obtaining pure heparin or LMWH appears to be purifying already existing contaminated samples
using affinity chromatography, but optimized methods for this protocol have not yet been
reported. In order for this highly needed anticoagulant to be used again, a new method for its
isolation is required.

154

FGF-1 is a heparin-binding protein that uses heparin proteoglycans to activate its cell
signaling pathways. In the absence of heparin/HS present, FGF-1 cannot bind to its tyrosine
kinase receptor with high affinity22,23,24. Based on structural features and sequence information
present in HBPs, such as FGF-1, a heparin-binding (HB) peptide was designed that is capable of
binding to heparin. This peptide, like other small molecules, can be immobilized on a solid
matrix for binding of its partner molecule, heparin. Peptides and antibodies have shown promise
in their coupling to NHS-Sepharose for protein partner or antigen binding studies25,26. Using this
method, we have designed an HB-affinity column that should tightly bind heparin. This method
enables heparin to be separated from other contaminating GAGs to achieve pure heparin for
future biomedical applications. In this study, there is a pressing need for a simple and costeffective isolation of pure heparin.

4.3. Materials and Methods
Isothermal Titration Calorimetry
ITC measurements were performed using iTC200 (MicroCal Inc., Northampton, MA) at 25°C.
Concentration of HB-peptide was maintained at 1:10 the concentration of the GAGs in 10 mM
phosphate buffer, 100 mM NaCl, pH 7.2. Unfractionated GAGs chosen were heparin sodium
salt from porcine intestinal mucosa (Sigma-Aldrich), hyaluronic acid sodium salt from bovine
vitreous humor (Sigma-Aldrich), dermatan sulfate from porcine intestinal mucosa (SigmaAldrich), and chondroitin sulfate hydrogen sulfate (Chem-Impex Int’l). All samples were
centrifuged at 13,000 rpm to remove insoluble particulates and later degasses under vacuum.
The corresponding GAG was titrated into HB-peptide at 1.3 µL injections with 12 sec intervals.
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The raw data was fit using binding models in the Origin Version 7.0 software supplied by
MicroCal Inc. The accuracy of the fitting was assessed using the given Χ2 values.

Coupling to NHS-Sepharose
N-hydroxysuccinimide (NHS)-activated Sepharose 4 Fast Flow resin (GE Healthcare Life
Sciences, Pittsburgh, PA) is a pre-activated agarose matrix that is designed for efficient
immobilization of small proteins and peptides. Preliminary coupling procedures were performed
using GSH. The coupling protocol provided by GE Healthcare Life Sciences
(www.gelifesciences.com) was followed precisely with only one minor change. In short, resin
was washed with 10-15 column volumes (CV) of cold 1 mM HCl. The resin was then washed
with 10 CV of coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 8.3) before the addition of the
ligand. Ligand was incubated with resin at 25oC for 4 hours or at 4oC for 16 hours. Coupling
efficiency was determined by using absorbance of sample before and after coupling at 205 nm by
following the protocol published by Scopes27. The pH of the coupling buffer was also varied
(pH 6, pH 8.3, and pH 8.8) to determine the best coupling conditions. After coupling occurred,
the activated groups were blocked using ethanolamine for 2-3 hours. The resin was then
regenerated using alternating solutions of 0.1 M Tris buffer, pH 8 and 0.1 M acetate buffer, pH
4.5. The resin was then stored at 4oC in 20% ethanol.

This same protocol was followed for the coupling of HB-peptide to NHS-Sepharose. Ligand (2
mg to 10 mg HB-peptide) was incubated in coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH
8.3) at varying temperatures as previously described. A column (labeled “negative”) was
prepared by following the same protocol without the addition of ligand.
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Fluoroisothiocyanate (FITC)-Heparin Binding
FITC-heparin obtained from Dr. David Zaharoff (University of Arkansas) was used to determine
the binding capability of heparin to HB-peptide that was coupled to NHS-Sepharose.
Fluorescence spectroscopy was performed on fractions collected from the binding experiment
using Hitachi F2500 fluorimeter, with an excitation wavelength of 488 nm and emission range of
500-600 nm. The emission maximum for FITC-heparin was 525 nm. The provided FITCheparin sample was diluted in 10 mM Tris-HCl, pH 8 to obtain a total volume of 1 mL (same as
the column volume). The fluorescence spectrum of this sample was obtained for both the HBSepharose and the negative control (without HB-peptide). The resins were equilibrated with 10
CV of 10 mM Tris-HCl, pH 8. After equilibration, FITC-heparin was incubated with the resin in
a gentle rocking motion at 4oC for 2-3 hours. After centrifuging the resin at 3500 rpm, the
supernatant was then decanted and centrifuged again at 13,000 rpm for 1 minute to remove any
resin particulates. After the supernatant was decanted, the resin was incubated with 10 mM TrisHCl with increasing concentrations of salt (100 mM to 2 M NaCl) for 10 minutes at 25oC for
each concentration. The initial binding of FITC-heparin was then performed at 25oC for 1 hour
as well to compare binding efficiency with that at 4oC. The preparation of FITC-heparin was
attempted but resulted in only a few molecules of FITC coupled to heparin. The protocol
produced by Nagasawa et al28, was modified. In short, 10 mg LMWH dissolved in 100 µL of 0.5
M carbonate buffer, pH 8.5. This mixture was added to a solution of 1.9 mL of DMSO
containing 13 mg FITC. A 1:10 heparin: FITC molar ratio was obtained to ensure efficient FITC
coupling. This solution was incubated at 37oC for 2 hours without rocking. The DMSO and free
FITC was dialyzed in Milli-Q H2O every hour for 12 hours. After dialysis, no color was
observed for the coupled FITC-heparin.
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NMR Spectroscopy of Glycosaminoglycans
Proton NMR experiments were performed using Bruker Avance 700 MHz NMR at 25oC.
Measurements were performed on unfractionated heparin, CS, and DS in Milli-Q H2O (90% H2O
+ 10% D2O). All 1H data were referenced to the resonance frequency of H2O (~ 4.7-4.8 ppm).

Glycosaminoglycan Binding to HB-Sepharose
HB-peptide was coupled to NHS-Sepharose (70% HB-peptide coupled) by the protocol stated
above. The coupled HB resin was equilibrated extensively (10-15 CV) using 10 mM phosphate
buffer, pH 7.2. The three GAGs chosen were DS, CS, and UFH. Each of these GAGs (5 mg)
was dissolved in 10 mM phosphate buffer, pH 7.2, and the solutions were mixed together. This
GAG mixture was incubated with the coupled resin at 4oC for 4 hours with gentle rocking. After
incubation, phosphate buffer containing 100 mM to 2 M NaCl was used (2 CV each) to elute the
GAGs. Each elution occurred after 15 minutes rocking at 25oC. The resin was centrifuged at
4500 rpm to settle the beads from which the liquid portions were dialyzed (MWCO 3 kDa) into
10 mM phosphate buffer, 100 mM NaCl, pH 7.2. The samples were then concentrated to 1 mL
and were then analyzed by 1H NMR spectroscopy on a BrukerAvance 700 MHz NMR at 25oC.
These spectra were compared to the standard spectra of the GAGs in Milli-Q water previously
acquired.

Isolation of Glycosaminoglycans from Chicken Intestines
Chicken intestines (obtained from Dr. Doug Rhoads, University of Arkansas) were mixed with
10 mM phosphate buffer, 100 mM NaCl, pH 7.2 and then blended using a high-speed blender
provided by Dr. Frank Millett. After homogenizing the sample, it was centrifuged at 6,000 rpm,
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and the solid layer (pellet) was first frozen in liquid nitrogen and then crushed using mortar and
pestle. The crushed solid was added to the liquid layer and centrifuged again at the same speed.
The resulting liquid layer (supernatant) was used for GAG isolation. To this sample, 2% sodium
metabisulfite was added as a preservative for future storage. A control sample was prepared in
similar fashion, but no enzyme addition occurred. To the liquid sample, DNase (0.5 mg/mL)
was added and incubated with slow shaking (50 rpm) at 37oC for 6 hours or 0.1 mg/mL for 16
hours. The sample was again centrifuged, and the two layers (pellet and supernatant) were
separated. Thermolysin (0.2 mg/mL) was then added to both layers and incubated at 70oC for 10
hours. The sample was again centrifuged, and two layers were separated. The liquid layer was
dialyzed against 10 mM phosphate buffer, pH 7.2.

Quantification of Glycosaminoglycan Content Using Azure A Assay
A 2 mg/100 mL solution of Azure A chloride (Sigma-Aldrich) in 1X PBS was used for the assay.
Varying amounts of unfractionated heparin were prepared (1-500 µg) using 1X PBS.
Absorbance measurements were acquired on an Agilent 8453 spectrophotometer at 620 nm after
30 min incubation. A solution containing 1 mL of Azure A and 1 mL of 1X PBS was measured
as the 100% absorbance reading. This standard curve was developed using the absorbance
reading given compared to the starting reading of 100% for the buffer and dye solution. The
GAG amount in chicken intestines was calculated by measuring the absorbance at 620 nm using
Azure A assay.
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4.4. Results and Discussion
HB-peptide has greater binding affinity for heparin than other GAGs: GAGs are polydispersed
polysaccharides, existing in various chain lengths of differing molecular weights. In this
instance, it is extremely difficult to identify a specific molecular weight for experiments.
However, average molecular weights for the GAGs have been reported, which are used for
calculating binding affinities for the peptide and different GAGs. Using different average
molecular weights, concentrations of the GAGs can be estimated and used for calculating the
binding affinities through ITC experiments. HA is a large polysaccharide with average
molecular weights in the thousands (kDa)29,30. In this context, a logical concentration for ITC
could not be obtained for appropriate binding. The peptide binds to the various unfractionated
GAGs in a 1:1 stoichiometry, and the spectra are hyperbolic (Figure 4.1). This change in
binding from LMWH and HS (3 kDa) is probably due to the extreme polydispersity of the
unfractionated polysaccharides. Large chains interact with the small peptide in a very different
manner than the smaller chains found in LMWH and HS. There are also small chains present in
the unfractionated GAGs as well that would interact with the peptide differently than the large
chains, compromising the exact binding mechanism. The dissociation constants that exhibited
the best X2 values were chosen for each GAG-peptide interaction, which are represented by the
curves shown below (Figure 4.1). UFH binds with the best affinity for the peptide (nM)
followed by DS (low µM) then CS (higher µM) and then HA that had no binding. It is expected
that this peptide bind best to heparin because it has similar structural features as other HBPs that
have good affinity for heparin.
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Figure 4.1 – Isothermograms of the titrations of HB-peptide with UFH (Panel-A), DS (Panel-B),
CS (Panel-C), and HA (Panel-B). A one-site binding model was used to fit the raw data from the
titration, which is shown in the top panel. The bottom panel shows the integrated data from the
raw data.
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The molecular weights that exhibited the best binding curves and number of binding sites, not
just dissociation constants, were chosen for analysis. As the estimated molecular weight drifts
farther from the actual average molecular weight (less accurate estimated molecular weight), the
binding curves do not fit the data as well. All of these variables were taken into account before
the dissociation constants were determined. Heparin contains the most sulfation content among
the GAGs, which gives it the highest negative charge. This greater negative character
contributes to its better binding affinity for positively charged molecules (i.e. HBPs and the HBpeptide). HB-peptide would then be expected to bind more specifically to heparin because 1) it
has similar structural features as the HBR of HBPs and 2) heparin contains more sulfate groups
(i.e. negative charge), which would bind tighter to this positively charged peptide. DS has been
shown to bind various heparin-binding proteins such as certain FGFs, which might explain the
similarly shaped curve as heparin31,32. This phenomenon is thought to be due to the flexibility of
the iduronic acid group present in heparin and DS, but not in CS33. The flexibility of these
groups, usually modified with sulfate groups, orient the negative charges in such a position for
ideal interaction with positively charged proteins. Even though DS possesses this ability, it does
not displace heparin/HS in the body naturally. DS does not however compete with HS in the
body for binding to FGF-2, which is probably due to the lack of kink or loop found in FGFbound HS34. CS is also a negatively-charged molecule because it contains sulfate groups. These
groups would interact with the positively charged peptide, causing some binding to occur.
Chondroitin sulfate does exhibit some binding affinity for the HB-peptide but the dissociation
constant is in the micromolar range, showing HB-peptide does bind with greater affinity to
heparin. HA did not show any binding for the peptide, probably due to HA lacking sulfate
groups. Other GAGs contain sulfate groups leading to their highly negative charge. HA does,
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however, contain carboxylate groups so some negative charge exists for this molecule but not as
much as the other sulfated GAGs. This property of HA could explain the lack of binding for the
positively charged peptide. As stated earlier, GAGs consist of chains of varying length, resulting
in high heterogeneity with regards to molecular weight. An average molecular weight is a value
that takes into account the various chain sizes for an overall estimation. In the literature, DS is
reported to be approximately 30 kDa to 50 kDa, whereas CS is close to 15 kDa, similar to
heparin35,36,37,38. For this reason, an average molecular weight of 50 kDa is used as the maximum
value for both GAGs; the molecular weight has not been reported to exceed this value. In the
literature, heparin shows an average molecular weight of 13 kDa to 15 kDa39,40. As the estimated
molecular weight of heparin draws near to 25 kDa, the dissociation constant falls in the
nanomolar range. No matter what molecular weight is used for calculation of dissociation
constants, based on the binding curves (Figure 4.1), heparin displays better binding affinity for
the HB-peptide. As the average molecular weight of each GAG is increased, the dissociation
constant, Kd, decreases (Figure 4.2).
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Figure 4.2 – Plot of change in dissociation constants (Kd) as a function of the molecular weights
of CS (green), DS (red), and UFH (blue).

The blue dashed line represents the estimated effect that increasing molecular weight of heparin
has on the corresponding dissociation constant. No matter what the exact molecular weight for
each of the GAGs is, the binding affinity of the peptide for heparin continues to be better
compared to the other GAGs. The binding affinity of HB-peptide is better for heparin than that
of the other GAGs, as seen by the dissociation constant falling into the low nanomolar range
(blue dashed line). These binding study results show promise for using HB-peptide as an affinity
column for the separation of GAGs. Based on the binding curves, a table has been generated
displaying the dissociation constants as a function of average molecular weight of the GAGs
(Table 4.1).

164

10 kDa
15 kDa
25 kDa
40 kDa
50 kDa
UFH
1.1
0.7
0.4
X
X
DS
10.7
7.1
4.3
2.7
1.9
CS
13.7
9.1
5.5
3.4
2.6
Table 4.1 – Binding affinities (Kd in µM) of HB-peptide for the various GAGs in 10 mM
phosphate buffer, 100 mM NaCl, pH 7.2 as their estimated average molecular weights are varied.
The number of binding sites (N), Χ2 value, enthalpy, and entropy produced from the binding of
HB-peptide to each of these GAGs is not shown but has been calculated for all interactions
(MicroCal Inc.). From these results, it appears that the HB-peptide can be used to separate the
GAGs from each other.

NHS-Sepharose can be used for successful immobilization of HB-peptide: Since the peptide
has good binding affinity for heparin compared to the other GAGs, it can be used as an affinity
resin in order to separate heparin from the other GAGs. NHS-Sepharose is a resin that is capable
of immobilizing small molecules such as peptides and antibodies onto which ligands and
antigens bind to their desired target. This activated resin is prepared by coupling Sepharose with
6-aminohexanoic acid, which is then activated by esterification with NHS. Ligands that have
primary amino groups are easily coupled to this ester group to form amide linkage, after which
the peptide amino groups displace the NHS group. Before coupling HB-peptide, GSH is
successfully coupled to NHS-Sepharose with yields up to roughly 70% coupling efficiency
(Table 4.2). This efficiency is achieved by using GSH in excess of 5:1 of the NHS groups
present.
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Blocking
Temp Time time
o
GSH:NHS pH ( C) (hour) (hour)
5:1
6
25
4 none
5:1
6
25
4 none
5:1
6
25
4 none
5:1
8.3
25
41
5:1
8.3
25
16 1
5:1
8.3
25
42

Coupling
efficiency
(%)
50
50
15
40
50
50

GST
amount
(ug)
10
10
10
500
500
200

5:1

8.3

25

50

350

5:1
5:1
25:1
5:1
100:1
commercial
GSH
none
none

8.3
8.3
8.3
8.8
8.8

25
25
25
25
4

50
40
20
20
40

300
100
100
100
100

pH of 1X Temp
o
PBS
( C)
7.2
25
6
25
7.2
25
7.2
25
7.2
25
7.2
25
4C
then
7.2
25C
gravity
flow at
7.2
25C
6
25
6
25
6
25
7.2
25

10
200
500

7.2
7.2
7.2

41

41
3 none
3 none
3 none
16 none

25
25
25

Time (hour)
4
4
4
0.5
0.5
0.5
1 hourat 4C
then 1 hourat
25C

Protein
binding

Abs at 280nm
used to detect
1
1
1
2
4
0.5
0.5

Table 4.2 – Conditions of GSH coupling to NHS-Sepharose. The buffer pH, temperature and
time of incubation, and mole-to-mole ratio of target ligand to NHS groups were varied to obtain
the most optimal coupling efficiency and subsequent protein binding.
Purification of GST-tagged proteins is currently accomplished by affinity chromatography using
commercially available GSH-Sepharose41,42. This method is applied to the experimentally
prepared GSH-Sepharose for the binding studies of GST and GST-C2A. Both proteins bind to
the prepared resin and only elute using excess GSH. It could be questioned whether or not
uncoupled NHS groups on the resin might nonselectively bind GST and allow it to bind to the
prepared GSH column. This problem is circumvented by blocking all uncoupled groups with
ethanolamine, which also removes excess GSH that did not couple to the resin. Both proteins
elute in 10 mM GSH, but some protein also elutes in 1X PBS (Figure 4.3). This finding is
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probably due to the number of GSH groups present on the experimentally coupled GSH resin is
less than the commercial GSH-Sepharose resin, which means less protein can be bound.
A.

B.
1

2

3

C.
1

2

3

1

2

3

4

Figure 4.3 – Binding studies of GST-C2A (Panel-A) and GST (Panel-B) to GSH-coupled
Sepharose and GST-C2A to commercially available GSH-Sepharose (Panel-C). Panel-A, Lane
1, unbound GST-C2A; Lane 2, flow-through; Lane 3, 10 mM GSH (eluted GST-C2A); Panel-B
(GST): Lane 1, unbound GST; Lane 6, 10 mM GSH (eluted GST); Panel-C (GST-C2A on
commercial GSH-Sepharose): Lane 1, GST-C2A; Lane 2, unbound GST-C2A; Lane 3, flowthrough; Lane 4, 10 mM GSH (eluted GST-C2A).
If the same amount of GST-tagged protein is loaded onto a resin with less available GSH, an
excess of a GST-tagged protein to available GSH groups occurs. There is always a chance of
such a small ligand as GSH getting buried in the beads due to their small size, which limits the
accessibility of the ligand (GSH) for its target (GST-tagged proteins). Using larger ligands such
as the HB-peptide that has 34 amino acid residues can circumvent this problem. Successful
binding and elution of GST-tagged proteins using GST-coupled NHS-Sepharose did occur. HBpeptide is also successfully coupled on NHS-Sepharose using the similar method as GSH. The
primary amino group at the N-terminal end of the peptide rapidly forms a stable amide linkage
with the 6-aminohexanoic acid, allowing the successful coupling onto Sepharose beads for
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further use as an affinity column for purifying heparin. The incubation temperature and time did
not cause a significant change in coupling efficiency (percentage) when the experimental
conditions were varied. The longer incubation time caused an increase of only 5-10% efficiency.
It would seem more appealing to save on time of coupling than to gain 5-10% yield. As the
amount of peptide (mg) that is loaded is increased, the corresponding amount of peptide (mg)
retained on the resin is also increased, as expected (Figures 4.4 and 4.5). No matter what amount
of peptide is applied to the resin, the efficiency (percentage) remains constant; with the
corresponding amount of peptide (mg) increasing that has adhered to the column. This
efficiency (percentage) is comparable to reported values in the literature for several other
proteins26,43.
75
70
65
60

Coupled efficiency (%)

55
50
45
40
35

25C

30

4C

25
20
15
10
5
0
2 mg

4 mg

6 mg

8 mg

10 mg

Amount of HB-peptide (mg)

Figure 4.4 – Plot of the coupling efficiency (percentage) for the coupling reaction of HB-peptide
to NHS-Sepharose as a function of the amount of HB-peptide (mg) used at at 25oC (blue) and
4oC (red).
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7

Amount of HB-peptide coupled (mg)

6

5

4

3

2

1

25C
4C

0
2 mg

4 mg

6 mg

8 mg

10 mg

Amount of HB-peptide (mg)

Figure 4.5 – Plot of the amount of HB-peptide (mg) coupled to NHS-Sepharose as a function of
increasing the amount of HB-peptide (mg) used at 25oC (blue) and 4oC (red).
The highest efficiency obtained for this coupling method is about 75% for 4oC and 70% for
25oC. In 1 mL of resin, the highest amount of peptide coupled is about 6 mg. There is a good
chance that if more peptide were added to this small amount of resin, overcrowding of the groups
would occur, resulting in steric hindrance. This would then cause less accessibility of groups to
bind to their ligand, heparin, and consequently leading to a decrease in heparin binding.

FITC-heparin has strong binding affinity for prepared HB-affinity column: Heparin is not
easily identified spectroscopically except for NMR, but this method is very susceptible to
changes in proton chemical shift values due to high salt concentrations. To bypass this problem,
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heparin is attached to a fluorescent dye, FITC. The elution of this colored heparin can also be
easily detected visually instead of by other tedious spectroscopic methods. In order to
methodically determine the exact binding efficiency of heparin to the prepared column,
fluorescence spectroscopy is useful. A question might arise if the heparin molecule is actually
binding to the attached HB-peptide or it is just physically adsorbed onto the resin itself, so a
column (deemed “negative”) is prepared without HB-peptide. Since the “negative” column does
not contain HB-peptide, it is not expected to bind FITC-heparin. As seen in the fluorescence
spectra for all of the FITC-heparin fractions that elute from the HB-column (Figure 4.6), the
majority of FITC-heparin is present in the 350 mM and 500 mM NaCl fractions. In contrast, the
“negative” column elutes heparin after the first round of binding, suggesting that heparin is
actually binding to the coupled peptide and not just adsorbed on the resin.
A.

B.

pre

pre

UB

350
500
UB
100

100
350

Figure 4.6 – Fluorescence spectra of FITC-heparin (in 10 mM Tris buffers, pH 8) elution from
HB-coupled-Sepharose (Panel-A) and “negative” column of NHS-Sepharose (Panel-B).
On average, about 60% of FITC-heparin is retained on the HB-column (elutes between 350 mM
and 500 mM NaCl), which is promising for large-scale heparin binding studies (Figure 4.7). The
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majority of FITC-heparin did not bind to the “negative” column, with approximately 75% eluted
in the unbound state.

90
HB
80

Negative

Percentage of FITC-heparin eluted

70
60
50
40
30
20
10
0
0

100

200

300

400

500

600

700

800

900

1000

NaCl concentration (mM)

Figure 4.7 – Plot of elution of FITC-heparin from HB-coupled-Sepharose (black line) and
“negative” column, NHS-Sepharose (red line).
The binding studies of FITC-heparin are normally performed using centrifugation of the resin
and decanting of the supernatant from the resin, which could result in a loss of FITC-heparin and
resin after every elution. For more in-depth binding studies, other methods such as flow
chromatography should be employed to avoid loss of FITC-heparin and resin in the future.
Another promising find is that even after several days of storage at 4oC, the affinity resin shows
only a slight decrease in binding efficiency (60% to 50%). It is desired to employ this HBaffinity column to separate heparin from the other GAGs (Figure 4.8), but a dye would not be
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present on naturally occurring heparin samples that contain other GAGs. In this case, there
needs to be another efficient method of detection of the GAGs without attaching a dye. It is
expected that CS, then DS, then heparin would elute from the HB-affinity column, based on the
binding affinity studies performed by ITC; heparin has greatest binding, then DS, then lastly CS.

Figure 4.8 – Cartoon representation of the separation of CS, DS, and heparin using HB-affinity
column and NaCl step-wise gradient.
Each glycosaminoglycan has specific fingerprint in proton NMR spectroscopy: NMR
spectroscopy, especially 1H NMR, has been used to successfully differentiate various GAGs as
well as identify OSCS and DS contaminants in heparin samples35,44. There are various
“standard” peaks that each GAG contains to identify it from the others. For example, Lee et al
has shown that the acetyl group in a proton spectrum (~ 2.0 ppm) can be used as a fingerprint for
the various GAGs45. There is however caution required when identifying the GAGs based on
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this peak alone because it is such a narrow range. For example, heparin’s methyl resonance is
around 2.05 ppm, CS has one from 2.00 to 2.06 ppm, and DS contains one from 2.07 to 2.09
ppm46,47. Again, the exact chemical shifts can change depending on the solvent used. The
presence of OSCS in heparin samples produces a peak at 2.15 ppm46. This extreme shift of 0.15
ppm from the corresponding 2.00 ppm methyl proton of the acetyl group in heparin would
actually be useful for the detection of OSCS impurity in heparin. For the other GAGs that still
need to be removed from heparin, other peaks need to be identified as markers. Based on the
analysis of several heparins, other peaks that are always present are 5.42, 5.23, 5.01, 4.82, 4.60,
4.40, 4.34, 4.27, 4.12, 4.03, 3.87, 3.77, 3.67, 3.40, and 3.2846. These peaks are extremely helpful
in identifying important peaks present in heparin. When comparing heparin to the other GAGs,
the NMR spectrum of each GAG needs to be measured in order to determine similarities and
differences in the GAG structures. The NMR spectra of all three GAGs are overlaid to visually
identify unique peaks of interest for each GAG (Figure 4.9).
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CS

DS

UFH

Figure 4.9 – The 1H NMR spectra of CS (green), DS (red), and UFH (blue) in 10 mM phosphate
buffer, 100 mM NaCl, pH 7.2 in 10% D2O at 298 K.
By obtaining all of the peaks that are present in each GAG, the peaks that are within 0.02 ppm of
each other are discarded. After this is performed, the peaks that are uniquely found in UFH, CS,
or DS alone were identified as important peaks in heparin (Figures 4.10, 4.11, 4.12).
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5.39
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5.29
5.20
5.18
5.01
4.33
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0

Chemical shift (ppm)

Figure 4.10 – Plot of the unique 1H NMR peaks present in the standard UFH sample.
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Figure 4.11 – Plot of the unique 1H NMR peaks present in the standard CS sample.
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Figure 4.12 – Plot of the unique 1H NMR peaks present in the standard DS sample.
These unique peaks can now be used to identify GAGs that are present in eluted fractions once
binding of a GAG mixture to HB-affinity column occurs. The few peaks that elicit a stronger
signal are used for detection of UFH, CS, and DS in the fractions collected from the affinity
column (Table 4.3). The peaks observed in both CS and DS are indistinguishable from each
other and are identified as strictly an impurity if found in the UFH sample.
Unique peaks in
Unique peaks in CS Unique peaks in DS
Unique peaks in CS and
UFH
DS
5.39
2.66
4.62
5.1
5.33
2.64
4.57
5.14
5.29
5.15
5.2
5.01
3.41
3.39
3.28
Table 4.3 – Isolated peaks used for identification of GAGs during binding studies on HB-affinity
column.
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Slight separation of GAGs is observed using HB-affinity column: After these “standard” peaks
are detected, they were then searched for in all of the fractions collected from the HB-affinity
column. Even though the methyl proton in the acetyl group around 2.0 ppm is a good marker for
most heparin samples, this peak is only present in fractions from 0 mM to 300 mM NaCl, and not
beyond this point. After 300 mM NaCl, this peak cannot be used to obtain information about
each GAG. Based on the ITC experiments, DS and CS do bind to HB-peptide but not as tightly
as heparin does. Binding of these GAGs is expected once applied to the affinity column, but not
tight binding that would require the addition of high salt concentrations to elute. DS has a better
binding affinity than CS, so DS would be expected to elute at higher salt concentration than CS.
Due to the polydispersity of the GAGs, the various-sized chains would have a propensity to bind
with different affinities to the HB-peptide. This phenomenon would most likely result in elution
of various chains of each GAG in each fraction. The main objective of this experiment is as
heparin is eluting (at high salt concentration), it would not contain any other GAG impurity.
From the NMR spectra different eluted fractions, heparin is present in all the fractions (Figure
4.13). Because of its heterogeneity in molecular weight, this finding is not unexpected. The
amount of sulfation is dependent on the polydispersity of the heparin sample, which leads to a
variation in negative charge for each chain. Unfractionated heparin contains chains of varying
lengths, which would bind to the HB-peptide with different strengths and behaviors, causing
them to be eluted in varying concentrations of salt. This phenomenon leads to a loss of heparin
during the purification process because some of the chains elute at lower salt concentrations.
The heparin sample is bound to the HB-affinity resin with different affinities, which does not
allow all of the heparin sample to elute only at high salt concentration. If the heparin sample
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consists of chains of the same molecular weight, we would ensure all of heparin would elute only
at high salt concentration.

Figure 4.13 – Overlay of 1H NMR spectra of all GAG fractions collected from the HB-affinity
column. Unbound is light pink, 0 mM NaCl is lime green, 100 mM NaCl is orange, 200 mM
NaCl is yellow, 300 mM NaCl is purple, 400 mM NaCl is green, 500 mM NaCl is red, and 2 M
NaCl is blue.
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From the unbound state to 100 mM NaCl, there is a reasonably good distribution of all three
GAGs (Figure 4.14, 4.15, 4.16). This is promising because CS and DS impurities in heparin
samples would elute at lower NaCl concentration, leaving pure heparin in fractions that elute at
higher NaCl (300 mM to 500 mM). Before the 2008 contamination scare, very small trace
amounts of impurities of GAGs were present in heparin samples, but they did not interfere with
the biological activity of pharmaceutical heparin.
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Figure 4.14 – Plot of “standard” peaks identified in the unbound fraction from HB-affinity
column. Heparin peaks are in blue, CS peaks are in green, DS peaks are in red, and the peaks in
both CS and DS denoted as “impurities” are in yellow.

179

0.9
0.8

Peak intensity/106

0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
7.98

5.39

5.2

5.13

4.99

3.43

3.4

2.64

2.53

2.33

2.3

2.28

Chemical shift (ppm)

Figure 4.15 – Plot of “standard” peaks identified in the 0 mM NaCl fraction from HB-affinity
column. Heparin peaks are in blue, CS peaks are in green, DS peaks are in red, and the peaks in
both DS and CS denoted “impurities” are in yellow.
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Figure 4.16 – Plot of “standard” peaks identified in the 100 mM NaCl fraction from HB-affinity
column. Heparin peaks are in blue, CS peaks are in green, DS peaks are in red, and the peaks in
both DS and CS denoted as “impurities” are in yellow.
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As the salt concentration increases all the way to 400 mM, heparin continues to be eluted with
high peak intensities but there are also peaks corresponding to the “impurities” peaks present in
both CS and DS. At this point it is still difficult to determine which GAG these yellow peaks
represent. It is interesting to observe larger peaks corresponding to heparin in the 200 mM NaCl
fraction (Figure 4.17), but it does not necessarily equate to larger yield of the heparin sample.
This finding could be due to the heparin chains that elute at 200 mM NaCl containing more
individual structural groups having more yield. For example, a longer chain of heparin contains
more individual groups that a shorter chain, which in turn, produces more signals in the NMR
spectrum. It is interesting to note that at 300 mM NaCl (Figure 4.18), two peaks representing CS
are present, even though it would be expected that CS would elute at a lower NaCl concentration.
After this point, however, there are no unique peaks corresponding to CS alone that are
discovered in the higher salt concentrations (>400 mM NaCl). Again, at 400 mM NaCl (Figure
4.19), the mysterious “impurity” peak exists along with peaks corresponding to heparin.
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Figure 4.17 – Plot of “standard” peaks identified in the 200 mM NaCl fraction from HB-affinity
column. Heparin peaks are in blue and the peak in both DS and CS denoted as “impurity” is in
yellow.
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Figure 4.18 – Plot of “standard” peaks identified in the 300 mM NaCl fraction from HB-affinity
column. Heparin peaks are in blue and the peak in both DS and CS denoted as “impurity” is in
yellow.
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Figure 4.19 – Plot of “standard” peaks identified in the 400 mM NaCl fraction from HB-affinity
column. Heparin peaks are in blue and the peak in both DS and CS denoted as “impurity” is in
yellow.
At 500 mM NaCl (Figure 4.20), the majority of peaks isolated are from heparin, which is
expected since through binding studies with ITC, heparin displayed a high binding affinity (nM
range) compared to the other GAGs. Also, FITC-heparin elutes from HB-affinity column at 350
mM and 500 mM NaCl, which is in agreement with the NMR data presented here. There are
residual peaks uncovered in the 2 M NaCl fraction (Figure 4.21), but their intensities are
extremely low compared to the other fractions (only trace amounts present). This could be due
to some small chains getting trapped in the resin beads, causing them to elute slower.
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Figure 4.20 – Plot of “standard” peaks identified in the 500 mM NaCl fraction from HB-affinity
column. Heparin peaks are in blue and the peak in both DS and CS denoted as “impurity” is in
yellow.
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Figure 4.21 – Plot of “standard” peaks identified in the 2 M NaCl fraction from HB-affinity
column. Heparin peak is in blue and the peaks in both DS and CS denoted as “impurities” are in
yellow.
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As the mysterious peaks of “impurities” still exist in the 500 mM and 2 M NaCl fractions, it can
be concluded that they belong to DS instead of CS. DS has a stronger binding affinity for the
HB-peptide, as observed from the ITC curves. CS, due to its moderate but less binding affinity
than DS, is expected to elute at lower salt concentration and especially in less than 500 mM and
2 M NaCl. As heparin is eluted from the column in each fraction and there were still some
impurities in the higher salt concentrations, further mutations need to be performed on the HBpeptide to enable it to selectively bind to heparin alone and not to the other GAGs.

Glycosaminoglycans can be isolated from chicken intestines: After the GAG elution is assessed
using HB-peptide as an affinity column, a commercial use of this peptide is desirable. It needs to
be examined if the HB-affinity resin can be used to isolate heparin in animal tissues. Normally,
heparin is isolated and purified from porcine intestines or bovine lungs48. Mad cow disease
became an issue early on, and it is difficult to distinguish heparin from pig and cow. To combat
this problem, other animal tissue sources need to be investigated for the isolation of heparin in
large yields. In order to obtain heparin in a cost-effective manner, the Kumar lab is examining
the possibility of isolating heparin from other animal tissue sources. Avian species, such as
turkey and chicken, have been shown to contain heparin49,9. With Tyson Inc. (with headquarters
in Northwest Arkansas) being the largest company dealing with chicken products, it may be a
viable proposition to develop methods to isolate and purify heparin from chicken intestines.
Contaminants are also present along with the proteoglycans and GAGs in chicken intestines that
interfere with the binding affinity of GAGs to the HB-affinity column. These contaminants, such
as DNA, proteins, and lipids need to be removed before heparin can be purified on the HBaffinity column. DNase is used to remove DNA, and thermolysin is chosen to remove proteins.
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DNA needs to be completely degraded because it is a negatively-charged molecule, which could
have some nonspecific binding affinity for HB-peptide. This would in turn interfere with the
GAG binding to HB-affinity column. DNase is used first because if thermolysin were used first,
it would completely inactivate DNase once it is added. In the next step, the thermostable
metalloproteinase cleaves proteins found in the sample. This enzyme preferentially cleaves the
N-terminal end of hydrophobic side chains (i.e. Leu, Phe, Ile, Val) as well as Met, His, Tyr, Ala,
Asn, Ser, Thr, Gly, Lys, Glu or Asp50,51. This enzyme is often times, and in our case, used as a
nonspecific proteinase to hydrolyze peptide bonds52. A flow chart (Figure 4.22) is provided
detailing the steps that are employed for the isolation of GAGs in chicken intestines.

Figure 4.22 – Flow-chart outlining steps for isolation of GAGs and pure heparin from chicken
intestines.
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The first step of this process is to determine if DNase is capable of removing DNA before the
removal of proteins is implemented. Agarose gel electrophoresis is used to detect DNA that is
present in various samples, which aids in determining if the DNase treatment is successful or not.
The use of DNase (Figure 4.23) removes the DNA present in the chicken samples (lane 1), as
seen on the agarose gel (lane 3), which is successful compared to the “control” sample that had
no enzyme present.
1

2

3

Figure 4.23 – DNase treatment of chicken sample after homogenization by blender occurred.
Lane 1, chicken sample—pre DNase treatment; Lane 2, “control” sample—post 37oC treatment
(no DNase addition); Lane 3, “test” sample—post DNase treatment.
Proteins are removed by thermolysin by its ability to degrade proteins at very nonspecific sites,
resulting in very small bits of peptides. The high temperature of 70oC also acts as alternative
method of denaturing other proteins not susceptible to thermolysin cleavage, because most
proteins are not stable at such high temperatures as thermolysin. This enzyme can also be used
to degrade the protein portion of the proteoglycan, resulting in GAG liberation from the cell
surface. GAGs that would have been lost as proteoglycans on the cell surface are now released
as free negatively-charged GAG molecules, ready to be separated on the HB-affinity column.
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All proteins in the “test” sample are degraded by thermolysin and heat as seen in lane 4, whereas
the “control” sample (lane 6) still contains some protein bands on the gel (Figure 4.24).
1
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Figure 4.24 – Thermolysin cleavage of proteins in the chicken sample after DNase treatment
occurred. Lane 1, chicken sample—pre thermolysin or DNase treatment; Lane 2, “test”
sample—post DNase treatment (supernatant); Lane 3, “test” sample—post DNase treatment
(pellet); Lane 4, “test” sample—post DNase (supernatant), post thermolysin; Lane 5, “test”
sample—post DNase (pellet), post thermolysin; Lane 6, “control” sample—post 37oC, post 70oC
treatment (no enzyme addition).
There is a decrease in the protein bands in the “control” sample, suggesting that the temperature
used (70oC) is optimal to denature proteins. Both enzyme treatments result in a cloudy mixture
that contains white debris as the top layer, characteristic of lipids. Using the heat and enzyme
process, lipids seem to also be removed without the use of an additional enzyme. This process
also removes cell debris and other proteins as seen by lane 3 even prior to proteolytic cleavage.
If thermolysin is still present in the supernatant even after centrifugation, passing the chicken
sample over the HB-affinity column would result in the enzyme’s removal from the GAGs
because it is not expected to have any affinity for the HB-peptide.
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Azure A assay shows only a small amount of GAGs are isolated from chicken intestines: Once
all the unnecessary contaminating components are removed, the amount of GAGs that are
isolated can be determined by the metachromatic properties of Azure A when bound to the
negatively-charged GAGs. Standard plots are generated, based on the absorbance of Azure A at
620 nm for known concentrations of heparin. The metachromasia of Azure A is sensitive to the
time of incubation. As seen in the plot of absorbance of the Azure A in the presence of heparin,
the absorbance at 620 nm decreases slightly as the time of incubation increases (Figure 4.25). To
obtain accurate results, an incubation period of 30 minutes is chosen to account for the slight
changes in the Azure A behavior over time.
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Figure 4.25 – Plot of the time course incubation of Azure A with varying amounts of heparin.
Each color represents a different amount of heparin (µg/mL).
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The absorbance of Azure A changes slightly over time but reaches a plateau from 20 minutes to
30 minutes. A longer incubation time removes the inaccuracy in absorbance reading that occurs
when less time is used (less than 20 minutes).

A standard plot is then developed showing the change in the absorbance of Azure A as a function
of the amount of heparin present in the sample at 30 minutes incubation (Figure 4.26). The yaxis was plotted as percentage of absorbance displayed because the starting point (no heparin
present) does vary from sample to sample.
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Figure 4.26 – Plot of the percentage of Azure A absorbance at 620 nm as a function of the
amount of heparin present in the sample.
As seen in the plot, there is a linear portion of the curve from 0-10 µg heparin, but beyond this
amount, the linearity is lost, and the curve plateaus. The linear component is used to estimate the
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amount (µg) of heparin is present in the test samples. The isolation of GAGs from the chicken
sample is such a small-scale process so it is not expected that a large amount of GAGs be
obtained. This reasoning is why the smaller range of heparin can be utilized. A log/log curve
was prepared for the range of 0-10 µg heparin to obtain more linearity for the curve (Figure
4.27).
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Figure 4.27 – Linear portion of standard Azure A assay curve obtained as a function of amount
of heparin.
Azure A detects sulfated GAGs and cannot distinguish between CS, DS, KS, and heparin. The
absorbance reading that is obtained from the chicken sample includes all GAGs present, not just
heparin. From the absorbance spectrum, the chicken sample gave an absorbance reading that
was about 91% of the initial reading (no heparin present) (Figure 4.28). Based on this value, the
amount of heparin that corresponds to this percentage on the standard graph is approximately 3.5
µg. This finding means the chicken sample contains about 3.5 µg of total GAG, not just heparin,
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which means the true amount of heparin present is less than this amount. Even though the
chicken sample did not produce a better quantity of GAGs, it is promising that the method
employed did yield some GAGs.

Figure 4.28 – UV-vis spectrum of Azure A absorbance with the chicken intestine sample after
DNase and thermolysin treatment.
The primary goal of this project is to isolate GAGs from chicken intestines, and if enough were
isolated, they would then be applied to the HB-affinity column. The preliminary procedure that
is accomplished is the isolation of GAGs, but only on a microgram level, and therefore is not
sufficient to separate by the HB-affinity column. As the preliminary isolation of GAGs is on a
small scale, future endeavors include a large-scale attempt to successfully isolate GAGs using
the simple and cost-effective process our lab has developed.
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Conclusions
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Heparin is an extremely important molecule that is naturally present in the body.
Exogenous heparin is also used as an anticoagulant during heart bypass surgeries and also to
prevent blood clot formation. In 2008, heparin became contaminated with GAGs that are
structurally similar to heparin. These contaminants activated various pathways that led to
anaphylactic shock, hypotension, and death for many around the world. There is a need for the
purification of heparin, which prompted our lab to delve into what molecules naturally bind to
heparin to hopefully separate this crucial GAG from the contaminants.
HBPs are a large class of very diverse proteins that specifically bind to heparin for their
activity to occur in the body. These unique proteins have distinct regions in their sequence
(HBR) responsible for their ability to bind tightly to heparin. The ability for HBPs to bind to
heparin for their function is not solely dependent on the amino acid sequence of the HBR, but
also on the spatial orientation of the residues once the protein folds correctly. Having the
positively-charged residues facing a certain direction enables them to come in contact with the
negatively-charged heparin molecule. Many studies have been performed on the structural
components of these regions to determine in exactly what manner they bind to heparin. Our lab
has constructed a heparin-binding peptide that is modeled after the structural features of the
HBPs, which enables the peptide to bind to heparin with high affinity.
The first use of this HB-peptide is as an affinity tag for the purification of various
recombinant proteins by heparin-Sepharose affinity chromatography. The proteins chosen (C2A,
CAlb3, and S100A13) are not known to naturally bind to heparin, which allows the HB-peptide
to hold all of the heparin-binding capability. These proteins were expressed and purified to
homogeneity under native and denaturing conditions (urea, not guanidine hydrochloride). HBfused C2A, CAlb3, and S100A13A eluted from heparin-Sepharose in 500 mM NaCl, 1 M NaCl,
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and 1 M to 2 M NaCl, respectively. The promising find was the expression and purification of
CAlb3 because in previous attempts, this protein has not been expressed or purified to
homogeneity in good yield. The affinity tag was also successfully removed by proteolytic
cleavage (thrombin and TEV protease). Preliminary studies have also revealed that HB-peptide
does indeed interact with heparin. Binding studies by ITC showed that HB-peptide binds with a
good affinity to heparin in a two-site binding model (Kd ~ 0.8 and 17 µM). HB-peptide also
adopts an alpha helical structure in the presence of heparin, which is also seen in other HBP
consensus motifs. There is a moderate change in structure once heparin binds to the peptide, as
seen by the shift in crosspeaks in 1H-15N HSQC spectroscopy.
Detection of the expression and purification profiles of the various HB-fusion proteins is
desirable, especially if the yield of proteins is too low to visually observe by SDS-PAGE.
Polyclonal antibodies generated against the first 12 amino acid residues in the HB-peptide
allowed for successful detection of HB-fusion proteins in crude cell samples during expression
and purification. The use of secondary antibodies oftentimes leads to nonspecific interactions to
occur, resulting in false signals on the nitrocellulose membrane. As we increased the salt
concentration from 150 mM NaCl to 750 mM NaCl, the nonspecific bands were successfully
removed from the membrane, enabling a more reliable detection method using the anti-HB
polyclonal antibodies. The antibodies were able to detect HB-fused C2A down to 10 ng in 150
mM NaCl and 50 ng when the salt concentration is increased. These antibodies were proven to
be specific towards the epitope in HB-peptide, whereas the target protein shows no binding to the
antibodies. This was seen in the antibodies detecting only the HB-fusion protein and HBpeptide, but not GST alone. These antibodies can also be used to detect HB-fusion proteins in
other crude cell lines, such as bacteria, yeast, and mammal.
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The original reason this HB-peptide was designed was for the separation of heparin from
other GAGs, ultimately leading to its purification. It needed to be determined that HB-peptide
binds specifically to heparin, compared to the other GAGs. Based on ITC measurements, the
peptide has stronger binding affinity for heparin (Kd ~ nM), then DS (Kd ~ low µM), then CS (Kd
~ higher µM), and lastly HA (no binding observed). This finding is promising that heparin
would bind the tightest to the HB-affinity column, allowing heparin to be separated from the
other GAGs. This affinity column works in a similar fashion as HBPs are purified on heparinSepharose. HB-peptide was successfully coupled onto NHS-Sepharose resin with efficiency as
high as 70%. This HB-affinity column was then used to monitor the elution profile of FITCheparin for initial binding studies. FITC-heparin eluted from the affinity column from 350 mM
to 500 mM NaCl, whereas the “negative” column that contained no HB-peptide did not retain
FITC-heparin past 0 mM NaCl. The HB-affinity column was then used to separate a mixture of
CS, DS, and heparin from one another fairly well. There were only a few “contaminating”
molecules of CS or DS present at higher salt concentrations as heparin eluted (400 mM to 500
mM NaCl), as observed by 1H NMR spectroscopy. Certain unique peaks present in each pure
GAG were used as identifiers for the specific GAG in a mixture. Another endeavor using HBaffinity column was the attempt to isolate GAGs from chicken intestines. After treatment with
DNase (removed DNA), thermolysin (removed proteins), and heat (removed lipids), 4 µg of total
GAGs were successfully isolated, as seen by the Azure A assay. This production of GAGs from
chicken intestines did not warrant enough yields to try and separate the mixture of GAGs using
the HB-affinity column.
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Future work that needs to be performed is the modification of the HB-peptide to bind
much tighter to heparin (low nM), leading to greater separation of GAGs from one another. If
heparin binds extremely tight to the HB-affinity column, and the other GAGs have no
comparison in binding affinities, heparin could then be eluted at extremely high salt
concentrations (>2 M NaCl). This high of salt concentration would not contain any other GAG
contaminant. Isolation of GAGs from chicken intestines needs to be optimized further to obtain
larger amounts of GAGs. This would enable the GAG mixture to be loaded onto the HB-affinity
column for the purification of heparin. The last modification that needs to occur is improvement
of Western blotting technique employed using the anti-HB polyclonal antibodies. There is a
need to reduce the nonspecific antibodies-antigen interactions seen by multiple bands on the
membrane. Monoclonal antibodies can be used for specific detection of HB-fusion proteins if
desired. Overall, this HB-peptide has proved to be a key player in recombinant protein
purification, immunoblotting, and heparin purification.
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granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and no
derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only, the
terms of the license are extended to include subsequent editions and for editions
in other languages, provided such editions are for the work as a whole in situ and
does not involve the separate exploitation of the permitted figures or extracts,
You may not alter, remove or suppress in any manner any copyright, trademark or
other notices displayed by the Wiley Materials. You may not license, rent, sell, loan,
lease, pledge, offer as security, transfer or assign the Wiley Materials on a stand-alone
basis, or any of the rights granted to you hereunder to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all times

205

remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or
their respective licensors, and your interest therein is only that of having possession of
and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or
to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you
shall not assert any such right, license or interest with respect thereto
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU.
WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN.
Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby.
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The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party.
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns.
In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
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The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and nonCreative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id-410895.html
Other Terms and Conditions:

v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Copyright Permission for Figure 2.32

Jacqueline Morris <jagreer@email.uark.edu>
To: eic@biochem.acs.org

Wed, Apr 20, 2016 at 8:39 AM

Hi,
I am writing my dissertation and I wanted to compare an NMR spectrum I have acquired to
one from a Biochemistry Journal article. The citation of the article is as follows:
Rajalingam, D.; Graziani, I.; Prudovsky, I.; Yu, C.; Kumar, T. K. S., Relevance of Partially
Structured States in the Non-Classical Secretion of Acidic Fibroblast Growth Factor.
Biochemistry 2007, 46 (32), 9225-9238
I wanted to reproduce an NMR spectrum (Figure 7) of C2A, just the NMR spectrum. Please
let me know what I need to do to acquire permission to reproduce this without modifying the
figure. Thanks,
Jacqueline Morris
PhD Candidate, University of Arkansas

Currey Courtney <eic@biochem.acs.org>
To: Jacqueline Morris <jagreer@email.uark.edu>

Wed, Apr 20, 2016 at 10:34 AM

Dear Ms. Morris,
Thank you for your inquiry. Yes, you may reproduce the NMR spectrum from this paper in
your dissertation.
Best of luck in your future endeavors.
Best regards,
Currey Courtney
Journal office administrator, Biochemistry
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